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Abstract 
 
 High throughput sequences are generating increasingly detailed catalogues of 
genetic variation both in human disease and within the larger population. To 
effectively utilise this rich data set for maximum research benefit, as a discipline we 
require robust, flexible, and reproducible analysis pipelines capable of accurately 
detecting and prioritising variants. While data-specific computational algorithms 
aimed at deriving accurate data from these technologies have reached maturity, two 
major challenges remain in order to realise the goals of elucidating the underlying 
genetic causes of disease as a means of developing custom treatment options.  The 
first challenge is the creation of high-throughput variant detection pipelines able to 
reliably detect sample variation from a variety of sequence data types. Such a system 
needs to be scalable, flexible, robust, highly automated, and able to support 
reproducible analyses in order to support both default and custom variant detection 
workflows. The second challenge is the effective prioritisation of the huge number of 
variants detected in each sample, a task required to reduce the large search space for 
causal variants down to variant lists suitable for manual interrogation.  This thesis 
describes six publications describing components of the larger informatics framework 
I have developed over the last four years to address these challenges, a framework 
designed from the onset to effectively manage and process large data sets with an end 
goal of utilising computational analysis of sequence data to further understand the 
relationship between genetic variation and human disease. The first publication 
“Reliably detecting clinically important variants requires both combined variant calls 
and optimized filtering strategies” describes a variant detection strategy designed to 
minimize false negative variants as is desired when utilising patient variation data in 
the clinic. The next four publications describe custom workflows developed for 
detecting variants in sequence data from different sample types, namely paired cancer 
samples (“Tumour procurement, DNA extraction, coverage analysis and optimisation 
of mutation-calling algorithms for human melanoma genomes”), pedigrees 
(“Reducing the search space for causal genetic variants with VASP: Variant Analysis 
of Sequenced Pedigrees”), mixed cell populations containing ultra-rare mutations 
(“DeepSNVMiner: A sequence analysis tool to detect emergent, rare mutations in 
sub-sets of cell populations”) and mouse exome data containing ENU mutations 
(“Massively parallel sequencing of the mouse exome to accurately identify rare, 
 x 
induced mutations: an immediate source for thousands of new mouse models”) . The 
last publication, “Comparison of predicted and actual consequences of missense 
mutations” focuses on the validation of computational tools that predict functional 
impact of missense mutations and further attempts to explain why many missense 
mutations predicted to be damaging do not result in an observable phenotype as might 
be expected. Collectively these publications detail efforts to reliably detect and 
prioritise variants across a wide variety of data types, efforts all based around the 
significant underlying software framework I have developed to better elucidate the 
link between genetic variation and disease. 
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Chapter 1: General Introduction 
1.1 Aims of the Thesis 
This thesis describes six publications detailing aspects of the larger 
informatics framework I developed over the last four years to reliably detect and 
prioritize variants from next generation sequencing (NGS) data. The framework 
addresses two main challenges in the field; first how to manage and process 
increasingly large volumes of data from a variety of sequence data types and 
second how to prioritize the huge number of variants detected in each sample. 
Collectively, this framework aims to further elucidate the often-complex 
relationship between genetic variation and disease.   
 
1.2 Overview 
The study of genetic variation and its effect on human disease has 
undergone a major transformation in the last ten years.  This has occurred due to 
a variety of factors including the arrival of commercially available NGS 
technologies, the generation of the first human reference genome (1), and the 
growing databases of known variation in both healthy individuals (2) and 
individuals with disease (3, 4). With over 250,000 human genomes sequenced to 
date and a doubling of this number expected in the next year alone (5), health 
sciences has truly entered the age of big data (6). While these exciting 
developments open many new research avenues, it is apparent that numerous 
computational challenges exist in the field that are yet to be resolved. For 
example, there currently is no dominant software framework able to manage and 
analyse large volumes of diverse sequence data nor is there a gold standard 
methodology for identifying disease-causing variants within the large 
background variation present in each individual.  
 
1.3 Gene-disease link 
Historically, the link between genes and disease has long been theorised 
with Archibald Garrod in 1908 coining the term “inborn errors of metabolism” to 
describe the increased incidence of alkaptonuria in consanguineous families 
which he suspected were caused by “transmissible elements within family” (7).  
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This understanding eventually led to the development of the first genetic linkage 
maps and linkage analysis methods, giving researchers for the first time a means 
of mapping the location of these elements responsible for inheritable diseases. 
During the twentieth century, increasingly complex linkage analysis methods 
capable of detecting specific genetic regions that co-segregate with affected 
family members were developed and refined eventually becoming a standard 
means of detecting the genomic regions linked to inherited disorders. Such 
approaches proved extremely successful mapping over 1000 monogenic diseases 
to date (8). Despite these successes, due to a variety of limitations in this 
approach, the cause of many diseases remained unknown particularly when 
studying complex/late onset disease as well as diseases with incomplete 
penetrance.  
 
1.4 DNA sequencing  
In addition to the creation of linkage maps, another critical development 
that greatly increased our understanding of the link between genes and human 
disease was the arrival of technologies for the sequencing of DNA molecules.  
The technology to sequence DNA was first developed in the 1970s with the 
arrival of the Maxam-Gilbert method (9) followed later by the invention of 
Sanger sequencing in 1977 (10), a technique which became the standard for the 
next 25 years. Over the ensuing decades, advances in both sequencing 
technologies and computational analysis of sequence data made DNA 
sequencing more reliable and cost effective. However sequencing complete 
mammalian genomes remained difficult and time consuming largely due to 
technical limitations of the time. As a result, it wasn’t until 2003 that the first 
draft of the human genome was generated using Sanger sequencing by a 
consortium called the Human Genome Project (HGP), effectively creating the 
initial human reference genome (1). The success of this project was the 
culmination of a worldwide collaboration of hundreds of labs internationally 
ultimately costing 3.4 billion USD and taking 13 years to complete. While costly 
and time consuming, the creation of a human reference genome by the HGP 
proved an enormous breakthrough in many ways, offering a new tool for 
researchers to utilise in the identification of many more disease-causing genes.  
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By combining linkage data with the annotated reference genome, researchers 
were, for the first time, able to generate small candidate gene lists and further to 
identify point mutations in DNA sequence within these genes common to 
affected family members.   
 
1.5 Draft human genome 
While the HGP effort generated the first complete draft of the human 
genome, another major effort was underway during this time led by Craig 
Ventner at Celera Genomics (11), a project that aimed to build a draft genome 
using the less expensive shotgun sequencing technique they pioneered. The 
eventual completion of this project marked the arrival of the second draft human 
genome, all of sudden making it possible to generate genome wide catalogues of 
genetic differences between individuals. Increasing sequencing efforts resulted in 
more and more sequence variation information being generated (both within and 
between species) leading to the eventual creation of the first publicly available 
variation database; the single nucleotide polymorphism database or dbSNP (2), 
an NCBI resource designed to capture all genetic variation identified in human 
populations. From its creation in 1998, the number of entries in dbSNP continues 
to grow each year with the latest human release (v144) containing over 150 
million unique variants, over 50 million of which were added in the last year 
alone (http://www.ncbi.nlm.nih.gov/SNP/snp_summary.cgi). Following this 
effort, interest in cataloguing variants relevant to specific diseases began to 
emerge, resulting in the creation of repositories such as COSMIC (12) for storing 
somatic mutations in cancer or ClinVar (4) for aggregating information about 
relationships among variation and human health. 
 
1.6 Next generation sequencing 
While the accumulation of variation information continued after the 
creation of the initial human reference genome, the pace changed dramatically 
with the development and widespread adoption of massively parallel sequencing 
technologies (Next-Generation Sequencing; NGS). NGS is commonly defined as 
the group of sequencing technologies that parallelize the sequencing of 
individual sequences in a single experiment, making it possible to sequence 
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millions or even billions of DNA molecules simultaneously. The first widely 
available platform was Life Sciences 454 released in 2004, a platform that 
offered an immediate 6X decrease in per base cost compared to traditional 
Sanger sequencing (13). Since this time, advances have continued apace with the 
cost of sequencing a mammalian genome dropping from $100,000,000 USD in 
2001 to $10,000,000 USD in 2007 all the way down to $1,000 USD in 2015 via 
the arrival of Illumina’s X-Ten sequencing system 
(http://www.illumina.com/systems/hiseq-x-sequencing-system/system.html). 
With the arrival of the $1,000 genome, both population scale and large disease 
genome sequencing studies have become economically feasible for the first time, 
although it must be mentioned these figures do not factor in the significant 
storage and analysis costs required for such large data sets (14).  
 
1.7 Sequence data growth 
Decreasing per-base sequencing costs means an ever-growing number of 
studies are using NGS sequence data to detect causal variants in a variety of 
diseases (15, 16), and that more and more genomes are being sequenced 
worldwide every year. In fact, it is estimated that 228,000 human genomes will 
be sequenced in 2015 which represents more genomes than have been sequenced 
up to the end of 2014 in total (5). Already, large population studies are being 
published such as the recent project sequencing 2636 Icelanders where 
researchers found an over-representation of homozygosity and rare protein-
coding variants, many of which proved important for disease (17). Ambitious 
plans are being formulated around the world to sequence millions more genomes 
in the coming years; for example Genome England recently announced their 
intention to sequence 100,000 genomes (http://www.genomicsengland.co.uk/the-
100000-genomes-project/), the NIH announced their plans to sequence 1,000,000 
genomes (http://news.sciencemag.org/biology/2015/01/white-house-fleshes-out-
obama-s-215-million-plan-precision-medicine), and China is discussing similarly 
ambitious plans (18). The decrease in sequencing cost is fuelling such projects 
and locally we observe huge increase in use of our infrastructure with almost 
1000 whole human genomes analysed as of December 2015, the majority of 
which have been analysed in the last 18 months following the arrival of the 
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Illumina X-Ten sequencing cluster at the Garvan Institute in Sydney 
(https://www.garvan.org.au/research/kinghorn-centre-for-clinical-
genomics/clinical-genomics/sequencing-services/hiseqXTen). Collectively, these 
and other ongoing sequencing projects mark the beginning of the big-data era in 
the health sciences.  
 
1.8 Computational challenges 
While the ability to generate huge amounts of sequence data in a cost 
effective manner removes a long-standing technical bottleneck, it presents 
several new computational challenges requiring flexible and robust software 
solutions. The first major challenge to address with large NGS data sets is how to 
effectively manage and analyse the data from increasingly large numbers of 
often-related samples. With each 30X whole genome sample typically generating 
0.1 terabyte (TB) of compressed raw sequence data and requiring hundreds of 
hours of compute time for basic variant detection alone, a great need exists for 
robust, flexible, and mature high-throughput bioinformatic analysis pipelines. 
The second major challenge is how to prioritise the huge number of variants 
detected in an individual genome in order to identify causal variant(s) 
responsible for the disease in an affected individual. This is a particularly 
daunting challenge given that each genome has a huge number of mostly benign 
variants with the average person having roughly 6 million SNVs, 650000 small 
indels, 14000 structural variants, and 250-300 loss of function variants (19). 
While numerous solutions exist to address both these challenges, there are 
currently no gold standard methodologies for either task resulting in an 
increasing number of in-house custom analysis pipelines and tools that string 
together a combination of various open source software and custom code.  
 
1.9 Clinical application 
One increasingly common application of NGS technology is the 
sequencing of individuals with rare monogenic diseases, a large worldwide 
health problem with one in every fifty individuals worldwide affected by one of 
the estimated 10000 rare monogenic diseases 
(http://www.who.int/genomics/public/geneticdiseases/en/index2.html). With 
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recent studies showing how treatment options can be altered based on patient 
variant information (16), clinicians are increasingly incorporating such 
information in their practice to identify both disease-causing and risk-factor 
variants that predispose patients to certain disease (20). Challenges remain 
however and while algorithms for reliably detecting variants from sequence data 
are relatively mature (21), the routine use of patient variation data to improve 
clinical outcome remains elusive with no ‘gold-standard’ methodology 
describing a current set of best practices. Initiatives such as the CLARITY 
challenge (22) are attempting to describe such best practices, while other more 
general frameworks such as ADAM (23) are tackling genomic data sharing 
issues, aiming to forge common standards and protocols to make sharing and 
computing genomic data seamless.  Despite these ongoing efforts, global 
standards remain elusive and in the interim increasingly complex in-house 
analysis pipelines are being developed to detect clinically significant variants. 
Standardising such analysis pipeline remains challenging due to numerous 
factors such as the wide variety of available analysis software (21) and project-
specific variant prioritisation strategies. Further, even when software choices are 
standardised, pipelines may still differ with regard to software version and 
parameters utilised with such differences often having a significant effect on 
variant calls. For example, SAMtools v0.1.19 incorporated base alignment 
quality (BAC) filtering as a default parameter for the first time, a change which 
produced a huge difference in the total number of variants called relative to 
earlier software versions.  Despite all these challenges, progress toward 
standardization has begun largely from the widespread use of the GATK system 
(24), although even within this framework there are two distinct algorithms for 
detecting variants, namely the unified genotype caller and the haplotype caller, 
both of which are typically updated during each new GATK release.   
 
1.10 Analysis pipelines 
Given the large number of in-house analysis pipelines, numerous options 
for the overall management of informatics pipelines have been developed which 
can be divided into easy to use web application like GALAXY (25) and Taverna 
(26) and language specific frameworks such as GATKs queue 
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(https://github.com/broadgsa/gatk/) or Bpipe (27). Developing a robust 
framework that is generalizable for the majority of common use-cases proves 
challenging however, with most software making assumptions about the inherent 
nature of the analysis pipeline. For example, frameworks commonly assume that 
any analysis workflow will be linear and processive, consisting of a series of 
discrete analysis steps such as sequence data quality control (QC), alignment, 
variant calling, annotation and variant prioritization. This assumption does not 
hold for all workflows however, with recent studies demonstrating significant 
differences in variant call quality between individual software and pipelines (28, 
29) meaning any enduring genomics framework must be designed to be highly 
flexible from the onset. 
   
1.11 Introduction for publication #1:  
“Reliably detecting clinically important variants requires both combined variant 
calls and optimized filtering strategies” (30) 
Given these known differences in software/pipeline performance, one 
approach is to aggregate variant calls from multiple software tools, with such 
results shown to yield an overall improvement in both sensitivity and specificity 
compared to any individual tool (31).  While running a linear analysis pipeline is 
suitable in many instances, it has become increasingly clear multiple variant 
callers are preferable, particularly in circumstances where either minimizing 
false positives or false negatives variants is a priority. For example, a pipeline 
designed for clinical use should focus on reducing the number of false negative 
variants, as failing to detect clinically important variants may represent a missed 
opportunity to improve clinical outcome. This publication details a 
comprehensive three-part study first assessing whether the choice of software 
and variant filtering impacts the overall variant call quality and secondly, using a 
melanoma cell line, if clinically important melanoma risk factor variants are 
uniformly detected under all software conditions tested. Lastly, I simulate 
various sequence contamination levels to determine whether contamination issue 
impacts variant callers uniformly, an important consideration when sequencing 
cancer samples which typically suffer from contamination (32).  Overall, the 
results imply careful software selection, variant caller filtering optimization, and 
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combining variant calls from multiple tools are all required to minimize false 
negative variants, an important consideration when utilizing variation data in a 
clinical context. 
 
1.12 Introduction for publication #2:   
“Reducing the search space for causal genetic variants with VASP: Variant 
Analysis of Sequenced Pedigrees” (33) 
While NGS data have proven extremely successful in studying 
monogenic diseases, it is increasingly common to sequence large numbers of 
individuals with polygenic or complex disease such as autism (34) or auto-
immune diseases (http://jcsmr.anu.edu.au/research/cpi). While the sequencing of 
unrelated individuals has resulted in the successful discovery of causal/disease-
associated variants for monogenic (15) and complex disease (35), many causal 
variants remain unidentified and are effectively lost in the noise arising from the 
millions of benign variants detected in each sample which produce no phenotype 
or are not related to the phenotype of interest. With 2% of all people carrying a 
non-damaging missense mutation in any given gene (36), routinely 
differentiating causal variants from background variation typically requires 
additional information to reduce the search space for causal variants. One of the 
simplest ways to reduce the search space is to sequence both affected and 
unaffected family members of a proband, as we are then able to both prioritize 
variants common to affected individuals and exclude benign variants shared 
between affected and unaffected individuals (37).  Being able to easily detect 
such private familial variants is important, particularly with studies identifying 
such variants as being causal (38). When sequencing a pedigree, in addition to 
yielding information on variant distribution within a pedigree, we can obtain 
additional pedigree level annotation information such as disease inheritance, 
genome phasing, and compound heterozygosity. We are able to  utilize this 
additional information for prioritization that is unavailable unless family 
members are sequenced. While numerous tools exist for variant prioritization 
within a single genome (39), the ability to concurrently analyse variants within 
pedigrees remains a challenge, especially should there be no prior indication of 
the underlying genetic cause of the disease. While tools are emerging to detect 
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causal variants in sequenced pedigrees, they tend to focus either on removing 
variants based on criteria deemed unlikely to be causal (40) or on variants 
matching specific inheritance models such as auto-dominant (41) or compound 
heterozygotes (42).  
 This publication describes the software package I wrote to reliably detect 
causal variants in sequenced pedigrees for any genetic disease, whether 
monogenic or complex (https://github.com/mattmattmattmatt/VASP). Designed 
to aggregate data for genetic variants across the entire pedigree without making 
any underlying assumptions regarding disease transmission mechanism, VASP 
enables powerful and customizable variation prioritization, allowing researchers 
to utilize their knowledge of the disease (e.g. expected inheritance pattern or 
mapped genomic region) to reduce the search space for causal variants. This tool 
enables users to greatly reduce the number of candidate causal variants down to a 
size suitable for manual interrogation, using single variant and pedigree-wide 
annotation coupled with custom filtering criteria.  
 
1.13 Introduction for publication #3:  
 “Tumour procurement, DNA extraction, coverage analysis and optimisation of 
mutation-calling algorithms for human melanoma genomes” (43) 
While NGS has successfully been utilised to detect causal variants in all 
types of Mendelian diseases, one of the earliest adopters of NGS sequencing is 
cancer sequencing and the accurate detection of somatic variants. In this 
approach, paired tumour and normal whole genome samples are sequenced in 
order to comprehensively characterise cancer genomes in a variety of tumour 
types (44).  The nature of variation in cancer genomes is fundamentally different 
from non-cancer genomes (inherited mutations germ line are thought to be 
important in only 5-10% of cancers (45)) with much of the current understanding 
of the genetics of cancer based on the understanding that a clone accumulates 
somatically acquired mutations that ultimately leads to malignant transformation 
(46). Large-scale cancer genome sequencing is actively being used to identify 
important somatic variants, some of which has been successfully translated into 
novel customised therapies. In melanoma for example, activating mutations of 
the MAPK pathway activator gene BRAF were first identified by routine genetic 
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screening and later shown to be highly prevalent across a number of cancers 
including melanoma (47). Following this discovery, BRAF inhibiting drugs were 
developed and then shown to arrest melanoma growth in a high percentage of 
BRAF mutation-positive patients and to prolong survival in advanced, metastatic 
melanoma – representing the first systemic therapy to do so (48). Importantly, 
this early success story demonstrates how the detection of a single somatic 
mutation led to the development and widespread adoption of a targeted therapy.  
Generally the first step in identifying possible novel therapeutic targets 
for any cancer type is the characterisation of the cancer genome in question, as is 
being done for numerous cancers via large-scale cancer sequencing efforts such 
the International Cancer Genome Consortium (ICGC) (49) and the Cancer 
Genome Atlas (TCGA) (http://cancergenome.nih.gov/). Both tumour and normal 
genomes need to be sequenced and somatic variants identified with tools such as 
MuSiC (50) and MuTect (51), software designed specifically to detect somatic 
variants in paired cancer samples. While such tools are suitable for many cancer 
types, differences with regard to both tumour purity (32) and mutational 
heterogeneity (52) amongst cancers means custom workflows are often required. 
In support of Bioplatforms Australia melanoma initiative to characterise the 
melanoma genome (http://www.bioplatforms.com/melanoma/), I developed a 
custom melanoma analysis pipeline to analyse 150 melanoma whole genomes, 
the largest melanoma genome sequencing project at the time. In this project, an 
initial pilot data set was generated sequencing three cancer genomes (primary 
tissue, metastatic tissue, and a metastatic cell line) to high coverage in order to 
empirically determine optimal coverage levels required for tumour and normal 
samples for each type of sample.  Once coverage levels were determined I 
reviewed both existing and custom solutions for detecting somatic variants in 
paired cancer genomes, analysing all three samples with a variety of tools before 
ultimately incorporating the best performing software into the pipeline.  
 
1.14 Introduction for publication #4:  
 “Comparison of predicted and actual consequences of missense mutations”. (53) 
 While fundamentally different sample types such as paired cancer or 
sequenced pedigrees require custom workflows, a common requirement of all 
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workflows is the prioritisation of the huge number of variants typically detected 
in each sample. Most workflows do this by incorporating a post-variant detection 
annotation step using tools such as AnnoVar (54) or Variant Effect Predictor 
(VEP) (55) to identify missense, nonsense, and splice-site mutations. With each 
genome containing thousands of missense variants and very few exhaustive 
experimental data sets available, practical interpretation of the functional 
consequence of missense mutations typically relies on a variety of functional 
inference tools such as Polyphen2 (56), SIFT (57), or CADD (58).  Most, if not 
all of the most accurate tools, rely heavily on multiple protein sequence 
alignment, with changes to highly conserved amino acids thought to be more 
damaging to a protein than changes to a non-conserved amino acid. While a 
useful approximation in many cases, it makes scoring of missense mutations 
extremely sensitive to the initial transcript selected for each organism included in 
the alignment (59), an important consideration now that the tools are being used 
to prioritise variants in the clinic. Unfortunately, clinicians are beginning to 
discover that in some cases the tool’s ability to predict the severity of the 
disruption to protein function does not always correspond to the observable 
clinical outcome or disease progression. For example, while prediction of the 
severity of missense mutations in the tumour suppressor gene TP53 shows some 
correlation to clinical outcome, the correlation is not significant (60). This 
observation and others of this nature have led many to conclude that functional 
inference tools lack the precision required for clinical usage (61). Given these 
known issues for individual tools, software has been developed to integrate the 
prediction of various individual tools, tools such as the popular Condel (62) 
which uses a weighted average of the normalised prediction scores. While such 
tools have been shown to improve accuracy in functional inference predictions 
(perhaps due to the minimisation of outlier effects), there is no large reduction in 
the number of missense mutations predicted to be damaging that do not cause an 
observable phenotype.  
 In two separate analyses, we attempted to measure the efficiency of the 
functional inference tools with the hope of gaining an understanding of the 
nature of the functional inference tools apparent ‘overcalling’ problem. The first 
data set consisted of 33 missense mutations bred to homozygosity in N-ethyl-N-
nitrosourea (ENU) treated mice spread across 23 essential immune system genes, 
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the mice identified as part of our larger system developed to identify protein 
altering mutations in the exome sequence of progeny from ENU treated G1 mice. 
In this data set we showed how only ~20% of missense mutations predicted to 
disrupt protein function produced a discernible phenotype, essentially replicating 
earlier studies that highlighted this overcalling problem. Several explanations for 
this overcalling phenomenon have been previously proposed, the most common 
being variable penetrance. While this experiment sidesteps the issue of variable 
penetrance (all genes caused a fully penetrant, detectable, and well-characterised 
phenotype when rendered null), two possible explanations for the overcalling 
remain. First, the possibility exists that defects in the immune system are being 
masked in vivo by compensation and the environment. The second possible 
explanation is that the differences between mouse and human proteins are 
responsible for the overcalling as most tools are calibrated using human protein 
data, so possibly the tools are inappropriate for scoring missense variants in non-
human variants. To address both these concerns, we utilized the exhaustive TP53 
data, where transcription enhancing activity measurements are available for all 
possible missense mutations (63). In this analysis, we compared comprehensive 
functional assay data with functional inference scores from a variety of tools and 
conclude that for all tools tested, almost half of all missense mutations predicted 
to be damaging produce no phenotype.  We conclude that there exists a subclass 
of “nearly neutral” (64) mutations that are subject to purifying selection yet 
produce little impact on clinical phenotype in any individual, a class of variants 
likely responsible for the apparent overcalling phenomenon.  
 
1.15 Introduction for publication #5:  
 “DeepSNVMiner: A sequence analysis tool to detect emergent, rare mutations in 
sub-sets of cell populations” (65) 
 While NGS sequence data typically is derived from a single 
homogeneous population, an increasing number of researchers are performing 
massively parallel sequencing on mixed populations of cells representing both 
wild type and disease state. Applications for this technology are broad ranging, 
with current examples including the detection of sequence variation in a variety 
of cancer subtypes (66) and the identification of the emergence of drug resistant 
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point mutations in virus (67) to name a few. The central technique that enables 
the mix of cells to be disambiguated is the attachment of a random unique 
identifier sequence (UID) to each DNA molecule either prior to or during the 
amplification step (68).  By attaching the UID at the onset, even though 
subsequent polymerase amplifications may introduce errors, real variants can be 
differentiated from amplification variants by grouping sequences with common 
UIDs and detecting variants within each group. While the laboratory techniques 
for attaching UIDs are relatively mature, there is currently no software capable of 
routinely detecting variants from mixed cell sequence data with UIDs attached.  
 To address this, I developed the software DeepSNVMiner to detect 
variants in these mixed data sets, a resource publicly available on github 
(https://github.com/mattmattmattmatt/DeepSNVMiner).  DeepSNVMiner allows 
robust and reliable identification of sequence variants present in a subset of 
sequences within a mixed DNA input sample.  This tool runs workflows required 
to support SafeSeq and similar UID tagged sequence datasets, and enables 
variant detection from single DNA molecules present within mixed 
heterogeneous sequence data.   
 
1.16 Introduction for publication #6:  
 “Massively parallel sequencing of the mouse exome to accurately identify rare, 
induced mutations: an immediate source for thousands of new mouse models” 
(69) 
 While this introduction has thus far focused on sequence data from 
human samples, another widespread application of NGS data is the sequencing 
of model organisms such as the mouse, an organism which has traditionally been 
used for modelling human disease and comparative genome analysis. There are 
over 450 inbred strains of mice (70) representing a wealth of phenotype and 
genotype varieties available for genetic study in addition to a large number of 
mouse models of human disease. Genetic analysis of mouse is typically 
performed on the C57BL/6 strain or another inbred strain due to the uniform 
genetic background. One common means of studying disease in the mouse is via 
treatment with N-ethyl-N-nitrosourea (ENU), a powerful mutagen that generates 
random single nucleotide germ line mutations allowing observable resultant 
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changes in traits or disease to be detected by phenotypic screening procedures 
(71).  While ENU screening has proven extremely successful it has traditionally 
been an extremely expensive and time-consuming process in which affected 
mice are outcrossed to another inbred mouse strain and causal variants 
meiotically mapped to a subregion of the genome using a panel of strain specific 
variants.  Following this, genes within each mapped region are identified with all 
exons Sanger sequenced and the causal variant identified within this reduced 
genomic region. While this method proved extremely successful, it is unsuitable 
for high-throughput sample processing primarily due to the investment required 
to take each mutation forward. Alternatively, it was theorised that if it proved 
possible to identify the causal variant by sequencing a mutated mouse, the time 
and cost required would drop dramatically making high-throughput processing 
possible. Further, as almost all ENU-induced causative mutations have been 
located either in exons (~75%) or splice donor-acceptor sites (~25%) (72), it is 
appropriate to utilize targeted exome sequencing to generate sequence data for 
the causal variants. 
 In this publication, we describe the high-throughput variant detection 
pipeline we built to reliably identify rare, ENU-induced de novo mutations in 
exome data from C57BL/6 mice.  While previous studies had suggested that 
exome sequence alone may not be enough to identify disease-causing induced 
mutations without extensive SNV validation (73), we have shown that exome 
sequencing as a sole source of information is sufficient by itself to identify ENU-
induced mutations selected by phenotype. The reliable detection of ENU-induced 
causal mutations from exome sequencing greatly reduces both the time and cost 
of ENU screening and offers an immediate source of thousands of new mouse 
models. 
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Abstract
A diversity of tools is available for identification of variants from genome sequence data.
Given the current complexity of incorporating external software into a genome analysis
infrastructure, a tendency exists to rely on the results from a single tool alone. The quality of
the output variant calls is highly variable however, depending on factors such as sequence
library quality as well as the choice of short-read aligner, variant caller, and variant caller fil-
tering strategy. Here we present a two-part study first using the high quality ‘genome in a
bottle’ reference set to demonstrate the significant impact the choice of aligner, variant cal-
ler, and variant caller filtering strategy has on overall variant call quality and further how cer-
tain variant callers outperform others with increased sample contamination, an important
consideration when analyzing sequenced cancer samples. This analysis confirms previous
work showing that combining variant calls of multiple tools results in the best quality resul-
tant variant set, for either specificity or sensitivity, depending on whether the intersection or
union, of all variant calls is used respectively. Second, we analyze a melanoma cell line
derived from a control lymphocyte sample to determine whether software choices affect the
detection of clinically important melanoma risk-factor variants finding that only one of the
three such variants is unanimously detected under all conditions. Finally, we describe a
cogent strategy for implementing a clinical variant detection pipeline; a strategy that
requires careful software selection, variant caller filtering optimizing, and combined variant
calls in order to effectively minimize false negative variants. While implementing such fea-
tures represents an increase in complexity and computation the results offer indisputable
improvements in data quality.
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Introduction
Rapid improvements in massively parallel sequencing technologies have dropped the cost of
sequencing to the point where it is feasible to use patient sequence data in the clinic in order to
identify both disease-causing and risk-factor variants that predispose patients to certain disease
[1]. While data-specific computational algorithms aimed at deriving accurate data from these
technologies have reached maturity [2], the routine use of genomic data for improving clinical
diagnosis and treatment requires formalizing existing research methods into clinical best prac-
tices; the goal of recent initiatives like the CLARITY challenge [3]. In the interim, bioinformati-
cians are increasingly developing local, in-house production variant detection pipelines, the
core of which typically consists of a highly customized workflow utilized by a relatively small
local user-base, being developed out of necessity as few available software systems support the
easy ‘pipelining’ of large biological datasets through multiple analytical tools to produce the
desired end result. As a result, standardization of such pipelines is challenging largely due to
the diversity of rapidly developing software tools being utilized, though some progress toward
standardization efforts are beginning to emerge from the widespread use of the GATK software
package [4].
The last several years has seen the creation of software frameworks for the management of
bioinformatics pipelines which generally fall into two categories; easy to use GUI and web
based approaches like GALAXY [5] and Taverna [6] compared to language specific frame-
works such as GATK’s Queue (https://github.com/broadgsa/gatk/), BPipe [7] and Snakemake
[8]. While these tools do address many of the key requirements of a high-throughput informat-
ics systems, they typically anticipate that analysis will be linear and processive, an assumption
which does not hold true in many instances. In addition, surprisingly few of these tools cur-
rently support large numbers of users, with the notable exception of GALAXY, which enjoys
active support from a large broad-based community of users and developers (https://biostar.
usegalaxy.org/). GALAXY and other web-based tools however, are not always the immediate
choice for a high-volume production system due to potential challenges with transferring large
volumes of data and the unavailability of highly specialized workflows.
Given the fast moving nature of both sequencing technologies and bioinformatic software
development, successful and enduring informatics frameworks must remain flexible with
regard to software selection, a central idea in the development of Bioconductor [9]. Such flexi-
bility requires systems to routinely evaluate new software particularly in light of recent publica-
tions demonstrating low concordance levels between variant detection pipelines [10, 11]. Such
differences arise not only due to software choices but also due to sequencing technology choices
with studies demonstrating large differences in variant calls using different exome capture sys-
tems [12–14] and whole genome sequencing platforms [15, 16]. While the choice of sequencing
technology and software is important, the internal parameters utilized for each algorithm are
also important, particularly the filtering options employed by variant callers, a feature known
to affect the overall variant call quality [17, 18]. Another important consideration for a frame-
work is the ability to support testing software both in isolation as well as in various combina-
tions (e.g. aligner / variant caller pairs) with previous studies showing the choice of short read
aligner significantly impacts downstream variant calling, particularly for indels [19]. Further,
with additional studies reporting both platform-specific [15, 20, 21] and software-specific [19]
variants, it is clear that ideally a framework will support variant calls from multiple tools and
sequencing platforms, particularly when avoiding false negative variants is the highest priority,
as is the case when using variation data in a clinical context.
Assessing the quality of variant calls from any variant detection pipeline is greatly facilitated
by the recent development of high quality reference data sets such as ‘genome in a bottle’ or
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GIAB [22]. Studies demonstrating low concordance levels amongst variant callers [23, 24]
demonstrate the importance of software selection and highlight the need for standardized
frameworks such as GCAT [25] which make it possible to assess variant calls relative to a set of
validated high quality variants. While such frameworks are useful for accessing the results
from a single processive analysis, tools such as BAYSIC [26] have shown that aggregating vari-
ants from multiple variant callers yields an overall improvements in both sensitivity and speci-
ficity compared to any individual tool, making it increasingly clear multiple variant callers are
preferable in circumstances where either minimizing false positives or false negatives are cru-
cial to a project. While many aspects of variant calling algorithms are similar, combining them
leads to a substantial improvement in output quality justifying their use in parallel in certain
circumstances. The utility of this approach is that through combining the relative sensitivities
of different tools, a broader sensitivity is gained through taking the union of multiple calling
methods. Similarly, performing variant calling through different algorithms in parallel, the
quirks or systematic errors of a single tool may be overcome by taking the intersection of
multiple approaches. It is for these reasons we have enabled combined variant calls in our in-
house high throuhgput production system, yet, given these advantages, few specific workflows
used in practice allow integrating tools in parallel in such a manner. This may be due to the
increased computational load or due to structural limitations of workflow management tools.
In this work we first seek to demonstrate the significant impact the choice of aligner, variant
caller, and variant caller filtering strategy has on both the number and quality of variant calls
using high quality NA12878 genotype calls as a baseline (ftp://ftp-trace.ncbi.nih.gov/giab/ftp/
data/NA12878/analysis/GIAB_integration/). Next, using the same data set, we replace increas-
ing portions of the GIAB sequence data with non-variant reference data to determine the effec-
tiveness of variant callers at increasing levels of simulated sample contamination. This is
important given the increased use of sequenced cancer data in the clinic with cancer samples
known to differ with regard to tumour purity [27], mutational heterogeneity [28], and subclon-
ality [29]. Finally, using a melanoma cell line control sample, we demonstrate the impact the
choice of software and filtering strategy has on the detection of clinically important melanoma
risk-factor variants. For all analyses, the three different variant types assessed in this study
(SNVs, small insertions, and small deletions) are analyzed independently to assess whether any
single algorithm is superior to all others tested for all variant types. We conclude by presenting
a cogent strategy for implementing a variant detection pipeline for clinical use; a pipeline
focused on minimizing the total number of false negative variants.
Materials and Methods
Samples
GCAT Sample. The two FASTQ files ‘illumina-100bp-pe-exome-150x’ were downloaded
from GCAT (http://www.bioplanet.com/gcat) and variant calls compared against GIAB high-
confidence genotypes for NA12878 (ftp://ftp-trace.ncbi.nih.gov/giab/ftp/data/NA12878/
analysis/GIAB_integration/). The sequence data consists of 45 million 100bp read pairs for
estimated exome coverage of 150X.
Melanoma cell line control sample. Biospecimens were provided by members of the
ABN-Oncology group, which is funded by the National Health and Medical Research Council.
Sample C001 is a control lymphocyte derived sample from a female patient available for down-
load at https://ccgapps.com.au/bpa-metadata/melanoma/sample/102.100.100.7688/ with the
corresponding tumour sample (not used in this analysis) also available at https://ccgapps.com.
au/bpa-metadata/melanoma/sample/102.100.100.7687/. For sequencing, the library construc-
tion was performed using TruSeq DNA Sample Preparation kits as per Illumina instructions.
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1 μg of sample DNA was fragmented into 300–400 bp average insert size with 3’ or 5’ over-
hangs. End repair mix was then used to convert the fragmented DNA into blunt ends by
removing the 3ʹ overhangs and the polymerase activity fills the 5’ overhang. The 3’ ends were
then acetylated to add a single “A” nucleotide to the 3’ to reduce chimera formation. Ligate
adapters were then used to attach adapters to the DNA fragments so they could be loaded into
a flow cell and purified to remove unligated adapters to generate a final product with an insert
size of 300–400 bp. PCR was then used to selectively enrich DNA fragments with adapter mole-
cules at both ends for sequencing. Post amplification quality controls were performed using
DNA High Sensitivity Labchips (Agilent Bioanalyzer). The libraries were then pooled and clus-
tered using the iBOT and ready for sequencing. The 100 bp pair-end library was sequenced on
a Hiseq2000 using a Truseq SBS V3-HS kit. The sequence data for C001 consists of 925 million
100bp read pairs for an estimated genome-wide coverage of 60X.
System and Implementation
All analyses described was performed using an in-house production genomics analysis frame-
work; a framework which bundles analytical processes as externally developed, compiled
binary objects, driven by a custom Perl module layer that wraps individual tools. Each step in
the workflow is driven at a scripting level and the command to these driver scripts and the
associated parameters are defined within an XML configuration file—which allows customiza-
tion, quick tool substitution, and straightforward change and extension of the workflow. Fur-
thermore, archived workflows may be easily recreated with this static XML file from a
particular analysis, along with the code repository revision number, allowing quick reproduc-
tion of archived analyses. Initially designed to detect SNVs in the exome sequence of progeny
of C57BL/6 laboratory mice exposed to the spermatogonial point-mutagen N-ethyl-N-nitro-
sourea (ENU) [30], the expanded framework includes workflows for SNV/indel detection in
human exomes and genomes, as well as custom multi-sample workflows to identify causal vari-
ation across sequenced human pedigrees [31] and paired tumour-normal analyses [32]. The
total versioned code-base currently utilizes an ever-changing catalogue of open-source compo-
nents combined with bespoke analysis tools–currently all linked via an underlying MySQL
(http://www.mysql.com) tracking database (S1 Fig) designed for persistence, archiving and
querying of summary results. A more detailed description of the design and implementation of
the system can be found in supplementary data (S1 File).
Expanded Software Assessment
The default variant calling workflow (S2 Fig) was expanded to pair three short read aligners
(BWA [33], Bowtie 2 [34], and Isaac-aligner [35]) with three variant callers (GATK [4], Isaac-
variant-caller [35], and SAMtools [36]), each of which was run with both with and without
additional filtering (Fig 1). For all 18 possible aligner/variant caller pairs, software was run
using either default options or as per suggestions in associated documentation (S1 Table). For
each aligner, reads were aligned to the human reference genome (assembly GRCh37) and a
sorted, indexed BAM file generated using SAMtools. Each BAM file was provided as input to
each variant caller to generate a VCF file of unfiltered variant calls. To obtain filtered variant
calls, GATK was run through variant quality score recalibration steps (VQSR) as documented
at https://www.broadinstitute.org/gatk/guide/article?id=2805, SAMtools was run with and
without full BAQ filtering and Isaac variant had all LowGQX annotated variants removed
(defined as variants with a GQX score less than 30 or not present with GQX being the mini-
mum of genotype quality score assuming variant and non-variant locus). Next, all variants
with quality scores of less than 40 were removed and variants regularized using custom code
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and further divided into SNVs, insertions, and deletions lists. These lists were reduced to only
variant contained in the high quality genotype GIAB regions and finally compared to the corre-
sponding GIAB variant type to obtain false positive rates. False negative rates were estimated
by taking all variants in the high confidence variant calling regions found to also overlap
ENSEMBL v75 canonical transcripts. This reduction in variant search space was required to
account for the fact that exome sequence data was utilized in this analysis.
Variants were classified as matching when the following criteria were met:
1. both variants are of the same types; either SNV, insertion, or deletion
2. both variants share the same start coordinate
3. both variants share the same end coordinate
To ensure consistent reporting of genomic coordinates for indels (an issue particularly
problematic with indels falling in repetitive genomic sequences), vcf files are regularized with
Fig 1. AnalysisWorkflow. BAM files from BWA, Isaac aligner, and Bowtie2 were paired with each of GATK, Isaac variant caller, and SAMTools run both
with and without additional filtering (VQSR, BAQ, and LowGQX respectively). Output vcf files were regularized using custom code and variants from GIAB
high quality regions taken forward to generate false positive and false negative rates.
doi:10.1371/journal.pone.0143199.g001
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indels assigned the lowest genomic coordinate; for example a missing GC in a string of repeat-
ing GC’s is recorded as a deletion of the first GC encountered in the 5’ to 3’ direction within
the larger repeat sequence range. Results are summarized for SNVs, deletions, and insertions
(S2–S4 Tables respectively).
Individual Software Assessment
To assess both the number and quality of variant calls for each aligner and variant caller in iso-
lation, for each tool the union of all variants from all pairing was calculated and overlapped
with GIAB variants and false positive and false negative rates calculated. For example, to assess
GATK SNV calling efficiency, the union of SNVs called by GATK (paired with BWA, Bowtie2,
or Isaac aligner input) was calculated and the merged list subsequently compared with high
quality GIAB SNVs. Variant calls unique to a single software tool were also identified (referred
to as ‘tool-specific variants’) and independently compared to GIAB variants to obtain false pos-
itive rates.
Overall Software Concordance
To measure the concordance of variant calls between the three aligners, the union of variants
detected by each aligner was calculated and both Venn diagrams (Fig 2) and ROC curves plot-
ted using genotype quality score (Fig 3) with the R packages VennDiagram [37] and ROCR
[38] respectively. Similarly, variant caller concordance compared the output of GATK, Isaac
variant caller, and SAMtools for both unfiltered and filtered variant calls. To assess how overall
variant quality changed relative to the frequency of detection the number of times a variant
was detected by all aligner / unfiltered variant caller pairs was calculated and divided into four
categories; variants detected by at least 1 pair (union), variants detected by all 9 pairs (intersec-
tion), variants detected by 2–8 pairs, and variants detected by only 1 pair.
Heterogeneous Sample Simulation
To determine the impact of sample heterogeneity on variant detection, increasing portions of
GIAB sequence data was replaced with mutation-free reference genome reads generated using
the SAMtools utility wgsim. For each simulated contamination level, the total sequence cover-
age level was kept constant at 150X with contamination levels of 0%, 25%, 50%, 75%, 90%,
95%, 98%, and 99% generated. At each level, reads were aligned to the reference genome with
BWA and SNVs called with GATK, Isaac variant caller, and SAMtools with filtering applied.
False negative and false positive levels were obtained by comparing variant calls to the GIAB
high quality variant regions.
Clinically Important Variants
To identify clinically important variants, all melanoma cell line control variants were over-
lapped with ClinVar (downloaded on October 24, 2014; [39]) and ClinVar entries classified as
‘pathogenic’ or ‘risk factor’ were identified with any melanoma risk factors variants prioritized.
Results
Individual Software Assessment
For each software tool, the union of all variants and tool-specific variants was calculated with
false positive and false negative rates determined for SNVs (Table 1), deletions (Table 2), and
insertions (Table 3). For each variant type, the false positive and false negative rates differed
substantially with even greater differences observed for the tool-specific variants. For the
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aligners, BWA called the greatest number of total SNVs and deletions while Bowtie2 generated
the most insertion calls. While Isaac aligner had fewer variant calls in general it had the lowest
false positive rates for SNVs and deletions, with BWA having the lowest false positive rate for
Fig 2. Software concordance Venn diagrams.Merged variant calls for each tool were overlapped with other tools of the same variety for each variant type.
Aligners are compared in row 1, variant callers without filtering in row 2 and variant callers with filtering in row 3.
doi:10.1371/journal.pone.0143199.g002
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insertions. Considering false negative rates, BWA had the lowest rate for SNVs and deletions
while Bowtie2 had the lowest rate for insertions. For the tool-specific variants, the results dif-
fered relative to variant type with BWA calling the most SNVs with the second lowest false pos-
itive rate, Bowtie2 calling the most deletions with the lowest false positive rate, and Isaac
aligner calling the most insertions with the lowest false positive rate. For the unfiltered variant
calls from the three variant callers, GATK called ~25% (59,275) more SNVs than either
SAMtools or Isaac variant caller while SAMtools called the greatest number of insertions and
deletions. SAMtools had the lowest false positive rate for SNVs while Isaac variant caller had
the lowest false positive rate for insertions and deletions. For the false negative rate, SAMtools
Fig 3. Software concordance ROC curves.Merged variant calls for each tool were calculated and ROC curves generated using the genome quality score.
Aligners are compared in row 1, variant callers without filtering in row 2, and variant callers with filtering in row 3.
doi:10.1371/journal.pone.0143199.g003
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had the lowest rate for deletions, Isaac variant caller the lowest rate for insertions, and GATK
the lowest rate for SNVs. Considering the tool-specific variants, SAMtools called the most
insertions and deletions and GATK the most SNVs with GATK-specific variants having con-
sistently low false positive rates, much lower than either SAMtools or Isaac variant caller spe-
cific variants. Finally, for the filtered variant calls, filtering uniformly increased the false
negative rate and decreased the false positive rate for SNVs while the effect on indel calls was
mixed. For indels only GATK filtering resulting in a decrease in the false positive rate with
SAMtools and Isaac variant caller filtering yielding higher false positive rates.
Overall Software Concordance
To assess the concordance of variant calls generated by the alignments from BWA, Bowtie2,
and Isaac aligner, the merged variant lists for each aligner were overlapped to generate Venn
diagrams with a similar approach taken to measure concordance levels between both filtered
and unfiltered variant calls generated by GATK, Isaac variant caller, and SAMTools (Fig 2).
For the three aligners, 73.26% of SNV calls were unanimously detected compared to only
Table 1. Total SNV calls and tool-specific SNV calls for each aligner and variant caller run with and without filtering.
Software Filter Total SNV Calls False Positive Rate False Negative Ratea Tool-speciﬁc SNVs Tool-speciﬁc FP Rate
Bowtie2 N/A 238829 8.44% 3.15% 2050 53.41%
bwa N/A 241513 8.55% 2.96% 3860 39.27%
Isaac_align N/A 183241 4.02% 3.31% 1030 36.12%
GATK None 229215 7.43% 2.91% 59275 15.19%
GATK VQSR 228239 7.06% 2.99% N/A N/A
Isaac_VC None 168348 6.35% 4.27% 7815 32.50%
Isaac_VC LowGQX 79366 4.56% 7.47% N/A N/A
Samtools None 169582 6.12% 3.68% 554 86.64%
Samtools BAQ 107243 3.84% 6.52% N/A N/A
The union of variant calls for each tool was calculated and false positive and false negative rates determined relative to high quality GIAB variants. Tool-
speciﬁc calls were also calculated, deﬁned as SNVs speciﬁc to a single tool.
aFrom bases overlap ENSEMBL v75 canonical transcripts.
doi:10.1371/journal.pone.0143199.t001
Table 2. Total deletion calls and tool-specific deletion calls for each aligner and variant caller run with and without filtering.
Software Filter Total Deletion Calls False Positive Rate False Negative Ratea Tool-speciﬁc Dels Tool-speciﬁc FP Rate
Bowtie2 N/A 3617 33.26% 23.73% 379 29.29%
bwa N/A 3676 30.88% 23.73% 252 46.03%
Isaac_align N/A 2976 25.5% 27.12% 157 43.95%
GATK None 2084 28.69% 27.12% 260 17.31%
GATK VQSR 2049 27.57% 28.18% N/A N/A
Isaac_VC None 2964 26.05% 23.73% 414 45.17%
Isaac_VC LowGQX 1602 31.34% 35.59% N/A N/A
Samtools None 3160 29.4% 27.12% 958 50.21%
Samtools BAQ 3247 30.49% 27.12% N/A N/A
The union of variant calls for each tool was calculated and false positive and false negative rates determined relative to high quality GIAB variants. Tool-
speciﬁc calls were also calculated, deﬁned as deletions speciﬁc to a single tool.
aFrom bases overlap ENSEMBL v75 canonical transcripts.
doi:10.1371/journal.pone.0143199.t002
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58.71% of unfiltered SNVs from the three variant callers. For deletions, the three aligners
shared 55.89% of all deletion calls compared to only 35.58% of unfiltered deletions from the
three variant callers. Lastly for insertions, the three aligners shared 52.89% of all insertion calls
compared to only 32.24% of unfiltered insertions from the three variant callers. In addition to
Venn diagrams, ROC plots were generated for each variant type using genotype quality as
input (Fig 3).
Variant Type Comparison
Variants were segregated based on the frequency of detection for each variant types (Table 4).
Overall, SNV calls exhibiting the greatest concordance levels with 43.45% of the total 245,360
SNVs detected by all pairs, 54.20% detected by 2–8 pairs, and 2.35% detected by a single pair.
Deletions had the next highest concordance levels with 27.61% of the total 4194 deletions calls
Table 3. Total insertion calls and tool-specific insertion calls for each aligner and variant caller run with and without filtering.
Software Filter Total Insertion Calls False Positive Rate False Negative Ratea Tool-speciﬁc Ins Tool-speciﬁc FP Rate
Bowtie2 N/A 4367 27.11% 22.39% 565 35.04%
bwa N/A 4073 20.94% 31.34% 215 61.40%
Isaac_align N/A 4180 31.27% 31.34% 843 14.95%
GATK None 2140 20.56% 35.82% 74 14.86%
GATK VQSR 2105 19.62% 37.31% N/A N/A
Isaac_VC None 3334 19.26% 25.37% 323 56.97%
Isaac_VC LowGQX 1634 23.32% 34.33% N/A N/A
Samtools None 4856 34.1% 22.39% 2102 41.29%
Samtools BAQ 4998 34.87% 20.90% N/A N/A
The union of variant calls for each tool was calculated and false positive and false negative rates determined relative to high quality GIAB variants. Tool-
speciﬁc calls were also calculated, deﬁned as insertions speciﬁc to a single tool.
aFrom bases overlap ENSEMBL v75 canonical transcripts.
doi:10.1371/journal.pone.0143199.t003
Table 4. Variant calls grouped by frequency of detection.
Variant Type Number of times variant detected (out of 9 total software pairs) Total Variant Calls False Positive Ratea False Negative Rate
SNV 9 (Intersection) 106594 3.29% 6.78%
> = 1 (Union) 245360 9.09% 2.90%
2–8 132989 12.18% N/A
1 5777 46.43% N/A
Deletion 9 (Intersection) 1158 14.68% 35.59%
> = 1 (Union) 4194 35.13% 23.72%
2–8 2326 36.54% N/A
1 710 63.80% N/A
Insertion 9 (Intersection) 1415 12.16% 46.26%
> = 1 (Union) 5524 35.36% 19.40%
2–8 2612 26.03% N/A
1 1497 73.55% N/A
Unﬁltered variants were grouped based on the frequency of detection within nine possible aligner/variant caller pairs and segregated into four bins;
variants in all 9 pairs, variants in at least 1 pair, variants in 2–8 pairs, and variants unique to 1 pair.
aFrom bases overlap ENSEMBL v75 canonical transcripts.
doi:10.1371/journal.pone.0143199.t004
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detected by all pairs, 55.46% detected by 2–8 pairs, and 16.93% unique to a single pair. Lastly,
insertions exhibited the lowest concordance levels with only 25.62% of the total 5524 insertions
detected by all pairs, 47.28% detected by 2–8 pairs, and 27.10% unique to a single pair.
Considering the union of all variant calls results in 245,360 unique SNV calls, 5524 unique
insertion calls, and 4194 unique deletion calls with an average of 205,115 SNVs, 3787 inser-
tions, and 3055 deletion calls per aligner/variant caller combination. Within these variant lists,
SNVs had the lowest false positive and false negative rates (9.09% and 2.90% respectively), fol-
lowed by deletions (35.13% FP and 23.72% FN), and insertions (35.36% FP and 19.40% FN).
Considering the intersection of all variants (i.e. only unanimously called variants) generated
106,594 unique SNV calls, 1415 unique insertion calls, and 1158 unique deletion calls, all of
which has lower false positive rates and higher false negative rates as expected. The false posi-
tive rate was 3.29% for SNVs, 14.68% for deletions, and 12.16% for insertions and the false neg-
ative rate was 6.78% for SNVs, 35.59% for deletions, and 42.26% for insertions. Finally, the
variants unique to a single pair contained large numbers of false positives for SNVs (46.43%
FP), deletions (63.80% FP), and insertions (73.55% FP).
Heterogeneous Sample Simulation
Using BWA alignments filtered SNV lists for GATK, Isaac variant caller, and SAMtools were
generated at simulated contamination levels of 0%, 25%, 50%, 75%, 90%, 95%, 98%, and 99%
(Table 5). Each variant caller detected substantially fewer variants as contamination levels
increased resulting in increasing false negative rates. The increase in the false negative rate was
not consistent across all variant callers however, with GATK still able to detect 60% of all SNVs
using only 10% of the original GIAB data compared to only 45% for Isaac variant caller and
35% for SAMtools. In general, GATK coped better with higher contamination levels than either
SAMtools or Isaac variant caller with similar patterns observed for both deletions and
insertions.
Clinically Important Variants
All variants calls from melanoma cell line control C001 were overlapped to ClinVar yielded
2266 matching SNVs and 9 matching deletions, all but four of which corresponded to existing
dbSNP entries. Of the 2266 SNV calls, 1894 were unanimously detected (83.6%), with the
remaining 372 (16.4%) missed by at least one software pair. From the ClinVar annotations,
three variants were annotated as known melanoma risk factors with only one of such variants
unanimously detected by all software combinations (Table 6).
Discussion
Ongoing efforts to characterize genetic variants for clinical action [40] and the ever-increasing
number of previously characterized variants routinely being used for decisions in the clinic [41,
42] illustrate the potential importance of a single variant. From the analysis of the melanoma
cell line control, we identified three important melanoma risk factor variants, two of which
were not detected unanimously under all software conditions (Table 6). One missed risk factor
variant, rs861539, was not detected by Isaac aligner when paired with any of the three variant
callers (SAMtools assigned a failing variant score of 11, Isaac variant caller assigned a failing
variant score of 8, and GATK did not flag the base as variant) highlighting the danger of relying
on a single tool for any analysis step. The other missed risk factor variant, rs1126809, was
missed by a single software combination (Bowtie2 and Isaac variant caller with filtering
applied) as a result of the variant being annotated as low quality, illustrating the danger of
applying aggressive filtering when considering variation data in a clinical context. While these
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two variants are significant in this instance, broader analysis of the GIAB data set showed that
all aligners and variant callers assessed in this study fail to detect true variants that are detected
by other algorithms, implying clinically important variants may be missed even when the top
performing software is utilized. Given the importance of detecting clinically important variants
accurately, the utility of first optimizing filtering strategies for individual algorithms and then
Table 5. SNV calls for GIAB data at simulated contamination levels.
Variant Caller Simulated Contamination Level Variant Calls False Positive Ratea False Negative Rate
GATK 0% 228239 6.62% 3.23%
25% 163041 6.22% 3.76%
50% 113263 5.50% 5.54%
75% 69416 4.77% 13.45%
90% 34018 4.13% 40.74%
95% 17321 4.08% 67.55%
98% 5662 4.06% 88.87%
99% 1696 4.25% 96.46%
Isaac VC 0% 79366 4.51% 7.90%
25% 73259 4.26% 12.84%
50% 61458 4.01% 18.56%
75% 43091 3.90% 31.59%
90% 23146 3.67% 54.76%
95% 10888 3.77% 76.29%
98% 3246 4.13% 92.60%
99% 887 5.41% 97.96%
SAMtools 0% 106332 3.78% 6.39%
25% 83337 3.66% 9.17%
50% 63382 3.46% 14.76%
75% 39853 3.29% 30.92%
90% 16660 3.16% 64.83%
95% 6365 3.03% 85.64%
98% 1534 3.46% 96.45%
99% 371 6.47% 99.18%
BWA alignments were used to generate ﬁltered SNV lists for GATK, Isaac variant caller, and SAMtools at simulated contamination levels of 0%, 25%,
50%, 75%, 90%, 95%, 98%, and 99%. Variant lists were overlapped to GIAB high quality variants to determine false positive and false negative rates.
aFrom bases overlap ENSEMBL v75 canonical transcripts.
doi:10.1371/journal.pone.0143199.t005
Table 6. Melanoma cell line control variant calls overlapping annotated ClinVar melanoma risk factors.
GRCh37 Coordinate
(dbSNP)
dbSNP id Missing Aligner / Variant Caller Pair (F = ﬁltered, U = unﬁltered) ClinVar Annotation
5:33951693 rs16891982 None Malignant melanoma of skin
11:89017961 rs1126809 Bowtie2/Isaac_vc (F) Increased risk of cutaneous
melanoma
14:104165753 rs861539 Isaac_aligner/GATK (U, F) Isaac_aligner/Isaac_vc (U, F) Isaac_aligner/
SAMtools (U, F)
Increased risk of cutaneous
melanoma
Variant calls from melanoma cell line C001 were overlapped to ClinVar and all annotated melanoma risk factors examined. Software pairs failing to detect
these variants are reported in column 3 with variants listed as unﬁltered (U) or ﬁltered (F) to reﬂect whether variant caller ﬁltering was applied.
doi:10.1371/journal.pone.0143199.t006
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combining variant calls from multiple variant callers is apparent as the increased output quality
quickly justifies any increased computation.
Using the GIAB reference data, we compared the false positive and false negative rates of
three short-read aligners paired with three variant callers run both with and without variant
caller filtering for SNVs, deletions, and insertions (S2–S4 Tables). Here we confirmed previous
work that the choice of aligner, variant caller, and variant caller filtering affects both the num-
ber of variants detected and their subsequent quality [11, 21, 23]. To better assess the perfor-
mance of each individual algorithm in isolation the union of all variants generated by each tool
was calculated for SNVs (Table 1), deletions (Table 2), and insertions (Table 3). While each
algorithm tested caused an observable effect on variant call quantity and quality, this effect dif-
fered with regard to the type of variant, the overall false positive and false negative rates, and
the quality of the tool-specific variants. For total variant calls, the variant caller choice had a
greater impact than the aligner choice with 36% more SNVs called by GATK than Isaac variant
caller, 51% more deletions called by SAMtools than GATK, and 127% more insertions called
by SAMtools than GATK. While the choice of aligner had less impact than the choice of variant
caller on total variant number, the effect was still significant with 32% more SNVs called by
BWA than Isaac aligner, 24% more deletions called by BWA than Isaac aligner, and 7% more
insertions called by Bowtie2 than BWA. The false positive rate also differed significantly rang-
ing for SNVs from 3.84% for SAMtools to 8.55% for BWA, for deletions from 25.5% for Isaac
aligner to 33.26% for Bowtie2, and for insertions from 19.26% for Isaac variant caller to 34.87%
for SAMtools. Similarly, the false negative rate varied significantly ranging for SNVs from
2.91% for GATK to 7.47% for Isaac variant caller, for deletions from 23.73% for BWA and
Bowtie2 to 35.59% for Isaac variant caller, and for insertions from 20.90% for SAMtools to
37.31% for GATK. When considering all variants called the range in quality is large, however
the range is even greater when considering tool-specific variants. Tool-specific variants repre-
sent an important variant subset as they serve to highlight differences amongst the individual
algorithm, with such variants being important to consider particularly when minimizing false
calls is a priority. For example, there are 59,275 GATK-specific SNVs of which almost 85% are
true variants meaning these will be missed unless GATK is utilized for SNV calling. While
GATK seems an excellent choice for SNV detection, it calls substantially less tool-specific
indels than SAMtools meaning no single algorithm is optimal for minimizing false calls across
all variant types. Such results demonstrate the utility of tool-specific variants for making
informed decisions about software selection; for example the consistently low false positive rate
of ~15% for all types of GATK-specific variants led us to incorporate it into our production
system. Collectively these results illustrate the significant and often-unpredictable effects the
choice of aligner and variant caller has on variant call quality and highlights the importance of
ongoing software appraisal and optimization.
Another important factor known to affect variant call quality is the filtering strategy applied
by each of the variant caller software suites [17, 18]. Each variant caller employs a distinctive
strategy for filtering; GATK uses variant quality score recalibration (VQSR), SAMtools uses
BAQ filtering, and Isaac aligner annotates questionable variants having low scoring genotype
quality as ‘lowGQX’. While these filtering strategies differ significantly algorithmically, they
share the common goal of trying to remove false positive variants from the original variant
lists. In our analysis, applying these filters mostly resulted in a reduced number of total calls as
expected, with the exception of BAQ filtering which resulted in a slight increase in the number
of indel calls as might be expected given it’s focus on removing false positive SNV calls around
candidate indels. Interestingly, only GATK VQSR filtering reduced the false positive rate and
increased the false negative rate across all variant types with both SAMtools and Isaac variant
caller filtering yielding increased false positive rates for indels indicating potential issues with
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their respective indel filtering strategies. While the reduction in false positive rate is important,
from a clinical context it is important to note that all filtering strategies removes true variants;
ranging from as few as 73 true positive SNVs with GATK to the extreme case of the Isaac vari-
ant caller filtering removing over 100,000 true positive SNVs. Overall, these results highlight
the large effect software choices make in both the precision and recall of variants.
In our analysis, no aligner / variant caller pair outperformed all other pairs across all variant
types, illustrating the importance of selecting software specific to each variant type. In general,
SNV calls yielded significantly lower false positive and false negative rates compared to indel
calls with unanimously detected SNVs having FP/FN rates of 3.29% and 6.78% compared to
14.68% and 35.59% for deletions and 12.16% and 46.26% for insertions (Table 4). This differ-
ence is even more apparent when considering the union of all SNV calls with FP/FN rates of
9.09% and 2.90% compared to 35.13% and 23.72% for deletions and 35.36% and 19.40% for
insertions. The higher false positive rate of indel calls might be explained if the GIAB reference
set was under-reporting indels however this seems unlikely with GIAB reporting a SNV to
indel ratio of 6:1 (2.89 million SNVs and ~465,000 million indels), a lower ratio than the 10:1
estimated by the 1000 genomes project [43]. A more likely explanation is that indels are scarcer
than SNVs and more difficult to detect due to challenges of aligning short reads around indels
[44] meaning the distinct patterns in alignments of short-read data requires distinct workflows
for SNV and indel detection [35]. A final possibility is that the variant callers assessed in this
analysis do not employ the most up to date methodologies for indel detection with new tools
such as Scalpel [45] and ABRA [46] utilizing microassembly in the detection of indels. Such
tools are reporting lower false positive rates than existing software and likely do offer improve-
ments in the overall quality of indel calls. Regardless, with variant detection software rapidly
improving, the need to select software specific to each variant type is clear.
Another increasingly common application utilizing variation data in the clinic is the use of
cancer samples as a way of advancing personalized treatment of cancer [47]. Working with
cancer samples has additional complications however, with factors such as sample contamina-
tion known to be a problem [27]. To measure the effect of contamination on variant detection,
an additional analysis was undertaken where GIAB sequence data was replaced with increasing
levels of non-variant reference data to simulate increasing levels of contamination (Table 5).
For simplicity, only the filtered SNV calls from GATK, Isaac variant caller, and SAMtools
were assessed and as expected, we observe large increases in false negative rates as the contami-
nation level increases. The ability to cope with contamination differed for the three variant
callers however with GATK outperforming the others significantly; for example at 50% con-
tamination levels GATK had a false negative rate of only 5.54% compared to 14.76% for SAM-
tools and 18.56% for Isaac variant caller. These results suggest additional considerations are
required when analyzing samples likely to suffer from contamination, as is often the case for
cancer samples. While this study focused on the detection of germ line variation, the nature of
variation in cancer is fundamentally different from non-cancer with much of the current think-
ing based on the understanding that a clone accumulates somatically acquired mutations that
ultimately leads to malignant transformation [48], with inherited germ line mutations thought
to be important in only 5–10% of cancers [49]. Somatic mutation detection is not addressed in
this study, however the design of this study could be easily applied to assess software such as
MuSiC [50] or MuTect [51], software specifically designed to detect somatic mutations in
paired samples.
While we have demonstrated the impact the choice of software, filtering strategy, and com-
bined variant calls have on resultant variant calls, differences in sample and library preparation
as well as coverage levels are also known to significantly affect variant calling [52]. For sample
preparation, differences in input DNA amount, sample age, and sample preservation method
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are known to be important as are library issues such as PCR amplification errors, primer biases,
chimeric reads, and barcode/adaptor errors. Depth of coverage has also been shown to have a
large impact on variant detection [53] and is of particular importance when considering con-
taminated samples such as tumors, with additional coverage typically required to compensate
for contamination. While in this study it is not feasible to exhaustively examine the impact of
all such factors on variant detection, the sequencing of larger and larger number of samples
will allow us to begin to understand the effect of such factors on variant detection.
Finally, we present a cogent strategy for creating a variant detection pipeline for clinical use
that focuses on minimizing the total number of false negative variants from the onset. For all
workflows, a single aligner is sufficient with BWA generating the greatest number of both SNV
and deletion calls and only 7% less insertion calls than Bowtie2. In this study, we show the sin-
gle most effective measure for minimizing false negative variants is combining the results from
multiple variant callers. Implementing this approach requires running multiple variant callers
in parallel and combining the results to take forward for analysis, an approach already imple-
mented by tools such as BAYSIC [26]. While combined variant calls is the ideal strategy, it
must be acknowledged that computational resources are often limited in which case it is prefer-
able to run BWA paired with GATK due to the low false negative rates, particularly for SNVs
and deletions. Finally, when sample contamination is likely to be an issue (as in cancer sam-
ples) GATK should be utilized as it outperforms Isaac variant caller and SAMtools at increas-
ing contamination levels. While the strategy presented represents the most effective use of the
tools assessed in this study, it is important to routinely reassess both new software and new ver-
sions of existing software to remain current in this fast moving field. Doing this routinely
requires that any framework designed to support clinical usage of variation information must
be able to easily run and benchmark a wide variety of software. Further, such a framework
must be able to run multiple variant callers and combine their output, a feature missing in
almost all modern pipeline frameworks.
Conclusion
Analysis of the GIAB reference dataset shows that the choice of aligner, variant caller, and vari-
ant caller filtering strategy significantly affects the quality of variant calls and that true variants
can be missed by individual software or removed during variant caller filtering. Analysis of the
melanoma cell line control shows only one of three melanoma risk factor variants is detected
unanimously with one variant missed completely by a single software tool and the other variant
removed during variant caller filtering. These results demonstrate the importance of develop-
ing a strategy based on reducing false negative variants when utilizing variation data in a clini-
cal context; a strategy that requires careful software selection, variant caller filtering
optimization, and combined variant calls from multiple variant callers.
Supporting Information
S1 Fig. Tracking database schema. Tracking database schema generated using MySQLWork-
bench. The database records all sample metadata, sequence data information, and the analysis
steps performed. Any previous analysis can be completely reproduced solely from the informa-
tion contained in the database.
(TIFF)
S2 Fig. Default pipeline workflow. Default workflow for the production in-house pipeline.
When new data is received the metadata is parsed to determine whether the sample is new and
if so, what type of sample it is with available options for single human, single mouse, human
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pedigree, or human cancer. If new data is added to an existing sample it is linked to the original
data and a new analysis run commences.
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S1 File. Detailed Variant Detection Workflow. Detailed description of design and implemen-
tation of high-throughput in-house variant detection pipeline.
(DOCX)
S1 Table. Short read aligner and variant caller versions and commands. All short read align-
ers and variant callers commands utilized in our example. The commands listed match the
exact commands run with the exception of the shortening of file names. The commands were
chosen by either following documentation suggestions, or else by using default options.
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S2 Table. SNV call overlaps with GIAB. SNV stats from all eighteen possible software combi-
nations derived from the pairing of the three aligners with each of the three variant callers run
both with and without filtering. SNVs were overlapped to GIAB SNVs and false positive and
false negative rates calculated.
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S3 Table. Deletion call overlaps with GIAB. Deletion stats from all eighteen possible software
combinations derived from the pairing of the three aligners with each of the three variant call-
ers run both with and without filtering. Deletions were overlapped to GIAB deletions and false
positive and false negative rates calculated.
(DOCX)
S4 Table. Insertion call overlaps with GIAB. Insertion stats from all eighteen possible soft-
ware combinations derived from the pairing of the three aligners with each of the three variant
callers run both with and without filtering. Insertions were overlapped to GIAB insertions and
false positive and false negative rates calculated.
(DOCX)
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S1 Text.  Detailed Variant Detection Workflow  
Sequence data for each sample is initially copied to a staging area on raijin 
(http://nci.org.au/nci-systems/national-facility/peak-system/raijin/) at the National 
Computational Infrastructure, the 38th largest supercomputer in the world 
(http://www.top500.org/). Metadata for each sample is loaded from an external 
sample tracking database and read directories created automatically with all sequence 
data copied from the staging area to the read directory using regular expressions to 
determine the destination for each file.  Next, sample metadata is loaded into a master 
configuration file containing information such the sample project, type of sample 
(cancer, pedigree, single, mouse, etc), read directory, and other relevant metadata 
specific to each sample. A cronjob running on the headnode of raijin checks for 
changes to the master config file and when new samples are identified the metadata is 
loaded into an internal tracking database (Fig S1) with all necessary HPC job files 
created simultaneously (similar to a tool like COSMOS (1)) and the initial BWA 
alignment jobs submitted (2). In order to reduce the overall run time multiple samples 
are analyzed in parallel, making the sole-limiting factor the amount of available 
compute resources. If the sample contains more than one lane of sequence data each 
lane is analyzed independently which offers two main advantages; lane-specific QC 
(which frequently serves in preventing corrupt lanes being merged with otherwise 
uncorrupted BAM files) as well as allowing new lanes to be added to existing samples 
at a later date if higher coverage levels are desired. To generate a BAM files, 
repetitively aligned reads are filtered out (identified by the XT:A:R tag) and a sorted 
BAM file generated using SAMtools (3). Alignment statistics are generated for each 
BAM file using the samtools flagstat command and only lanes with 90% or more of 
the reads aligning pass lane QC. When all individual lanes for a sample have passed 
QC, BAM files are merged into a single BAM file and run through samtools (3) 
rmdup to remove candidate PCR duplicates. Variants are next called using either 
samtools/bcftools (4) or GATK (5) best practices. Jobs are split up into chromosome-
by-chromosome jobs (using a map-reduce like approach (6)), which run 
independently while a cronjob running on the headnode detecting when all jobs are 
complete and proceeds to merge the chromosome-by-chromosome results and submit 
the next job to run.  Variants are annotated using ENSEMBL variant effect predictor 
(VEP) (7) and overlapped with ENSEMBL canonical transcripts and splice site 
variants, defined as the 10bp either side of a coding exon. Additional annotations not 
available from standard annotation tools are next added, annotations such as ExAC 
(http://exac.broadinstitute.org/about) or mouse phenotype information from MGI 
(http://www.informatics.jax.org/). Lastly, variant reports for SNVs and indels are 
generated and prioritized by several measures such as novel or low frequency 
variants, nonsense and missense mutations, high polyphen2 (8)  and low SIFT (9) 
scores amongst others. Numerous custom filtering options to reduce the variant search 
space with filters based on genomic region, gene name, population allele frequencies, 
and polyphen/SIFT score are also available. 
For running individual system commands, a generic framework was 
developed to reflect the fact that any large workflow can be broken down into smaller 
analysis components and ultimately individual system commands.  To run a single 
analysis step, the wrapper first reads the sample’s configuration file to retrieve 
relevant step information such as job pre-requisites, command arguments, and 
compute requirements. After checking prerequisite conditions have been met, job(s) 
are submitted and monitored until completion when step-specific QC is performed 
with the exact command recorded in both the tracking database (Fig S1) and the 
detailed log file. The final task performed by the wrapper is the submission of the 
next analysis job, a process that continues until the final analysis step is completed. 
The detection and recovery from both processing and hardware errors is also 
implemented in our system, using an approach similar to eHive (10).  The system 
works to detect both catastrophic errors (errors that cause the entire analysis to halt) 
and non-catastrophic errors (errors that do not cause analysis to halt but generate 
incorrect output). Non-catastrophic errors can be particularly problematic both in 
wasting ensuing CPU cycles and in making it difficult to pinpoint the exact point of 
failure in long running analysis.  
 Importantly, the system output is entirely reproducible, a feature which cannot 
be assumed in biological sciences as highlighted by a study discovering less than half 
of the microarray studies published in Nature Genetics were reproducible (11).  To 
achieve reproducibility (a main goal of the GALAXY framework (12)), our system 
employs multiple tracking methods, an underlying mysql database and a detailed log 
file, with each method capable of independently reproducing previous results. While 
this design decision was initially implemented to ensure output consistency, it has 
proven useful in diagnosing pipeline crashes by offering two distinct reference points 
for pinpointing the exact point of failure.  Full reproducibility requires more than 
detailing how commands were run, it requires the versioning of all files and binaries 
with all relevant version numbers recorded.  This applies to the version of external 
binaries, the version of the larger code base, and the version of external annotation 
data sets.  External annotation data in particular represents a challenge for 
reproducibility with rapid updates and changes to format typical of these external data 
sets.  To manage such annotations consistently, all annotations are read from the 
original data source and stored locally in a standardized file format with standard file 
names.  Annotation files from a single source are stored in time-stamped directories 
thus allowing the most up to date information to be automatically detected and 
utilized during analysis. This consistent handling allows for seamless updates as new 
annotations become available while additionally simplifying batch re-analysis when 
important annotation sets like dbSNP (13) are updated.  
While here we describe the default workflow (Fig S2), the system is flexible 
with regard to software selection thus providing a ready-made testing environment, a 
feature currently available with tools like Nestly (14). This testing environment can be 
utilized both in determining optimal parameters for individual algorithms but also in 
determining effective software combinations by testing aligners and variant callers 
together for example. Currently a selection of some of the most utilized aligners and 
variant callers are available to facilitate such analyses (bowtie2 (15), BWA (2), isaac 
(16), GATK (5), isaac_variant_caller (16), and SAMtools (3)). 
To address the often-low concordance rates between variant callers (17) and 
variant calling pipelines (18) our system allows the use of multiple variant callers 
with options for taking forward either the union or the intersection of raw variant calls 
depending on project-specific circumstances, similar to the approach taken by 
BAYSIC (19). In general taking the union of variants gives higher false positive rates 
and lower false negative rates while taking the intersection of variants gives lower 
false positive rates and higher false negative rates.  									
		
	
S1	Figure.	Tracking	database	schema.	Tracking	database	schema	generated	using	MySQL	Workbench.	The	database	records	all	sample	metadata,	sequence	data	information,	and	the	analysis	steps	performed.		Any	previous	analysis	can	be	completely	reproduced	solely	from	the	information	contained	in	the	database.					
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S2	Figure.	Default	pipeline	workflow.	Default	workflow	for	the	production	in-house	pipeline.		When	new	data	is	received	the	metadata	is	parsed	to	determine	whether	the	sample	is	new	and	if	so,	what	type	of	sample	it	is	with	available	options	for	single	human,	single	mouse,	human	pedigree,	or	human	cancer.	If	new	data	is	added	to	an	existing	sample	it	is	linked	to	the	original	data	and	a	new	analysis	run	commences.	 	
	
S1	Table.	Short	read	aligner	and	variant	caller	versions	and	commands.			
Software	 Version	 Commands	bowtie2	 2.2.3	 1)	bowtie2	–p	16	-1	fq1	-2	fq2	–x	hg19	|	samtools	view	–bt	hg19.fa.fai	-	|	samtools	sort		-		>	bt2.bam			bwa	 0.7.10	 1)	bwa	aln	–t	16	hg19	fq1	>	r1.sai	2)	bwa	aln	–t	16	hg19	fq2	>	r2.sai	3)	bwa	sampe	hg19	r1.sai	r2.sai	fq1	fq2	|	samtools	view	–bt	hg19.fa.fai	-	|	samtools	sort		-		>		bwa.bam				isaac	aligner		 01.14.08.28	 1)	isaac-align	-r	sorted_reference.xml	--base-calls-format	fastq-gz	–j	16	–m	40	–keep-aligned	back	–realign-gaps	yes	-o	isaac_align	–b	readdir		GATK	(raw)	 3.2.2	 1)	java	-jar	GenomeAnalysisTK.jar	-T	UnifiedGenotyper	-I	bwa.bam	-o	bwa_gatk.vcf	-R	hg19.fa	–glm	BOTH	-metrics	bwa_gatk.metrics	-rf	MappingQuality	-mmq	10		GATK	 3.2.2	 1)	java	-jar	GenomeAnalysisTK.jar	-T	VariantRecalibrator	-R	hg19.fa	-input	bwa_gatk.vcf	-recalFile	bwa_gatk.snv.recal	-tranchesFile	
(VQSR)	 bwa_gatk.snv.tranches	-resource:hapmap,known=false,training=true,truth=true,prior=15.0	hapmap_3.3.hg19.sites.vcf		-resource:omni,known=false,training=true,truth=true,prior=12.0	1000G_omni2.5.hg19.sites.vcf	-resource:1000G,known=false,training=true,truth=false,prior=10.0	1000G_phase1.snps.high_confidence.hg19.sites.vcf	-resource:dbsnp,known=true,training=false,truth=false,prior=2.0	dbsnp_138.hg19.vcf	-an	QD	-an	MQ	-an	MQRankSum	-an	ReadPosRankSum	-an	FS	-an	DP	-mode	SNP	2)	java	-jar	GenomeAnalysisTK.jar	-T	ApplyRecalibration	-R	hg19.fa	-input	bwa_gatk.def.vcf	-tranchesFile	bwa_gatk.snv.tranches	-recalFile	bwa_gatk.snv.recal	-o	bwa_gatk.vqsr.snv.vcf	--ts_filter_level	99.5	-mode	SNP	3)	java	-jar	GenomeAnalysisTK.jar	-T	VariantRecalibrator	-R	hg19.fa	-input	bwa_gatk.vcf	-recalFile	bwa_gatk.indel.recal	-tranchesFile	bwa_gatk.indel.tranches		-resource:mills,known=false,training=true,truth=true,prior=12.0	Mills_and_1000G_gold_standard.indels.hg19.sites.vcf	-resource:dbsnp,known=true,training=false,truth=false,prior=2.0	dbsnp_138.hg19.vcf	--maxGaussians	4	-an	QD	-an	MQ	-an	MQRankSum	-an	ReadPosRankSum	-an	FS	-an	DP	-mode	INDEL	4)	java	-jar	GenomeAnalysisTK.jar	-T	ApplyRecalibration	-R	hg19.fa	-input	bwa_gatk.def.vcf	-tranchesFile	bwa_gatk.indel.tranches	-recalFile	bwa_gatk.indel.recal	-o	bwa_gatk.vqsr.indel.vcf	--ts_filter_level	99.0	-mode	INDEL		isaac	variant	caller	(raw)		
1.0.6	 1)	configureWorkflow.pl	–bam	bwa.bam	–ref	hg19.fa	--config	config.ini	2)	make	–j		16		
Isaac	variant	caller	(No	LowGQX	variants)		
1.0.6	 1)	grep	-v	LowGQX	bwa_isaac.vcf	>	bwa_isaac.noLowGQX.vcf	
Samtools	(no	BAQ	filtering)		
0.1.18	 1)	samtools	mpileup	-C50	-uDBf	hg19.fa	bwa.bam	|	bcftools	view	-vcg	-		>	bwa_samools.noBAQ.vcf	
Samtools	(BAQ	filtering)	 0.1.18	 1)	samtools	mpileup	-C50	-uDf	hg19.fa	bwa.bam	|	bcftools	view	-vcg	-		>	bwa_samools.vcf		All	short	read	aligners	and	variant	callers	commands	utilized	in	our	example.		The	commands	listed	match	the	exact	commands	run	with	the	exception	of	the	shortening	of	file	names.	The	commands	were	chosen	by	either	following	documentation	suggestions,	or	else	by	using	default	options.			 	
	
	
	
S2	Table.	SNV	call	overlaps	with	GIAB.			
Aligner	 Variant	Caller	 Total	SNVs	 SNVs	Match	
GIAB	
%	SNVs	
Match	GIAB	Bowtie2	 GATK	(raw)	 224436	 208759	 93.01%	Bowtie2	 GATK	(filtered)	 223085	 208232	 93.34%	Bowtie2	 isaac	(raw)	 159982	 150434	 94.03%	Bowtie2	 Isaac	(filtered)	 74316	 71354	 96.01%	Bowtie2	 Samtools	(filtered)	 105900	 101920	 96.24%	Bowtie2	 Samtools	(raw)	 166722	 156807	 94.05%	BWA	 GATK	(raw)	 225546	 210043	 93.13%	BWA	 GATK	(filtered)	 224671	 209788	 93.38%	BWA	 isaac	(raw)	 166528	 156026	 93.69%	BWA	 isaac	(filtered)	 78002	 74484	 95.49%	BWA	 Samtools	(filtered)	 106322	 102301	 96.22%	BWA	 Samtools	(raw)	 167295	 157330	 94.04%	isaac_	 GATK	(raw)	 182928	 175666	 96.03%	isaac	 GATK	(filtered)	 182703	 175546	 96.08%	isaac	 isaac	(raw)	 129105	 124657	 96.55%	isaac	 isaac	(filtered)	 70499	 67964	 96.40%	isaac	 Samtools	(filtered)	 82164	 79728	 97.04%	isaac	 Samtools	(raw)	 120000	 115689	 96.41%		Snv	stats	from	all	eighteen	possible	software	combinations	derived	from	the	pairing	of	the	three	aligners	with	each	of	the	three	variant	callers	run	both	with	and	without	filtering.		SNVs	were	overlapped	to	GIAB	SNVs	and	the	percent	matching	calculated.	
		
S3	Table.	Deletion	call	overlaps	with	GIAB.		
	
Aligner	 Variant	Caller	 Total	
Deletions	
Deletions	
Match	GIAB	
%	Deletions	
Match	GIAB	Bowtie2	 GATK	(raw)	 1997	 1455	 72.86%	Bowtie2	 GATK	(filtered)	 1934	 1441	 74.51%	Bowtie2	 isaac	(raw)	 2829	 2146	 75.86%	Bowtie2	 Isaac	(filtered)	 1471	 1041	 70.77%	Bowtie2	 Samtools	(filtered)	 2594	 1898	 73.17%	Bowtie2	 Samtools	(raw)	 2565	 1886	 73.53%	BWA	 GATK	(raw)	 1918	 1435	 74.82%	BWA	 GATK	(filtered)	 1862	 1415	 75.99%	BWA	 isaac	(raw)	 2680	 2074	 77.39%	BWA	 Isaac	(filtered)	 1376	 1013	 73.62%	BWA	 Samtools	(filtered)	 2753	 2018	 73.30%	BWA	 Samtools	(raw)	 2657	 1976	 74.37%	isaac	 GATK	(raw)	 1615	 1295	 80.19%	isaac	 GATK	(filtered)	 1603	 1288	 80.35%	
isaac	 isaac	(raw)	 2223	 1763	 79.31%	isaac	 Isaac	(filtered)	 1156	 886	 76.64%	isaac	 Samtools	(filtered)	 2390	 1822	 76.23%	isaac	 Samtools	(raw)	 2356	 1808	 76.74%	
	Deletion	stats	from	all	eighteen	possible	software	combinations	derived	from	the	pairing	of	the	three	aligners	with	each	of	the	three	variant	callers	run	both	with	and	without	filtering.		Deletions	were	overlapped	to	GIAB	deletions	and	the	percent	matching	calculated.	
	
S4	Table.	Insertion	call	overlaps	with	GIAB.		
	
Aligner	 Variant	Caller	 Total	
Insertion	
Insertions	
Match	GIAB	
%	Insertions	
Match	GIAB	Bowtie2	 GATK	(raw)	 2114	 1689	 79.90%	Bowtie2	 GATK	(filtered)	 2052	 1666	 81.19%	Bowtie2	 isaac	(raw)	 3245	 2647	 81.57%	Bowtie2	 Isaac	(filtered)	 1577	 1218	 77.24%	Bowtie2	 Samtools	(filtered)	 3793	 2842	 74.93%	Bowtie2	 Samtools	(raw)	 3678	 2808	 76.35%	BWA	 GATK	(raw)	 1936	 1601	 82.70%	BWA	 GATK	(filtered)	 1901	 1591	 83.69%	BWA	 isaac	(raw)	 2985	 2488	 83.35%	BWA	 Isaac	(filtered)	 1447	 1174	 81.13%	BWA	 Samtools	(filtered)	 3553	 2865	 80.64%	BWA	 Samtools	(raw)	 3451	 2803	 81.22%	isaac	 GATK	(raw)	 1718	 1460	 84.98%	isaac	 GATK	(filtered)	 1702	 1448	 85.08%	isaac	 isaac	(raw)	 2542	 2160	 84.97%	isaac	 Isaac	(filtered)	 1284	 1082	 84.27%	isaac	 Samtools	(filtered)	 3826	 2604	 68.06%	isaac	 Samtools	(raw)	 3796	 2592	 68.28%	
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2.2 Further discussion 
In this two-part study described in this publication, I aimed to answer the 
following questions.  
1) Does the choice of aligner, variant caller, and variant caller filtering 
significantly affect the quantity and quality of resultant variant calls? 
2) In general, does software perform consistently for SNVs, insertions, and 
deletions?  
3) Do we get higher quality variant calls by combining the output of multiple 
variant callers?  
4) Can we demonstrate using a real patient data set, how software choices affect 
the detection of clinically important variants? 
5) What is the ideal strategy for variant detection pipelines being used for 
clinical application?  
 
This publication describes two separate analyses to answer the five main 
questions. First, using Illumina’s validated platinum HapMap (74) genome 
NA12878 (http://www.illumina.com/platinumgenomes/) I generated variant calls 
for SNVs, deletions, and insertions resulting from pairing three aligners (bowtie2 
(75), BWA (76), and isaac_aligner (77)) with each of three variant callers 
(GATK (24), isaac_variant_caller (77), and SAMtools (78)) run both with and 
without additional filtering steps. A merged list of variants was generated for 
each software tool assessed and compared to NA12878 high-confidence variant 
calls to obtain false positive and false negative rates and all variant lists 
overlapped and displayed using Venn diagrams. To determine whether 
combining the output of multiple tools generated higher quality variants, four 
subsets of the total variants were analysed independently: the union of all variant 
calls, the intersection of all variant calls (i.e. unanimous variant calls), variants 
detected by a single software pair, and variants detected by at least two software 
combinations but not unanimously. In the second part of the study, to 
demonstrate the impact software choices have on the detection of clinically 
important variants, a melanoma cell line was analysed using a similar 
methodology with ClinVar (4) ‘melanoma risk-factor’ variants identified and 
examined across all software combinations. In the concluding section, I propose 
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a cogent strategy for implementing a variant detection pipeline for clinical use, a 
strategy that focuses on minimizing false negative variants from the onset. 
The first analysis replicates previous studies demonstrating the significant 
impact software selection has on overall variant quality (29, 79) and how this 
impact is inconsistent across different variant types (80). In this analysis, no 
single aligner / variant caller pair was found to outperform all other combinations 
across the three types of variants assessed, namely SNVs, deletions, and 
insertions. Thus, in order for a pipeline to utilise the most effective tool for 
detecting each specific variant type, it must minimally support multiple variant 
detection tools for different variant types. This analysis also confirms previous 
work (31) showing that combined variant calls from multiple tools yield higher 
quality resultant variant sets, for either specificity or sensitivity, depending on 
whether the intersection or union, of all variant calls is used respectively. 
Building on these findings, the second part of the study demonstrates using a real 
melanoma data set how two of the three total ClinVar annotated melanoma risk 
factor variants are not detected unanimously by all software assessed. 
Importantly, the two variants not detected unanimously are missed for entirely 
different reasons; a single aligner fails to detect one variant completely no matter 
what variant caller is used, while the other variant is filtered out as low quality 
by a single variant caller. While in this instance these two variants are 
particularly important, the work on the NA12878 reference set demonstrated how 
each tool detected high-confidence variants unique to that software, meaning no 
single tool is immune to false negative variants that are detectable with other 
tools. These results demonstrate the importance of initial software selection, 
optimized filtering strategies, and combined variant calls in minimizing false 
negative variants.  Further, the increased output quality from such a strategy 
quickly justifies any increased computation costs given the importance of 
accurately detecting clinically actionable variants when incorporating variation 
information in the clinic. Collectively, these results indicate that any framework 
designed to support clinical usage of variation information needs to be capable of 
benchmarking and supporting a wide variety of software. Further, such a 
framework is ideally able to run multiple variant callers and combine their 
output, a feature missing in almost all modern pipeline frameworks.  
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The results of this and similar earlier analyses played a significant role in 
both the initial design and ongoing development of the in-house production 
genomics analysis framework I have developed and managed over the last four 
years. Internally, this framework works by bundling modular analytical processes 
as externally developed, compiled binary objects, with everything driven by a 
custom Perl module layer designed to wrap the individual tools. These custom 
modules manage the entire workflow in a highly automated fashion: automating 
steps such as data import, setup, execution, result parsing, logging, archiving, 
and even error handling. The system is extremely flexible with each step run in 
the workflow driven at a scripting level by a pre-defined list of system 
commands contained in an XML configuration file - a design that allows 
customisation, quick tool substitution, and straightforward change and extension 
of the workflow. Importantly, all workflows are entirely reproducible using a 
combination of XML configuration files, versioning of code base and 
annotations, and recording the version of all external binaries utilised. Designed 
to originally detect ENU SNVs in mouse exomes (69), flexible design has 
enabled numerous custom workflows to be incorporated including sequenced 
human pedigrees (33) and paired tumour-normal cancer samples (43).  The total 
code-base currently consists of 30,000+ lines of predominantly Perl code and 
utilizes an ever-changing catalogue of open-source components combined with 
bespoke analysis tools – currently all linked via an underlying MySQL 
(http://www.mysql.com) tracking database designed to manage sample metadata, 
sample progress within the pipeline, and summary of results. Overall the 
flexibility, high level of automation, and reproducibility of results has allowed 
the framework to endure in a high-throughput production environment for five 
years. To date, over 3000 exomes and 1000 genomes have been analysed 
resulting in eight publications to date detailing discoveries made by this 
framework (see Chapter 8).  
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Chapter 3: Reducing the search space for causal 
genetic variants with VASP: Variant Analysis of 
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Abstract
Motivation: Increasingly, cost-effective high-throughput DNA sequencing technologies are being
utilized to sequence human pedigrees to elucidate the genetic cause of a wide variety of human
diseases. While numerous tools exist for variant prioritization within a single genome, the ability to
concurrently analyze variants within pedigrees remains a challenge, especially should there be no
prior indication of the underlying genetic cause of the disease. Here, we present a tool, variant ana-
lysis of sequenced pedigrees (VASP), a flexible data integration environment capable of producing
a summary of pedigree variation, providing relevant information such as compound heterozygos-
ity, genome phasing and disease inheritance patterns. Designed to aggregate data across a
sequenced pedigree, VASP allows both powerful filtering and custom prioritization of both single
nucleotide variants (SNVs) and small indels. Hence, clinical and research users with prior know-
ledge of a disease are able to dramatically reduce the variant search space based on a wide variety
of custom prioritization criteria.
Availability and implementation: Source code available for academic non-commercial research
purposes at https://github.com/mattmattmattmatt/VASP.
Contact: matt.field@anu.edu.au
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
While exome sequencing has been successfully utilized in the discov-
ery of causal variation using small numbers of unrelated individuals
(Ng et al., 2010) it is becoming clear that this approach is insuffi-
cient to reliably identify the genetic causes in many cases (Yang
et al., 2013). Increasingly, genetic variation information from
related individuals is being employed to reduce the search space for
causal variants, by both the prioritization of variants common to af-
fected individuals and the exclusion of benign variants shared be-
tween affected and unaffected individuals. The effective analysis of
sequenced pedigrees requires new tools capable of combining vari-
ant specific and pedigree wide annotations with powerful filtering
options to dramatically reduce the causal variation search space.
Current tools focus on either progressively removing variants based
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on criteria deemed unlikely to be causal (Li et al., 2012) or by focus-
ing on variants matching specific inheritance models [compound
heterozygotes (Kamphans et al., 2013); autosomal dominant
(Koboldt et al., 2014)]. Here, we present variant analysis of
sequenced pedigrees (VASP), a tool that integrates and summarizes
information across a sequenced pedigree without making any as-
sumptions regarding disease inheritance further providing the full
integrated pedigree variation information for subsequent prioritiza-
tion. VASP is standalone software written in Perl derived from our
original variant detection pipeline (Andrews et al., 2012).
2 Methods
VASP integrates variant information from each pedigree member and
aggregates this information on a per variant basis, describing, among
other things, the likely inheritance pattern while simultaneously incor-
porating external annotation. Furthermore, VASP uses parental allele
segregation patterns to determine phasing of variants and identifies
genomic blocks common to affected pedigree individuals. VASP and
other tools that aggregate information across a pedigree are critical
for successful causal variant detection as they automate a complex
task too labor intensive to perform manually.
2.1 Input
2.1.1 Input files
Two input files are required; a pedigree (PED) file representing pedi-
gree structure and a variant call format (VCF) file containing variant
information. The third required argument is either a variant effect pre-
dictor (VEP) annotation file (McLaren et al., 2010) or the path to a
local VEP installation when no annotation file is readily available.
Optional input files include a text file with the path to individual
binary sequence alignment/map (BAM) files used for determining
zygosity and inheritance patterns. VASP is able to support any genome
build providing all input files refer to the same reference genome.
2.1.2 Input filters
A key feature of VASP is flexible options with prioritization and
ordering of variants based on stipulated criteria being specified at the
outset. Filtering options include specific inheritance patterns, genomic
region, gene name, population allele frequency, phasing information,
number of affected/unaffected variant individuals and certain
polyphen2 and sorting intolerant from tolerant (SIFT) categories.
Combining parameters results in a dramatic reduction in the length of
candidate variant lists—and the remaining variants will better corres-
pond to hypotheses about the genetic basis of a particular disease.
2.1.3 Input variant set
Variant callers typically employ a quality score as a cutoff, above
which lie a set of presumed high-quality variant calls. In reality, vari-
ants above this cutoff often include false positives, whereas variants
below this cutoff include true positives (Weisenfeld et al., 2014). To
minimize and potentially avoid this problem, the union of all vari-
ants called within the pedigree is used as the initial input variant set.
This approach allows variant calls at a particular genomic position
to be reconciled across the pedigree, potentially correcting calls lying
near the cutoff for a single individual.
2.2 External variant annotation
Individual variants are annotated with VEP data including
population frequency information from dbSNP (Sherry et al., 2001)
and the 1000 genomes project (Genomes Project et al., 2010) as
well as SIFT (Kumar et al., 2009) and PolyPhen2 (Adzhubei et al.,
2010) scores for estimating the functional effect of missense
mutations.
2.3 Pedigree-wide annotation
2.3.1 Genome phasing and de novo mutations
Whenever possible the parental allele inherited by each child is
determined, and this information is clustered into genomic blocks of
presumed shared inheritance to obtain genome-phasing information.
Variants demonstrating segregation differences between affected
and unaffected children are further prioritized. In addition, any vari-
ant exhibiting Mendelian inconsistencies is annotated, with special
attention paid to putative de novo mutations (i.e. non-mutant, un-
affected parents and a heterozygous offspring).
2.3.2 Disease inheritance patterns and compound heterozygosity
For each variant in the pedigree the inheritance is determined and
annotated accordingly. The zygosity of particular variants is prefer-
entially determined from raw sequence data obtained from BAM
files using SAMtools (Li et al., 2009) but failing this the required
genotype field (GT) and optional allele depth (AD) tags from the
VCF file are utilized. Compound heterozygote genes are also anno-
tated, defined as genes containing at least one heterozygous SNV or
indel inherited from each parent with unaffected and affected sib-
lings not sharing identical heterozygous variants. These variants
must further be heterozygous in all affected individuals and not be
homozygous in any unaffected individuals. These compound hetero-
zygous genes are further prioritized in cases where each parent con-
tributes rare or novel alleles.
2.3.3 Gene variability statistics
For each gene three measures of variability are reported; total num-
ber of variants, total number of unique variant coordinates and per-
centage of total transcript bases found variant. Increased gene
variability may be relevant to particular diseases but also may be in-
dicative of read alignment issues (often due the presence of gene du-
plicates) or may indicate the gene is functionally redundant and thus
not functionally constrained.
2.4 VASP output and ordering
VASP reports contain all variants detected in at least one pedigree
member and categorises variants as either novel, rare (0–2% popula-
tion frequency), no frequency (known variant but no frequency data
available) or common (>2% frequency). For each variant VASP re-
ports both pedigree-wide information (such as inheritance pattern
or phasing data) as well as variant-specific information (such as pop-
ulation frequency or polyphen score). By default VASP reports are
sorted progressively on four measures: variant category (novel, rare,
no frequency and common), the number of variant affected samples
(in descending order), the number of unaffected variant samples and
lastly the variant population frequency.
3 Results
VASP makes no assumptions regarding the underlying disease trans-
mission mechanism, an apparent strength when compared with
similar software (Supplementary Table S1). Instead, VASP provides
powerful filters with the aim of allowing researchers to harness their
additional knowledge of the disease to generate reduced variant lists
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suitable for manual interrogation. One current limitation of VASP is
that it can only be run on the command line.
Five pedigrees (Supplementary Table S2) were analyzed to calcu-
late variant segregation statistics with pedigree G1 (Supplementary
Figure S1) variant lists (Supplementary Table S3) taken forward to
illustrate the effect of various filtering strategies (Supplementary
Table S4). To date VASP has been used to analyze 45 pedigrees and
found strong candidate causal variants in 15 of these (33.3%).
These 15 pedigrees exhibit a wide array of disease transmission
mechanisms including autosomal dominant and recessive inherit-
ance, de novo mutations, compound heterozygosity and more com-
plex multi-gene cases. This variety in transmission mechanisms
within this relatively small group sharing similar diseases illustrates
the importance of flexible pedigree analysis software.
We present VASP, a flexible tool for identifying putative causal
variants from pedigree sequence data. Through aggregation of data
for genetic variants across pedigree members, VASP allows power-
ful, custom variation prioritization, taking advantage of external
datasets and prior knowledge of disease incidence and inheritance
patterns. With this tool users have the opportunity to greatly narrow
the number of candidate causal variants, using custom criteria, to a
size suitable for manual interrogation.
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Table 1. Pedigree Analysis Software Comparison 
Software	 CLI/GUI*	 Filter	Output	 Inher-itance	 Com-het	 Phasing/	Linkage	 Expression	Data	
Gemini CLI	 Y	 Y	 Y	 Y	 N	
KGGSeq CLI	 Y	 Y	 Y	 Y	 N	
Mendel Scan CLI	 Y	 Y	 N	 Y	 Y	
plink CLI	 Y	 Y	 N	 Y	 N	
pVAAST CLI	 Y	 Y	 N	 N	 N	
VariantStudio/ 
TruSight One GUI	 Y	 Y	 N	 Y	 N	
VAR-MD CLI	 N	 Y	 Y	 Y	 N	
VASP CLI	 Y	 Y	 Y	 Y	 N	
 
*Command line interface (CLI) or graphical user interface (GUI) 
Table 2. Sequenced Pedigree Composition 
Family ID # Affected (Parents) 
#Unaffected 
(Parents) Total Samples 
A8 4 (2) 0 (0) 4 
A10 3 (1) 1 (0) 4 
G1 2 (0) 3 (2) 5 
R2 2 (1) 2 (1) 2 
S1 2 (0) 3 (2) 5 
 
Variant segregation statistics 
On average, a union of 34,049 variants were in identified in each 
affected pedigree (32,761 snvs and 1288 small indels) overlapping 
either a coding base or a splice site (defined as within 10bp of a 
coding base) with reference to the canonical transcript from 
ENSEMBL v73.   
 
An average of 32,500 variants (95.5%) were consistent with Men-
delian inheritance, with an additional 768 variants on average 
(2.2%) being of ambiguous provenance due to insufficient read 
coverage in at least one pedigree member.  The remaining 798 
variants (2.3%) on average displayed some form of Mendelian 
inconsistency in at least one parent-child pair of which an average 
of 159 variants (0.5%) were classified as de novo.  
 
Disease inheritance was calculated in these five pedigrees.  An 
average of 31,769 variants (93.3%) did not match any known dis-
ease inheritance pattern with the remaining 2280 (6.7%) variants 
classified as either autosomal dominant, autosomal recessive, X-
linked dominant, or X-linked recessive.  Of these 2280 variants an 
average of 991 were autosomal dominant (43.5%), 1254 were au-
tosomal recessive (55%), 13 were X-linked dominant (0.6%), with 
22 X-linked recessive (0.9%) variants on average.  
 
Compound heterozygosity classification yielded an average of 987 
variants (2.8%) distributed across 170 genes or 1.8% of all total 
variant genes.  
 
Effects of Filtering Strategies 
Pedigree G1 was further analysed to illustrate the effect of apply-
ing some of the different filters available in VASP on the raw vari-
ant lists. Pedigree G1 contains two unaffected parents, one pro-
band, one affected brother, and one unaffected brother.  For each 
filter tested the following fields are reported; the number of vari-
ants passing each filter, the percentage of variants removed by the 
filter, and the number of distinct genes overlapping the variants 
that pass each filter.  
Table 3. Pedigree G1 Variants 
Family Member Total SNVs Total Indels Total  Variants 
Mother 22660 646 23306 
Father 21935 679 22614 
Proband 22477 661 23138 
Brother  (affected) 22132 640 22772 
Brother (unaffected) 23932 663 24595 
 
In total pedigree G1 contains 32418 distinct variants distributed 
across 11577 genes. 
 
Figure 1: Pedigree G1 
	
Table 4. Filtering Effect on Raw Variant 
Filter Number 
Variants 
Per cent 
Filtered Out  
Total Genes 
De novo 60 99.81% 55 
Autosomal dominant 4 99.99% 4 
Autosomal recessive 145 99.55% 101 
Compound heterozygous 469 98.55% 115 
Mother allele to affected+ 643 98.02% 411 
Father allele to affected+ 1145 96.47% 810 
Parental allele blocks* 337 98.96% 156 
Damaging polyphen 1268 ^90.54% 1104 
Deleterious SIFT 2472 ^81.57% 1948 
Polyphen AND SIFT 918 ^93.15% 830 
Nonsense Mutation 101 99.69% 96 	
+Heterozygous parent exclusively passes variant allele to affected children and refer-
ence allele to unaffected children 
 
*Blocks of 3 or more variants matching the above definition 
 
^Percentages based on 13412 missense mutations 		
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3.2 Further discussion 
This publication describes a new variant data prioritisation tool, Variant 
Analysis of Sequenced Pedigrees (VASP), which is software written to detect 
causal variants within sequenced families or pedigrees. With an increasing 
number of projects sequencing families in order to detect causal variants, no 
simple automated mechanism existed to examine variants in the context of the 
entire pedigree, meaning researchers were resorting to manually manipulating 
individual sample variant lists to obtain this information for variants of interest. 
While such an approach is appropriate for a select number of variants, it proved 
unsuitable for the examination of the huge number of variants contained across 
the entire pedigree. In addition to the difficulty of automating this approach, 
another shortcoming resulted from the fact that pedigree members were analysed 
in isolation, meaning no pedigree wide information (e.g. disease inheritance, 
genome phasing, and compound heterozygosity) was available despite the fact 
that calculating such information is highly suitable to automation. Further, while 
pedigree wide annotation is informative for specific variants of interest, it also 
represents a powerful mechanism for prioritising variants, particularly when 
researchers have existing knowledge of the disease transmission mechanism and 
large lists of variants unsuitable for manual interrogation. 
 Prior to the implementation of VASP an exhaustive search of existing 
tools was performed to determine whether suitable tools existed for routinely 
identifying causal variants in pedigrees. While a handful of tools exist, none 
proved flexible enough for our needs particularly with regard to disease 
transmission mechanism, pedigree structure, and filtering options. Existing tools 
tended to either focus on a single disease transmission mechanism (e.g. 
compound heterozygosity (42) or autosomal dominant (41)) or else employ a 
winnowing strategy by successively removing variant deemed unlikely to be 
causal (40).  While effective in many instances, such strategies inevitably make 
certain assumptions about the disease that will not hold in many cases. For 
example, tools that focus on a single disease transmission mechanism will not be 
effective when the mechanism differs from the expected model while tools that 
progressively filter out variants often encounter issues due to incomplete 
penetrance, pedigree sample mix-ups, and the addition of rare and disease-
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causing variants to dbSNP (2).  Given these known limitations, VASP was 
created to be free from assumptions regarding the underlying disease mechanism 
and to feature a huge number of available filtering options.  
VASP has a number of unique features compared to existing software. 
First, as mentioned, it makes no assumptions regarding the transmission of the 
disease making it suitable for the examination of either monogenic or polygenic 
disease, an important distinction from other existing tools. Another important 
feature is that VASP takes the union of all variants called across the entire 
pedigree and obtains raw sequence information from BAM files for every 
member of the pedigree regardless of whether a variant was detected in that 
particular pedigree member. This is an important feature as variant callers 
typically employ a quality score as a cut-off, above which lie a set of presumed 
high-quality variant calls. In reality identifying a perfect cut-off value is 
impossible however, as there are inevitably false positive variants above the cut-
off and true positive variants below the cut-off (81). By taking the union of all 
pedigree variants as input, calls at a particular genomic position can be 
reconciled across the pedigree, potentially correcting calls lying near the cut-off. 
Importantly, raw sequence data is used to determine zygosity for each pedigree 
member with this information used for calculating disease inheritance, thus 
giving the most accurate representation of the inheritance based on the actual 
sequence data, not whether a variant fell above or below an imperfect cut-off 
value. Another novel feature of VASP is the use of genome phasing information 
to identify genomic regions consistent with certain disease inheritance patterns. 
To do this, VASP obtains genome phasing information by using parental 
sequence information to determine the allele inherited by each child, with the 
phasing information clustered into haplotype blocks. Variants demonstrating 
segregation differences between affected and unaffected children are further 
prioritized and identified as candidate autosomal dominant variant hotspots. To 
ensure flexibility, users are able to precisely define the nature of a hotspot with 
regard to the number of consecutive variants segregating in this manner and the 
minimum genomic length of these blocks. 
One of VASP’s greatest strengths is the variety of custom filters 
available, filters allowing researchers to dramatically reduce the search space for 
causal variants based on their inherent knowledge of the disease. Filters are 
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broadly divided into two categories, pedigree wide annotation filters and variant-
specific annotation filters. Pedigree wide filters include disease inheritance 
mechanism (autosomal or X-linked dominant / recessive, compound 
heterozygosity, and de novo mutations as well as genomic block hotspots as 
described above. Variant specific filters include variant score cut-off, SIFT and 
polyphen function inference predictions, population allele frequency, specific 
gene(s), or genomic regions. Collectively, these filters are run either individually 
or in combination resulting in a dramatic reduction in the length of candidate 
variant lists with the remaining variants better corresponding to the hypotheses 
about the genetic basis of the particular disease.  
To date VASP has been used to analyse 45 pedigrees and identified 
strong candidate causal variants in 15 cases for a success rate of 33.3%, similar 
to the 25% success rate reported by existing tools (36). The program has been 
used to study pedigrees from a wide variety of projects with resultant 
publications coming from studies of lupus (16), Wiedermann-Steiner syndrome 
(82), and serrated polyposis (38) to date. Almost 75% of all pedigrees studied to 
date are part of a wide scale study to identify the genetic cause of complex auto-
immune diseases and interestingly, candidate causal variants exhibit numerous 
disease transmission mechanisms such as autosomal dominant, autosomal 
recessive, de novo mutations, compound heterozygosity and even complex multi-
gene interactions. This variation in transmission mechanisms within this 
relatively small group sharing similar diseases illustrates the importance of 
flexible pedigree analysis software.  
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Whole genome sequencing (WGS) of cancer patients’
tumours offers the most comprehensive method of identifying
both novel and known clinically-actionable genomic targets.
However, the practicalities of performing WGS on clinical
samples are poorly defined. This study was designed to test
sample preparation, sequencing specifications and bioinfor-
matic algorithms for their effect on accuracy and cost-effi-
ciency in a large WGS analysis of human melanoma samples.
WGS was performed on melanoma cell lines (n¼15) and
melanoma fresh frozen tumours (n¼222). The appropriate
level of coverage and the optimal mutation detection algor-
ithm for the project pipeline were determined. An incremental
increase in sequencing coverage from 36X to 132X in mel-
anoma tissue samples and 30X to 103X for cell lines only
resulted in a small increase (1–2%) in the number of
mutations detected, and the quality scores of the additional
mutations indicated a low probability that the mutations were
real. The results suggest that 60X coverage for melanoma
tissue and 40X for melanoma cell lines empower the detec-
tion of 98–99% of informative single nucleotide variants
(SNVs), a sensitivity level at which clinical decision making
or landscape research projects can be carried out with a high
degree of confidence in the results. Likewise the bioinformatic
mutation analysis methodology strongly influenced the num-
ber and quality of SNVs detected. Detecting mutations in the
blood genomes separate to the tumour genomes generated
41% more SNVs than if the blood and melanoma tissue
genomes were analysed simultaneously. Therefore, simul-
taneous analysis should be employed on matched melanoma
tissue and blood genomes to reduce errors in mutation
detection. This study provided valuable insights into the
accuracy of SNV with WGS at various coverage levels in
human clinical cancer specimens. Additionally, we investi-
gated the accuracy of the publicly available mutationdetection algorithms to detect cancer specific SNVs which
will aid researchers and clinicians in study design and imple-
mentation of WGS for the identification of somatic mutations
in other cancers.
Key words: Cancer, coverage, genomics, melanoma, methods, mutation,
pathology, sequencing, treatment, whole genome.
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INTRODUCTION
Whole-genome sequencing (WGS) of fresh-frozen tumours has
enabled the characterisation of the entire genomic profile of a
patient’s cancer, theoretically allowing the identification of
virtually all possible genomic drivers, disease modifiers and
risk factors, thereby facilitating the selection of the most
appropriate treatment options for an individual patient’s dis-
ease.1,2 Unlike whole exome sequencing (WES), which only
analyses the portion of DNA that is transcribed into proteins
(1.2% of the genome), WGS covers the entire genome. Until
very recently, the use of WES or WGS in the clinical setting has
been restricted by the prohibitive costs of sequencing and the
additional necessary computing resources needed to perform
downstream data analysis. However, with the advent of new
technologies, the cost of WGS of a patient’s genome has
recently dropped below US$1000.3 Therefore, we can expect
its clinical use to rapidly expand due to greater accessibility to
clinicians and affordability for patients. In fact many small
scale trials have already implemented WGS in the clinic,
resulting in altered clinical care based on the increase in
knowledge of the cancer genome and the development of novel
therapies that target the protein products of specifically mutated
genes.4–6
The successful implementation of the technology in the
clinic or in a research setting relies upon sound methodological. Unauthorized reproduction of this article is prohibited.
llege of Pathologists of Australasia. All rights reserved.
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2 WILMOTT et al. Pathology (2015), 00(00), Monthapproaches and despite technological advances, some of the
practicalities of performing WGS are not well outlined for
clinical samples.7 Methodological factors that need to be
considered in performing WGS on clinical samples include:
appropriate sample selection, storage, preservation and macro-
dissection for tumour enrichment, DNA preparation, sequen-
cing specifications and accuracy of the variant detection
algorithms. The importance of sample selection and DNA
extraction can be overlooked, leading to unusable or inaccurate
data.8 Patient biopsies often contain an assortment of tumour
and non-tumour cells such as immune, stromal and endothelial
cells. The presence of the latter in substantial numbers reduces
the ability to detect somatic mutations within tumours by
genome sequencing and can lead to false negative mutation
calls.9–11 This can have serious consequences for patient care,
as patients with false negative results could be incorrectly
designated as ineligible for a personalised treatment that could
have been effective.
Another major factor to consider when performing WGS is
the number of replicate sequences (or reads) of the genome that
is required to accurately identify all mutations present. Sequen-
cing coverage (X) expresses the average number of times an
average nucleotide base will have been read in a given
sample.12 However, coverage varies across the genome due
to variability in sampling and ease of sequencing; it is desirable
to maximise coverage to obtain data on a greater proportion of
the genome. Selecting the appropriate coverage for a project is
often a balancing act between sensitivity and costs, with
increased levels of coverage producing more reliable and
sensitive variant detection capabilities but at an increased cost.7
For sequencing projects, this results in a choice between
increased coverage per sample but lower overall sample num-
bers or higher sample numbers and reduced sensitivity to detect
rare or low frequency events. Deciding upon the appropriate
coverage levels for a WGS assay is a vital aspect of clinical and
research WGS. Coverage levels of 10–30X to detect putative
germline mutations (usually derived from blood DNA) have
been suggested, while higher coverage levels (>40X) are
considered necessary for mutation detection with tumour
samples due to contamination by normal cells, tumour hetero-
geneity and amplification bias.7,13
The algorithms and processing tools that are used to convert
raw sequencing data into annotated lists of mutations can often
be the most expensive and infrastructure-intensive aspect of the
WGS process. The sequencing platforms produce large text
files of nucleotide sequences that need to be aligned to the
reference genome using algorithms such as the Burrows–
Wheeler aligner (BWA).14 Variant detection algorithms such
as SAMtools can then detect alterations between the genomes
based on the probability of a variant occurring in that genomic
region,15 whilst taking into account sequencing error and
predicted polymorphism rates. There are over 205 tools for
WGS data analysis that differ in their statistical approach,
number of variants identified and type of mutations detected
by each algorithm.16,17 However, for matched blood and mel-
anoma tissue samples, these algorithms are founded on two
basic principles of detecting somatic mutations in cancer: (1)
subtraction method, whereby the mutations are compared to a
synthetic reference genome separately for the matched blood
and the tumour samples, then mutations present in the blood are
removed from the tumour calls by subtraction or filtering; (2)
simultaneous detection of the matched tumour and blood
samples uses probability based statistics to filter mutationsright © Royal College of pathologists of Australasiathat are unique to the tumour sample.18 The choice of the
bioinformatics variant detection algorithm and methodology
has an effect on the data produced from the raw WGS.19
In the present study, part of the Australian Melanoma
Genome Project (AMGP) which will complete WGS of 400
human melanomas by the end of 2015, we performed a rigorous
optimisation process for sample preparation, quality control,
sequencing coverage level analysis and the mutation detection
methodology via the WGS of 222 patients’ matched melanoma
and normal white blood cell genomes. The results of this study
provided some valuable insights into the accuracy to detect
single nucleotide variants (SNVs) at various coverage levels in
different sample types. Additionally, we investigated the
accuracy and specificity of the simultaneous versus the sub-
traction methodology using publicly available mutation
detection algorithms.
METHODS AND MATERIALS
Study overview
WGS was performed on genomic DNA extracted from matching blood and
melanoma tissue samples on the Illumina HiSeq2000 platform (Illumina, USA).
The study was designed to optimise the sample preparation, sequencing
specifications and bioinformatic algorithms to decide upon the most accurate
and cost-efficient methodology to be used in the AMGP. We began with a pilot
study that performed WGS on a cell line and melanoma tissue samples to
determine the appropriate level of coverage and optimise the mutation detection
algorithms. Samples were sequenced in individual flow cell lanes and the data
later combined to simulate incremental levels of coverage, 20–60X for blood
genomes and 40–100X for tumour genomes. Variant detection was then
performed at increasing coverage levels to determine the appropriate coverage
for each DNA source. We then optimised the mutation detection algorithms to
determine the methodology that produced the most reliable and accurate
variant detection.
Specimen collection
The tissue and blood samples analysed in the current study were obtained from
Australian melanoma biospecimen banks, which include the Melanoma Institute
Australia (MIA) (n¼ 198), Queensland Institute of Medical Research (QIMR)
(n¼ 15), Ludwig Institute for Cancer Research (n¼ 5), Peter MacCallum
Cancer Centre/Victorian (n¼ 4) biospecimen banks. All tissues and bloods
form part of a prospective collection of fresh-frozen samples accrued with
written informed patient consent and institutional review board approval [MIA
is covered by the Sydney South West Area Health Service institutional ethics
review committee (Royal Prince Alfred Hospital zone), the Ludwig Institute for
Cancer Research is covered by the Austin Hospital committee and the Peter
MacCallum Cancer Center]. Clinical and follow-up details were collected on all
patients as approved by the aforementioned research ethics committees.
Study population
Patients were selected for WGS based on the availability of fresh frozen
melanoma tissue and blood that fulfilled the following clinical criteria:1. P. Urimary melanoma with a patient matched melanoma metastasis (any
metastatic site).2. Primary melanoma with greater than 3 years clinical follow-up and prior
mRNA array data or known sentinel lymph node biopsy (SLNB) status.3. Regional lymph node metastasis with greater than 3 years of clinical follow-
up data and prior mRNA array data.204. Distant metastasis to the small intestine (limited to 8 samples) or brain
(unlimited number of samples).5. Melanomas of any stage of disease that arose from mucosal epithelium. Any
sample with a primary melanoma that bordered cutaneous epithelium
was excluded.6. Melanomas of any stage of disease that arose from acral skin. Any sample
with a primary melanoma that bordered non-acral skin was excluded.7. Human melanoma cell lines with prior drug screen data were also included
(limited to 15 samples).nauthorized reproduction of this article is prohibited.
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AUSTRALIAN MELANOMA GENOME PROJECT 3Patients were excluded if they had received prior chemotherapy or radio-
therapy to the biopsy site or if they had existing exome or WGS data available.Tissue DNA extraction and quality assessment
Fresh surgical specimens were macro-dissected and tumour tissue was procured
(with as little contaminating normal tissue as possible) and snap frozen in liquid
nitrogen within 1 hour of surgery. For primary tumours, only macroscopically
visible tumour was banked. The fresh-frozen tumour samples were sectioned on
a cryostat (CM1520; Leica, Germany) and the slides were stained with hae-
motoxylin and eosin (H&E). Areas with high tumour content (>80% if possible)
were marked and reviewed by pathologists (RV and RAS). The following
features were evaluated for the selected area: percentage of tumour nuclei,
percentage of non-tumour nuclei, percentage area displaying necrosis, degree of
pigmentation (Fig. 1A–D; absent, mild, moderate, severe), predominant cell
shape (Fig. 1E–G; epithelioid, spindle and mixed epithelioid and spindle),
tumour cell size of the most cellular portion of the tumour, and the density of
tumour-infiltrating lymphocytes (TILs) as previously described and depicted in
Fig. 1H–K.20–23 Cell size was measured as the longest dimension of the nuclei
in ten representative cells using the measure tool in Leica’s LAS software on
photomicrographs taken using a 20 objective (Fig. 1L; DM2000; Leica).
The minimum tissue criterion needed for inclusion in the study was a macro
or microdissectible tumour area containing greater than 80% tumour content
and less than 30% necrosis as marked. Samples that needed tumour enrichment
underwent macrodissection using a marked H&E slide as a reference to remove
non-tumour or necrotic tissue under sterile conditions (Fig. 1M,N). Tumour
DNA was then extracted using DNeasy Blood and Tissue Kits (69506; Qiagen,
Germany), according to the manufacturer’s instructions. Blood DNA was
extracted from whole blood using the Flexigene DNA Kit (51206; Qiagen).
All individual samples were quantified using the NanoDrop (ND1000; Thermo-
Scientific, USA) and Qubit dsDNA HS Assay (Q32851; LifeTechnologies,
USA) and DNA size and quality were tested using electrophoresis gels. Samples
with a concentration of less than 50 ng/mL or absence of a high molecular weight
band in electrophoresis gels were excluded from further analyses.
Cetyltrimethyl ammonium bromide (CTAB) DNA clean-up
Excessive melanin pigment was removed from tissue-derived DNA using a
modified CTAB clean-up process.24 Briefly, fresh CTAB was made with 50 mM
Tris-HCL, 1% CTAB (#52365; Sigma, USA), 4 M urea (#U5378; Sigma), 1 mM
EDTA and RNAse-free water. Per 100mL of DNA elution buffer, 39mL of 5 M
NaCl was added, then 500mL of CTAB-Urea solution added, mixed and left
overnight at 48C on a rotator. Samples were then spun at 15,000 g for 15 min at
48C. Supernatant was discarded and the DNA pellet resuspended in 200mL of
buffer ATL, to which 200mL of buffer AL and 200mL of absolute ethanol were
added and the subsequent solution pipetted onto a DNA extraction column.
Columns were spun and washed in buffer AW1, AW2 and the DNA was eluted
in 100mL of buffer AE.
Whole genome sequencing
WGS was undertaken at three Australian sequencing facilities (Australian
Genomic Research Facility, Ramaciotti Centre for Genomics, John Curtin
School of Medical Research) managed by the Australian government infra-
structure enabling body, Bioplatforms Australia, and also at Macrogen (South
Korea). All facilities carried out the following protocols. Library construction
was performed using TruSeq DNA Sample Preparation kits as per Illumina
instructions. Sample DNA (1mg) was fragmented into 300–400 base pair (bp)
average insert size with 30 or 50 overhangs. End repair mix was then used to
convert the fragmented DNA into blunt ends by removing the 30 overhangs and
the polymerase activity fills the 50 overhang. The 30 ends were then acetylated to
add a single ‘A’ nucleotide to the 30 to reduce chimera formation. Ligate adapters
were then used to attach adapters to the DNA fragments so they could be loaded
into a flow cell and purified to remove unligated adapters to generate a final
product with an insert size of 300–400 bp. PCR was then used to selectively
enrich DNA fragments with adapter molecules at both ends for sequencing. Post-
amplification quality controls were performed using DNA High Sensitivity
Labchips (Agilent Bioanalyzer; Agilent, USA). The libraries were then pooled
and clustered using the iBOT and ready for sequencing. The 100 bp pair-end
library was sequenced on a Hiseq2000 using a Truseq SBS V3-HS kit (Illumina).
Each sample was analysed in the minimum number of lanes to generate the total
data output (i.e., full lanes dedicated to one sample rather than multiplexingright © Royal College of pathologists of Australasiaunless a half lane is needed to achieve the final desired output). FASTQ files
were then sent to the bioinformatics pipeline for analysis.
Detection of somatic nucleotide variation
To detect somatic variants in each sample, a variant detection pipeline was
implemented that was derived from an existing pipeline originally designed for
mouse exome analysis.25 The new pipeline consists of a MySQL tracking
database Supplementary Fig. 1, http://links.lww.com/PAT/A38 in addition to
a versioned code base containing custom Perl code, external annotation files,
and external binaries. For each new patient, an automated script enters sample
and sequencing metadata into the tracking database, information such as tumour
and tissue type as well as the number of lanes for the each tumour and control
sample. The script further creates all the necessary files for submission of jobs
onto the 57,000-processor compute cluster raijin (http://nci.org.au/nci-systems/
national-facility/peak-system/raijin/) hosted at the National Computational
Infrastructure (NCI) at the Australian National University. The utilisation of
the NCI was required as analysis of each pair of patient samples requires 1000
CPU hours and 1 terabyte of storage. Once entered into the system, each sample
followed a pre-defined workflow (Fig. 2) ensuring reproducible results and
further allowing users to make consistent comparisons across samples analysed
at different stages of the project. This workflow consisted of three main phases:
alignment, variant detection and annotation.
i) Alignment
Each individual paired lane was aligned to the human reference genome
GRCh37 using the short read aligner BWA14 with default parameters unless
a non-standard base quality encoding was utilised. Repetitively aligned reads
were filtered out from the SAM file and a sorted BAM file generated. Alignment
statistics were generated from the BAM file using the SAMtools15 flagstat
command and only lanes with 90% or more of the reads aligning to the reference
genome were further processed. When all the sequencing lanes for a patient had
been aligned and had passed quality control steps, single merged BAM files
were created for the control sample and each tumour sample using SAMtools
merge. Duplicate reads were subsequently removed from each merged BAM file
using the SAMtools rmdup command, a step that aims to avoid the detection of
false positive variants arising due to PCR duplication. Coverage levels for each
sample were computed and checked against minimum requirements of the
project (40X for control / cell line tumour samples and 60X for tissue derived
tumours).
ii) Variant detection
Variant detection utilised SAMtools and BCFtools to generate a VCF file for
each chromosome. Variants were filtered first on their variant quality score
(>40, higher score indicating reduced risk of false base call) and then their CLR
score (>60), a score that measures the probability that the tumour and control
had different genotypes. Variants from each chromosome were next merged and
classified according to variant type (SNVs or indels) and further segregated into
germline, LOH, or somatic categories with only somatic variants processed
further.
iii) Annotation
All variants were overlapped with ENSEMBL’s canonical transcripts and run
through the variant effect predictor (VEP).26 to determine whether the SNVs
represented non-synonymous changes and to obtain additional annotations.
Polyphen and SIFT scores were extracted in order to prioritise variants by
predicting the functional impact of the missense mutations on the protein.
Variants that overlapped with exon splice sites (defined as 10 bases either side of
exon) were considered the most likely to be pathogenic. Finally, variants were
overlapped with dbSNP27 to determine whether the variant had been previously
reported in the general population and to record allele frequencies of variants
matching dbSNP.
To compare the somatic variants with previous cancer studies, we annotated
genes in Vogelstein’s influential paper28 and provided a link to the COSMIC
repository.29 Variants found to have an exact coordinate match to existing
COSMIC entries were further annotated with special attention paid to variants
previously detected in melanoma studies.
The final step was the generation of separate variant reports for SNVs and
small indels that integrated all the information calculated during analysis which
was accessed from the tracking database. The reports contained sequence
information for the variants in the tumour and control samples as well as
extensive gene annotations and links to external resources.. Unauthorized reproduction of this article is prohibited.
Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
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Fig. 2 Workflow of patient data through the bioinformatics process.
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Patients and melanoma samples
At the time of writing this report, 222 matched bloods and tissue
samples from 204 patients had been contributed from the
biospecimen banks of MIA (n¼ 198), QIMR (n¼ 15), Peter
MacCallum Cancer Centre (n¼ 5) and the Ludwig Institute for
Cancer Research (n¼ 4), all of which had undergone WGS.
The melanoma samples comprised 18 primary melanomas with
patient matched metastasis, 30 primary melanomas with long-
term (>3 years) clinical follow-up data, 18 primary melanomas
with known SLNB status, 62 regional lymph node metastases
with long-term (>3 years) clinical follow-up data, 19 cerebral
metastases, eight small intestine metastases, 15 melanoma cell
lines with prior drug screen data, 25 (8 primary and 17
metastatic) acral melanomas and nine (6 primary and 3 meta-
static) mucosal melanomas. Figure 3 depicts the selection and
exclusion process of the samples that underwent WGS. In total,
over 445 patients were identified as having fresh frozen mel-
anoma tissue in the MIA biospecimen bank that fitted the
criteria for the study. The major causes of exclusion from
the study were lack of a blood or other germline sample
(n¼ 93) and prior radiotherapy or chemotherapy (n¼ 17).
Tissue and DNA quality controls excluded 83 samples due
to low tumour content (<80%), high necrosis (>30%) and
consequent poor quality DNA. A proportion of patients had
undergone prior genome sequencing in other studies and there-
fore were excluded from this analysis (n¼ 30).
Seventy-nine primary melanomas were suitable for WGS,
the subtypes of which included 26 nodular (33%), 14right © Royal College of pathologists of Australasiasuperficial spreading (SS) (18%), 11 acral lentiginous (14%),
nine desmoplastic (11%), five SS with a dominant dermal
nodule (6%) and one lentigo maligna melanoma (1%). The
subtype of 13 cases (17%) was unknown at time of analysis
(Fig. 4A, B). Additionally, 142 metastatic melanoma samples
were included in the WGS study, comprising 21 in-transit
metastases, 72 regional lymph node metastases, 34 distant
metastases and 15 cell lines (Fig. 4A, C). The subtype of the
likely causal antecedent (‘culprit’) primary was determined
using a published algorithm,30 indicating that the metastatic
samples were derived from 19 acral lentiginous, four desmo-
plastic, 40 SS, 40 NM and eight SS with a dominant dermal
nodule. In eight cases the primary melanoma was occult.
The primary melanoma subtype for 23 samples is still to be
determined.
Genomic DNA quantification and quality controls
During the DNA extraction process it became apparent that the
eluted DNA remained pigmented when extracted from pig-
mented melanoma tissue. This was a concern as melanin has
been shown to inhibit PCR reactions and can interfere with
downstream library preparation.13 Additionally, the DNA from
pigmented samples demonstrated a significant over-estimation
in DNA concentration when measured with the spectrometry-
based NanoDrop compared with the fluorometric based Qubit
assay ( p¼ 0.008; Supplementary Fig. 2A, http://links.lww.
com/PAT/A38): pigmented samples often measured many fold
higher using the NanoDrop compared to the Qubit assay due to
the absorbance attributable to melanin. The pigmented DNA. Unauthorized reproduction of this article is prohibited.
Copy
CE: ; PAT-D-15-00076; Total nos of Pages: 11;
PAT-D-15-00076
Sample categories
Database tissue
audit
Clinical and tissue
audit
DNA extraction and
quality controls
Samples that 
underwent WGS
Primary with patient
matched metastatic
melanoma
50 patients
identified
Patients included
n = 18
Patients included
n = 65
Patients included
n = 62
Patients included
n = 8
Patients included
n = 19
Patients included
n = 9
Patients included
n = 25
Exclusion:
chemo/RT
n = 13
Exclusion:
no germline
available n = 30
Exclusion:
no germline
available n = 30
Exclusion:
no germline
available n = 9
Exclusion:
no germline
available n = 17
Exclusion:
no germline
available n = 2
Exclusion:
no germline
available n = 5
Exclusion:
chemo/RT
 n = 2
Exclusion:
pathological
 n = 5
Exclusion:
pathological
 n = 9
Exclusion:
inadequate
 tissue n = 11
Exclusion:
inadequate
 tissue n = 14
Exclusion: DNA
 QC n = 3
Exclusion:
chemo/RT
 n = 2
Exclusion: DNA QC
n = 15
Exclusion: DNA 
QC n = 10
Exclusion: existing
sequencing data
n = 6
Exclusion: existing
sequencing data
n = 4
Exclusion: existing
sequencing data
n = 5
Exclusion: existing
sequencing data
n = 4
Exclusion: existing
sequencing data
n = 8
Not needed due to
sufficient numbers
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106 patients
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40 patients
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52 patients
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metastases
Small intestine
metastases
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Fig. 3 Patient inclusion and exclusion process for the patient cohorts. A database audit of the biospecimen banks yielded candidate samples. Patient samples were
excluded on the presence of appropriate germline samples, prior radio or chemotherapy, poor quality tumour (<80% tumour content or >30% necrosis), poor quality or
quantity of genomic DNA (lack of high molecular weight band in electrophoresis gel, concentration <50 ng/mL and <1mg total) or existence of prior exome or whole
genome sequencing data.
6 WILMOTT et al. Pathology (2015), 00(00), Monthalso appeared heavily smeared on electrophoresis gels (Supple-
mentary Fig. 2B, http://links.lww.com/PAT/A38).
Therefore any pigmented tissue samples that produced pig-
mented DNA, smearing on electrophoresis gels or had abnor-
mally high NanoDrop readings underwent a cleanup process
using a modified CTAB method.24 We measured the DNA
concentration before and after the clean-up process on both
assays. The concentrations of the CTAB clean-up DNA was
reduced in the NanoDrop readings but the Qubit readings were
often stable or increased due to differences in elution volumes,
suggesting minimal loss of double stranded DNA and removal
of melanin ( p¼ 0.476). Subsequent electrophoresis gels of the
cleaned-up DNA show less DNA fragmentation following
CTAB treatment (Supplementary Fig. 2B, http://links.lww.
com/PAT/A38) and the copy number plots from the WGS data
shows an intact genome (Supplementary Fig. 2C, http://
links.lww.com/PAT/A38).
Optimal coverage level determination
In order to determine optimal coverage levels, two melanoma
tissue samples and one melanoma cell line were sequenced to
depths of at least 100X. Sequence data were then subsampled to
test tumour coverage levels in one sequencing lane increments,
ranging from 30–132X against a control cover level of three
lanes of sequencing. For each coverage level, somatic variants
were identified, average quality scores calculated and variants
compared to dbSNP v135.31
For the melanoma tissue samples (SCC09 and SMU11),
Table 1 shows <1% additional variants were identified at
124–132X compared to 61–64X coverage levels. Furthermore,
somatic variants identified at 61–64X have mean SNV qual-
ities of 212 and 216 while the variants added at 124–132X are
of lower quality with means of 90 and 65 (Fig. 5A–D).
However, 0.7–2.4% of SNVs were added at coverage levels
less than 60X (Table 1). Consequently, for melanoma tissue
samples we concluded that coverage above 60X only results in
a minor increase in the total number of additional variants, the
majority of which have quality scores that are indicative of falseright © Royal College of pathologists of Australasiapositive variants. The coverage analysis was then performed on
the genome derived from melanoma cell line A15. This showed
that increasing coverage from 30X to 40X resulted in a 1%
increase in the total number of SNVs that were detected at 103X
(Fig. 5E), with the gain in the number of SNVs levelling off
below 1% beyond 43X. Less than 1% more variants were
identified at 103X compared to 43X and these variants had
a mean quality of 70 compared to 209 mean quality for variants
at 43X (Fig. 5F). Therefore, we selected a minimum coverage
of 40X for all cell line derived samples. Likewise, coverage
below 40X for blood derived DNA resulted in a reduction of
1.5–5% of total SNVs compared to coverage greater than 40X
(Table 1 and Fig. 5G–I). Therefore coverage of at least 40X
was recommended for blood derived genomes Fig. 4D.
Variant detection optimisation: independent versus paired
variant detection
Two options for somatic variant detection were initially con-
sidered. The first option was to call variants independently on
the tumour and normal samples using SAMtools/BCFtools
followed by extraction of tumour unique somatic variants by
detecting variants present in the tumour sample and absent in
the normal sample. The second option was to call variants
simultaneously using SAMtool’s paired mode followed by an
additional filtering step on the CLR score. Several samples
were analysed to determine which method generated more
reliable tumour specific variant calls.
Detection of variants simultaneously yielded an average of
40% less somatic variants with virtually all variant calls being a
subset of variants detected using the independent detection
method (Fig. 6). Further examination of the 40% of variants
detected solely with the independent method revealed that they
generally fell into the following categories: (1) the tumour
sample contained a variant while the normal sample had
insufficient coverage to make a variant call either way, or
(2) the tumour sample variant was slightly above the variant
cut-off score while the normal sample was slightly below the
variant cut-off (Supplementary Fig. 3, http://links.lww.com/. Unauthorized reproduction of this article is prohibited.
Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
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Fig. 4 Summary of melanoma sample type, melanoma subtype of the primary melanoma and coverage levels of the samples within the study. (A) Histogram of the
samples included in the WGS study and their various tissue types; (B) melanoma subtype of the primary melanoma samples; (C) melanoma subtype of the culprit primary
melanoma of all the metastatic melanoma samples; and (D) histogram depicting the coverage levels of the blood (mean 51X) and tumour (mean 79X) genomes of the
samples process at time of publication.
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Table 1 Depth of coverage and single nucleotide variant (SNV) detection
Sample
Coverage
(Lanes)
Total somatic
SNVs
Number SNVs added
at this coverage level
Mean SNV quality
of added SNVs
Percentage of
total SNVs detected
A15 (tumour) 30X (3) 98297 N/A N/A 98.4
A15 (tumour) 43X (4) 99267 970 76 99.4
A15 (tumour) 56X (5) 99543 276 67 99.7
A15 (tumour) 70X (6) 99738 158 65 99.9
A15 (tumour) 80X (7) 99740 2 62 99.9
A15 (tumour) 93X (8) 99868 128 66 100.0
A15 (tumour) 103X (9) 99884 16 64
SCC09 (tumour) 38X (3) 157338 N/A N/A 97.6
SCC09 (tumour) 51X (4) 159352 2014 85 98.8
SCC09 (tumour) 64X (5) 160255 903 87 99.4
SCC09 (tumour) 79X (6) 160699 444 90 99.7
SCC09 (tumour) 92X (7) 160955 256 90 99.8
SCC09 (tumour) 105X (8) 161098 143 97 99.9
SCC09 (tumour) 119X (9) 161157 59 97 100.0
SCC09 (tumour) 132X (10) 161214 57 97
SMU11 (tumour) 36X (3) 322406 N/A N/A 98.3
SMU11 (tumour) 47X (4) 325846 3440 77 99.3
SMU11 (tumour) 61X (5) 327149 1303 69 99.7
SMU11 (tumour) 74X (6) 327660 511 66 99.9
SMU11 (tumour) 86X (7) 327891 231 63 99.9
SMU11 (tumour) 99X (8) 328051 160 61 100.0
SMU11 (tumour) 111X (9) 328089 38 61
SMU11 (tumour) 124X (10) 328142 53 60
A15 (Lymphoblast cell line) 33X (3) 93664 N/A N/A 93.9
A15 (Lymphoblast cell line) 46X (4) 98212 4548 178 98.5
A15 (Lymphoblast cell line) 55X (5) 99738 1526 136
SCC09 (blood) 36X (3) 152682 N/A N/A 95.0
SCC09 (blood) 49X (4) 160699 8017 183
SMU11 (blood) 39X (3) 322659 N/A N/A 98.5
SMU11 (blood) 53X (4) 327660 5001 159
8 WILMOTT et al. Pathology (2015), 00(00), MonthPAT/A38). As variants in these categories are likely to either be
false positives or inconclusive we concluded that the simul-
taneous detection method yielded more reliable somatic variant
calls and was utilised in our analysis.
DISCUSSION
The accuracy and sensitivity of WGS data depends on appro-
priate sample preparation, sequencing specifications and the
selection of an appropriate mutation detection algorithm. The
current study determined the optional WGS coverage for
human melanoma tissue and blood genomes and optimised
freely available mutation detection algorithms to accurately
call mutations unique to the tumour genome, whilst limiting
false positive calls.
Our study found that an increase in sequencing coverage
from 60X to 120X in melanoma samples resulted in a minimal
increase in the detection of SNVs, the quality of which indi-
cated they could be false positive calls or in a minor subpopu-
lation of tumour cells. Likewise, melanoma cell line genomes
reach saturation for SNV discovery at around 40X, most likely
due to their greater purity and increased homogeneity. The
study suggests that these coverage levels empower the detec-
tion of 99% of informative SNVs, which would represent a
sensitivity level at which clinical decision making or landscape
research projects can be carried out with a high degree of
confidence. However, lower coverage WGS (5–15X) has been
used to detect high frequency variants in genome wide associ-
ation studies and by The Cancer Genome Atlas,32 but the
sensitivity to detect rare or low frequency events is diminished.
Nevertheless, variant detection algorithms and sequencing
technologies are constantly evolving, with improvements beingright © Royal College of pathologists of Australasiamade to the accuracy, speed and ability to accommodate lower
levels of coverage.33,34 Therefore, the appropriate coverage
levels for a specific project may vary depending on the tissue
type, sequencing technologies, detection algorithms and the
type of questions the data needs to address.
Likewise the detection methodology, subtraction versus the
simultaneous variant detection, had significant effect on the
number and quality of SNVs detected, finding that the sub-
traction methodology with SAMtools resulted in a 41%
increase in the number SNVs detected over the simultaneous
detection method. These results are similar to those of other
studies that found the additional SNV calls are the result of
library preparation bias, sequencing errors and mutation detec-
tion artifact due to read depth imbalances that represent false
positive calls.25 Therefore, the simultaneous detection
approach should be employed on matched tumour and control
genomes to reduce false positive variant calls.
The current study highlights some basic steps that are
required to achieve high quality input DNA and accurate
sequencing data from clinical melanoma specimens. The key
to achieving this is the accurate evaluation and selection of
areas of tumour for macrodissection by a skilled pathologist.
With careful macrodissection of the pathologist-selected
tumour region and subsequent quality controls, factors that
contribute to erroneous results such as low tumour content,
excessive necrosis or misclassified samples can be better
avoided. If the tissue analysed is suboptimal, this can have
long-term implications for further research as the genome
sequencing results are made publicly available for use by
the wider cancer research community. Therefore the process
of sample selection and preparation is critical in WGS as
subsequent results depend upon the accuracy of these steps.. Unauthorized reproduction of this article is prohibited.
Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
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Fig. 5 Number and quality of SNV detection at simulated coverage levels. (A,B) SCC09 tumour genome: increasing coverage from 38 to 132X only generated 2.5%
additional SNVs, with a total of 161,214 SNVs identified at 132X at an average quality of 212 (arrow, mean quality of SNVs detected greater than 32X). (C,D) SMU11
tumour genome: increasing coverage from 36 to 124X only generated 1.8% additional SNVs, with a total of 328,142 SNVs identified at 124X at an average quality of 216
(arrow, mean quality of SNVs detected greater than 36X). (E,F) A15 tumour genome: increasing coverage from 30 to 103X only generated 1.6% additional SNVs, with a
total of 99,543 SNVs at an average quality of 209 (arrow, mean quality of SNVs detected greater than 30X). (G) SCC09 blood genome: increasing the coverage from 36 to
49X added 8017 (5%) additional SNVs with a mean quality of 212 for all SNVs identified. (H) SMU11 blood genome: increasing the coverage from 39 to 53X added 5001
(1.5%) additional SNVs with a mean quality of 216 for all SNVs identified. (I) A15 lymphoblast cell line: increasing the coverage from 33 to 46X added 4548 (5%) and
from 46 to 55X added another 1526 (1.5%) SNVs with a mean quality of 209 for all SNVs.
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Fig. 6 Venn diagram depicting the overlap between the subtraction and
simultaneous detection methods using SAMtools mpileup. 70% more candidate
SNVs were identified with the subtraction method (SNV single) and virtually no
new variants added with paired method (paired SNVs).
10 WILMOTT et al. Pathology (2015), 00(00), MonthMelanoma tissue preparation for WGS is especially proble-
matic for sequencing due to naturally occurring melanin which
interferes with spectrometer-based DNA quantification and
PCR reactions.24 The presence of melanin in the library prep-
aration can inhibit library preparation and may even induce
sequencing artifact. We sought to remove pigmentation prior to
library preparation using the CTAB clean-up method. Results
show this process removes pigment and improves the quality of
the genomic material on electrophoresis gels, which is then
suitable for WGS. The results show that cleaning the DNA with
CTAB results in minimal loss of genomic material as measured
via Qubit and the copy number plots of the WGS of these
samples appears to be consistent with non-pigmented tumour
genomes. Therefore, a fluorometric based method should be
used to accurately quantify double-stranded DNA concen-
trations in melanoma-derived DNA and a modified CTAB
clean-up protocol can be used to produce suitable genomic
material for WGS from heavily pigmented samples.
The Australian Melanoma Genome Project has performed
WGS on 222 human melanoma samples and gained valuable
insight into WGS and analysis of clinical melanoma samples.
Data generated by the project will be made publicly available in
order to make a substantial impact on future melanoma diag-
nosis and treatment. The current study outlines practical guide-
lines for sample preparation, quality control, sequencing
methodology and mutation detection algorithms that will aid
researchers and clinicians in sequencing patient-derived mel-
anoma samples on a large scale.
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4.2 Further discussion 
This publication describes work to build a new variant detection pipeline for 150 
whole melanoma genome paired samples, which at the time, represented the 
largest melanoma genome sequencing project anywhere.  To do this the 
following analyses were required: 
1) Identify the best software for reliably detecting somatic variants within 
paired normal/tumour samples 
2) For all library types (cell line, primary tissue, and metastatic tissue) 
determine optimal coverage levels for both tumour and normal samples 
3) Create a complete variant detection pipeline for detecting somatic 
mutations that is robust, high-throughput, automated, and reproducible  
First, in order to determine an appropriate method for somatic variant detection 
in paired tumour/normal samples, a review of existing tools was required. There 
exists a plethora of genomic analysis tools with a recent publication surveying 
205 such tools (21), many of which prove suitable for detecting somatic variants. 
The challenge is that the underlying statistical approach of these tools differs, 
resulting in output variant lists highly variable with regard to both quality and 
quantity of variant calls.  This means there is not, as of yet, any gold standard 
methodology for detecting somatic variants in cancer; in fact even within large 
cancer genome projects such ICGC (49), multiple workflows using a variety of 
tools are supported. In general, detecting somatic mutations in paired 
tumour/normal samples follows one of two fundamentally different approaches. 
The first approach involves calling variants independently in both the tumour and 
the normal and obtaining somatic mutations by filtering out variants from the 
tumour sample that are shared with the germ line sample.  This method is 
sometimes called the ‘subtraction method’ and has been used in several high 
profile cancer studies (83) and has the advantage of not requiring any 
modifications to existing variant detection workflows, only requiring an 
additional filtering step.  The second approach is to simultaneously analyse 
matched tumour and normal samples using a joint probability-based statistical 
approach, the basis of methods such as MuTect (51), or SAMtools somatic mode 
(78).  This method is called the ‘pairwise method’ and has the advantage of 
considering the nature of the sequence content from both the tumour and the 
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normal sample before classifying a variant as somatic. To determine which 
method was more suitable for melanoma samples, I ran all three-sample types 
(cell line, primary and metastatic tumour samples) through SAMtools using both 
the default mode and the paired somatic mode for comparison. Overlapping the 
variant lists from the two method showed the subtraction method generated 
substantially more somatic variant calls than the pairwise method, typically in 
the order of 40% more variants, and further that all variants detected by the 
pairwise method were also detected using the subtraction method. Closer 
examination of the additional variants detected by the subtraction method 
revealed the variants fell into two categories: 1) the tumour sample contained 
sufficient depth and non-reference bases to score above the variant cut-off while 
the normal sample had insufficient coverage to make a definitive variant call 
either way or 2) both tumour and normal contained variant bases with the tumour 
variant score slightly above the variant cut-off and the normal variant score 
slightly below the variant cut-off. As variants in these categories are likely to be 
either inconclusive (as in case 1) or false positives (as in case 2) the pairwise 
method was ultimately chosen due to it yielding a more reliable set of somatic 
variant calls containing a smaller number of false positives. These conclusions 
support previous studies demonstrating the superior performance of pairwise 
variant detection compared to subtraction variant detection (84). 
 Once the variant detection method was selected, the optimal coverage 
levels needed to be determined for all library types utilised in this project; 
namely tumour and normal samples from cell lines, primary tissues, and 
metastatic tissue. These levels were important to establish specifically for 
melanoma, as there existed no large-scale melanoma whole genome sequencing 
repositories at the time. Melanoma-specific levels needed to be determined 
empirically as tumour purity (32) and mutational heterogeneity (52) are different 
for each cancer type, with both factors known to affect the required coverage 
levels. To determine the values, a pilot project was undertaken where one of each 
sample type was sequenced to extremely high depth for both tumour and normal 
libraries. Sub-sampling was utilised to simulate lower coverage levels and 
variants called at each level, with each level designed to be roughly 10X apart.  
First, to establish baselines, variants detected both at the lowest and highest 
simulated coverage level (30X and 120X respectively) were identified. Then for 
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each 10X increment in coverage, variants not detected at previous coverage 
levels were identified and analysed independently to access the quality of the 
variants unique to each coverage level.  The final summary contained the per 
cent of the total variants detected at each coverage level as well as the number 
and quality of the new variants detected at that level, thus allowing an informed 
decision to be made.  As sequencing depth decisions typically boil down to a 
cost-benefit analysis between the sensitivity/specificity of variant calls and the 
number of samples able to be sequenced given a fixed budget, it was important to 
make an informed decision based on real empirical data from melanoma 
samples.  These pilot analyses were subsequently used as the sole information on 
which to base the required sequence depth to be obtained for tumour and normal 
tissue samples. This analysis yielded several important findings that ultimately 
resulted in more effective use of the limited resources available for the project. 
First, optimal coverage levels differ for cell line libraries and libraries from tissue 
samples, likely explained by issues with cross contamination of both tumour and 
normal samples. Second, there is very little gain in the number of variant calls 
beyond 60X for tumour tissue samples and 40X for cell line tumour samples with 
at least 98% of the total variants are detected by these coverage levels, results 
that differ from Illumina’s current suggestion of 80X minimum tumour coverage 
(http://www.illumina.com/technology/next-generation-sequencing/deep-
sequencing.html).  Further, variants added at the higher coverage levels were 
uniformly of lower quality than variants detected at lower coverage levels and 
more likely to be false positives.  
 Lastly, an analysis pipeline that both manages and analyses the large 
number of melanoma samples was needed, a pipeline that was flexible, high-
automated, and supported reproducible bioinformatic workflows. At the time, we 
had a mature variant detection pipeline for mouse exomes (see Chapter 7) (69) 
that met many of these requirements as it was running in an high performance 
computing (HPC) environment on the supercomputer raijin, housed within the 
National Computational Infrastructure, the largest cluster in the southern 
hemisphere (https://nci.org.au/systems-services/national-facility/peak-
system/raijin/).  In the end, borrowing many of the same design principles, a 
more sophisticated melanoma variant detection pipeline was created to handle 
the increasingly large and complex sequence data sets. Numerous additional 
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features were incorporated including the ability to manage multiple sequencing 
lanes per sample, the ability to call pairwise variant calls from tumour and 
normal samples, the addition of cancer annotation information, and the 
parallelisation of the variant detection step previously requiring 10 days to run in 
serial. The final version of the pipeline effortlessly processed the melanoma 
samples and remains in production today following the addition of several 
configurable components that allow it to be used with a variety of human and 
mouse cancer types. 
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Each person’s genome sequence has thousands of missense vari-
ants. Practical interpretation of their functional significance must
rely on computational inferences in the absence of exhaustive
experimental measurements. Here we analyzed the efficacy of
these inferences in 33 de novo missense mutations revealed by
sequencing in first-generation progeny of N-ethyl-N-nitrosourea–
treated mice, involving 23 essential immune system genes. Poly-
Phen2, SIFT, MutationAssessor, Panther, CADD, and Condel were
used to predict each mutation’s functional importance, whereas
the actual effect was measured by breeding and testing homozy-
gotes for the expected in vivo loss-of-function phenotype. Only
20% of mutations predicted to be deleterious by PolyPhen2 (and
15% by CADD) showed a discernible phenotype in individual ho-
mozygotes. Half of all possible missense mutations in the same
23 immune genes were predicted to be deleterious, and most of
these appear to become subject to purifying selection because few
persist between separate mouse substrains, rodents, or primates.
Because defects in immune genes could be phenotypically masked
in vivo by compensation and environment, we compared infere-
nces by the same tools with the in vitro phenotype of all 2,314
possible missense variants in TP53; 42% of mutations predicted by
PolyPhen2 to be deleterious (and 45% by CADD) had little measur-
able consequence for TP53-promoted transcription. We conclude
that for de novo or low-frequency missense mutations found by
genome sequencing, half those inferred as deleterious correspond
to nearly neutral mutations that have little impact on the clinical
phenotype of individual cases but will nevertheless become sub-
ject to purifying selection.
de novo mutation | immunodeficiency | evolution | nearly neutral | cancer
The genome sequence of any particular person contains ex-tensive protein-altering genetic variation and de novo point
mutations (1), of which only a minority are unambiguously dele-
terious and introduce premature stop codons or disrupt normal
mRNA splicing. When considering a person with a suspected
genetic illness, the first clinical question is whether any of the
mutations identified in their genome sequence involve essential
genes whose disruption is known to cause a phenotype resembling
that of the patient in question. The most numerous class of pro-
tein-altering mutations is missense mutations, where a single co-
don is altered to encode a different amino acid. On average, 2% of
people carry a missense mutation in any given gene (2). Hence, by
chance, missense mutations will often be found in genes that are
seemingly relevant to a person’s disease phenotype, and the next
key clinical question is whether or not these substitutions alter the
function of the corresponding protein. Short of mutational studies
of all possible amino acid substitutions coupled with comprehen-
sive functional assays, the sheer number and diversity of missense
mutations present in each person’s genome means that their
functional importance must presently be addressed primarily by
computational inference.
Many tools now exist that use diverse information to make in-
ferences of the functional importance of single amino acid sub-
stitutions (3, 4). The majority of better-performing tools use a
protein multiple sequence alignment and judge the importance of
residues depending on their conservation across available ho-
mologous sequences. Notably, these tools are sensitive to the
sequence choice in the input alignment (5). Some examples of
commonly used tools that use a sequence conservation approach,
with diverse methods to calculate conservation, are SIFT (6),
MutationAssessor (7), MAPP (8), AlignGVGD (9), PANTHER
(10), and GERP (11). Protein structural information is also in-
cluded in other tools to judge whether an amino acid substitution
may importantly alter protein stability or catalysis, but few com-
monly used tools rely just on these data alone (3).
The widely used PolyPhen2 and CADD tools (12, 13) integrate
a number of different information sources, including sequence-
and structure-based features (and in the case of CADD, the re-
sults of other tools), and use a machine learning approach to
categorize variants as benign or deleterious. It is worth noting that
Significance
Computational tools applied to any human genome sequence
identify hundreds of genetic variants predicted to disrupt the
function of individual proteins as the result of a single codon
change. These tools have been trained on disease mutations and
common polymorphisms but have yet to be tested against an
unbiased spectrum of random mutations arising de novo. Here
we perform such a test comparing the predicted and actual ef-
fects of de novo mutations in 23 genes with essential functions
for normal immunity and all possible mutations in the TP53 tu-
mor suppressor gene. These results highlight an important gap
in our ability to relate genotype to phenotype in clinical genome
sequencing: the inability to differentiate immediately clinically
relevant mutations from nearly neutral mutations.
Author contributions: L.A.M., M.A.F., B. Beutler, B.W., E.M.B., A.E., C.C.G., and T.D.A.
designed research; L.A.M., M.A.F., Y.S., V.C., S.J., A.P., B. Balakishnan, R.L., Y.Z., S.L., B.W.,
and T.D.A. performed research; S.L., B. Beutler, and T.D.A. contributed new reagents/analytic
tools; L.A.M., M.A.F., Y.S., V.C., S.J., A.P., B. Balakishnan, R.L., Y.Z., S.L., B. Beutler, B.W., E.M.B.,
A.E., C.C.G., and T.D.A. analyzed data; and M.A.F., C.C.G. and T.D.A. wrote the paper.
Reviewers: J.-L.C., The Rockefeller University; and A.F., Imagine Institute, Hôpital Necker
Enfants Malades.
The authors declare no conflict of interest.
Freely available online through the PNAS open access option.
See Commentary on page 11426.
1L.A.M. and M.A.F. contributed equally to this work.
2C.C.G. and T.D.A. contributed equally to this work.
3To whom correspondence may be addressed. Email: c.goodnow@garvan.org.au or dan.
andrews@anu.edu.au.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1511585112/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1511585112 PNAS | Published online August 12, 2015 | E5189–E5198
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
SE
E
CO
M
M
EN
TA
RY
inference tools that integrate diverse information, such as PolyPhen2
and SNAP (14), do not necessarily have efficacy better than sim-
pler tools (3). Interestingly, there is further utility in integrating the
predictions of individual methods (15), even those that are very
similar or that already integrate wide ranges of information, po-
tentially due to minimization of outlier effects.
Functional inferences of the severity of protein disruption only
weakly predict disease incidence, disease severity, or clinical
outcome. For example, functional inferences of missense vari-
ants in the cystic fibrosis gene, CFTR, are not well correlated
with disease incidence or severity (16). Similarly, the functional
inference of mutation severity in the tumor suppressor gene,
TP53, does not correlate significantly with patient clinical out-
come (17). An emerging consensus has formed that functional
inference scores lack the sensitivity and specificity for their
clinical use (18–20). The human genome of any particular indi-
vidual likely contains many apparently unambiguous disease-
associated variants (1), and these very often occur in people without
symptoms (21). Variable penetrance is most frequently cited to
explain the presence of deleterious variants in asymptomatic in-
dividuals, although a prevalent viewpoint is that functional in-
ference tools overcall pathogenic variants (22). Most validation of
the various predictive algorithms have used test sets of selected
mutations that are known or likely to be disease causing (such as
recurrent mutations inferred to be driver mutations in cancer) and
likely to be benign (such as germ-line polymorphisms present at
high frequency in the human population). What remains to be
tested, in essential genes that produce a clear mutant phenotype,
is how often do predicted deleterious variants produce the ex-
pected mutant phenotype? This question sidesteps the thicket of
variable penetrance issues and allows direct appraisal of whether
functional inferences accurately predict disruption of the gene/
protein in question.
Here we addressed this question by breeding to homozygosity
and phenotyping mice with 1 of 33 potentially disruptive de novo
point mutations residing in 23 essential immune system genes.
Should a mutation disrupt the function of the gene in which it
occurs, we expected to observe a previously characterized im-
mune system phenotype specific to that gene. We found that only
4 of 20 missense mutations predicted to be “probably damaging”
or “possibly damaging” by PolyPhen2 produced the expected
mutant phenotype. This apparent overcalling of deleterious vari-
ants by computational tools was not simply due to masking of
immune defects in vivo, because when the algorithms were com-
pared with systematic in vitro phenotyping of all possible missense
mutations in TP53, only half of the mutations predicted to be
deleterious caused a clear reduction of transcription-enhancing
activity. Interestingly, the large set of apparent false-positive TP53
inferences has a mean distribution of measured transcriptional
activities that is 14.2% lower than the set of TP53 mutations
predicted to be benign, consistent with population genetics
models that predict a large class of nearly neutral mutations. We
present evidence that the apparent overcalling of deleterious mu-
tations by functional inference tools is not a failure of the inference
tools per se, but elucidates a critical gap between these inferences
and our understanding of how mutations yield phenotypes mea-
sured in individuals as opposed to small differences in fecundity
compounded over hundreds of generations in large populations of
competing individuals.
Results
Identification of Induced De Novo Mutations in Essential Immune
Genes. To identify large numbers of de novo point mutations
that have yet to be subject to phenotypic selection, we previously
developed a system to exome sequence and accurately identify
single nucleotide, protein-altering variants in the progeny of
C57BL/6 laboratory mice exposed to the spermatogonial point-
mutagen N-ethyl-N-nitrosourea (ENU) (23). As part of a larger
project aimed at producing an ENU-induced mouse mutant for
each gene in the mouse genome, we developed a resource of mice
with identified mutations and corresponding exome sequence data
(databases.apf.edu.au/mutations and mutagenetix.org/incidental/
incidental_list.cfm). First generation (G1) offspring from male
mice treated with ENU have a mean of 45 nonsynonymous de
novo mutations (23), although the functional effect of each mu-
tation is largely unknown. Mutations induced by exposure to ENU
are likely to have diverse functional consequences, from benign to
severely deleterious. This diversity replicates that of spontaneous
nonsynonymous de novo mutations that arise in humans at an
average rate of 0.75 mutations per child (24). It is also likely to
replicate the functional spectrum of inherited nonsynonymous
variants in recessive genes that occur at frequencies below 1% in
the human population.
To gain an understanding of the functional effects of these
phenotypically unselected point mutations, we propagated 33
mutations within 23 genes and bred mouse pedigrees to bring
these to homozygosity. Mutations were propagated if they pro-
duced a nonsynonymous alteration in genes that, when rendered
null, were already known to cause a fully penetrant, well-charac-
terized phenotype in the mouse immune system that was readily
detectable by flow cytometry of peripheral blood lymphocytes
(details of these genes and the expected phenotypes are given
in Table S1). Loss-of-function mutations in 11 of the 23
studied genes (BTK, DCLRE1C, DOCK8, IL2RA, IL7R, JAK3,
LIG4, PRKDC, PTPRC, RAG1, and RAG2) are also already
known to cause human immune deficiency with Mendelian
inheritance.
Mouse-Specific Calculation of Mutation Functional Impact. The ma-
jority of tools that infer the functional consequences of missense
sequence variants are understandably built to analyze human
sequence data. By default, the inferences made with these tools
for model organisms, such as the mouse, using human-specific
data sources are inherently of lower and mixed accuracy. We
substituted the internal data sources within PolyPhen2 to pro-
duce mouse-specific values (see Materials and Methods for de-
tails). Table S2 shows PolyPhen2 values for the 33 de novo
mutations in immune genes, calculated using both human- and
mouse-specific implementations, and human inferences for the
mouse mutations made with CADD. Although the mouse- and
human-specific PolyPhen2 values are generally well correlated,
several values cannot be calculated in humans due to lack of con-
servation between mouse and human amino acids at the position
in question (which is also a limitation when calculating CADD
scores for mouse mutant orthologs from human sequence infor-
mation). Of the values that can be calculated, several PolyPhen2
values change between deleterious and benign categories (Il7r,
Lig4, Rasgrp1, and Tnfaip3) depending on the species of database
used. Human-specific PolyPhen2 and CADD scores are also
highly similar.
We also calculated functional impact inferences using the
sequence homology-based methods SIFT (6) GERP (11),
MutationAssessor (7), and PANTHER (10), using mouse input
sequences (Table 1 and Table S3) and generated weighted av-
erage scores from these diverse measures using Condel (15).
Table 1 shows that the functional inference scores for each of the
de novo mutations are generally in agreement. There are small
differences between functional inference tools regarding the
deleterious/benign cutoff used by each different tool, but these
are not a predominant feature of the data (Table S3). Occasion-
ally, a single tool produces a discordant inference to the other tools,
such as the benign call by PolyPhen2 of the Ptpn6 variant at
chr6:124682374. Potentially one tool is making a better call than
each of the other tools, although as Condel validation shows, re-
moval of these outlier functional inferences improves the accu-
racy of the inferences overall (15).
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In Vivo Phenotypic Consequences of Nonsense and Missense Mutants.
For each mutation, heterozygous G1 animals were bred with
unrelated mice and heterozygous mutant offspring identified by
allele-specific genotyping. These mutant offspring were inter-
crossed to yield third-generation (G3) offspring, of which 25%
were expected to be homozygous for the mutation. Peripheral
blood, or the spleen when necessary for particular mutants (e.g.,
Dock8), was collected from homozygous mice, and leukocyte
subsets were analyzed by flow cytometry. A panel of antibodies
was used for flow cytometry capable of detecting abnormalities
in lymphocyte subsets that characterize mice with well-defined,
homozygous loss-of-function mutations in each of the 23 genes
(Table S1). Particular attention was also paid to the detection of
subtle hypo- and hypermorphic alterations within the lymphocyte
subsets as detectable by flow cytometry of blood samples, such as
the compensating shift toward the CD44hi subset of T cells that
occurs when thymic T-cell output or peripheral T-cell survival is
subtly decreased. We nevertheless recognize that these in vivo
phenotyping tests may fail to detect some hypomorphic alleles
due to compensating processes in the immune system and lack of
exposure to pathogenic microbes in the environment where these
mice were raised.
Three of the 33 de novo mutations taken to homozygosity in-
troduced premature stop codons, two in Dock8 and one in Dclre1c
(also called Artemis), and all three resulted in the expected im-
mune system in vivo blood cell phenotype (Table 1). Introduction
of a premature stop codon is rarely ambiguous because these
eliminate a portion of the protein and often cause the transcript
to be degraded by nonsense-mediated decay unless the pre-
mature stop codon occurs within 55 nucleotides 5′ to the ter-
minal intron (25). All three of the nonsense mutations studied
here bear this out.
By contrast with the nonsense mutations, only 4 of 30 missense
variants (13%, in Btk, Ets1, Il7r, and Rag1) screened for an ex-
pected gene-specific loss-of-function blood cell phenotype had
a detectable change in the expected lymphocyte subpopulations
relative to WT mice analyzed in parallel (Table 1). This result is
consistent with previous evidence comparing the frequency of
overt null mutations to missense mutations in sets of unpheno-
typed incidental ENU mutations to sets of ENU mutations
Table 1. Predicted and observed effect of unselected de novo ENU mutations in 23 essential immune genes
Gene
symbol
Num hom
tested
Mut phen
obs?
UniProt
identifier
AA
change
Polyphen
category
Polyphen
score
SIFT
cat.
GERP
score*
Mut
Assessor cat.
PANTH
subPSEC†
Condel
cat.
CADD
Phred-like
score‡
Dclre1c 3 Yes Q8K4J0 L95Stop
Dock8 1 Yes Q8C147 R1630Stop
Dock8 3 Yes Q8C147 F1885Stop
Ets1 4 Yes P27577 P334L Prob. Dam. 1 Del. 3.97 Medium −2.3993 Del. 19.09
Hnrnpl 5 No Q8R081 A118D Prob. Dam. 1 Del. 3.74 Medium −4.06474 Del. 22
Tnfaip3 3 No Q60769 F394S Prob. Dam. 1 Del. 3.27 Medium § Del. 16.78
Satb1 2 No Q60611 V99A Prob. Dam. 0.999 Toler. Low −4.11365 Neutral 20.7
Btk 3 Yes P35991 Y152H Prob. Dam. 0.998 Del. 3.91 Low −2.39271 Del. 27
Prkdc 8 No P97313 D382G Prob. Dam. 0.997 Del. 3.91 Medium −3.61416 Del. 23.6
Il7r 3 Yes P16872 T56P Prob. Dam. 0.985 Del. 2.92 Low § Del. 12.47
Lig4 4 No Q8BTF7 Y335C Prob. Dam. 0.985 Del. 2.32 § 25.7
Itch 1 No Q8C863 H563L Prob. Dam. 0.972 Del. 3.61 Medium −3.98029 Del. 21.5
Tbx21 7 No Q9JKD8 E481A Prob. Dam. 0.971 Toler. 3.22 Low −0.97263 Neutral 15.79
Prkdc 4 No P97313 I1010T Poss. Dam. 0.935 Del. 3.17 Medium −1.55087 Del. 25.9
Bcl2 3 No Q4VBF6 T175A Poss. Dam. 0.924 Toler. 3.04 Neutral −2.00435 Neutral 14.68
Dock8 5 No Q8C147 N1567Y Poss. Dam. 0.904 Del. 3.66 Medium −4.15438 Del. 26
Dock8 5 No Q8C147 K26E Poss. Dam. 0.894 Del. 3.92 Low § Del. ¶
Rag1 1 Yes P15919 E803G Poss. Dam. 0.879 Del. 3.83 High −2.75501 Del. 29.2
Il2ra 2 No P01590 V230A Poss. Dam. 0.763 Del. 1.89 Low −2.25488 Del. ¶
Rasgrp1 4 No Q9Z1S3 K659R Poss. Dam. 0.712 Toler. 3.49 Low −1.80793 Neutral 22.2
Jak3 2 No Q62137 I663V Poss. Dam. 0.705 Del. Low −3.23261 Del. jj
Cd74 1 No P04441 I203F Poss. Dam. 0.434 Toler. −2.02 Medium −2.04615 Neutral 17.91
Prkdc 5 No P97313 V3389L Benign 0.346 Toler. 3.73 Medium § Neutral 21.5
Ptprc 3 No P06800 K921R Benign 0.322 Toler. 2.64 Low −0.99775 Neutral 21.9
Rag2 2 No P21784 D424G Benign 0.151 Toler. 3.51 Medium −2.32166 Neutral ¶
Prkdc 2 No P97313 Y2044F Benign 0.097 Toler. 3.35 Medium −2.36465 Neutral 13.5
Tnfaip3 1 No Q60769 K41E Benign 0.049 Toler. Neutral −0.78466 Neutral 22.3
Ptpn6 4 No P29351 D90E Benign 0.015 Del. −5.96 Medium § Neutral 12.48
Lig4 1 No Q8BTF7 N158K Benign 0.013 Toler. −0.667 § 15.95
Prkdc 3 No P97313 V3589A Benign 0.007 Toler. −1.75 Low −1.69134 Neutral jj
Dock8 4 No Q8C147 T1748A Benign 0.001 Toler. 2.51 Neutral −1.77255 Neutral 14.89
Cd22 1 No Q3UP36 M157V Benign 0 Toler. 2.65 Neutral −0.93903 Neutral ¶
Itpkb 2 No B2RXC2 L228P Benign 0 Toler. −1.04 Neutral § Neutral ¶
AA, amino acid; cat., category; Del., deleterious; Mut Assessor cat., MutationAssessor category; Mut phen obs?, mutant phenotype observed?; Num hom,
number of homozygotes; Poss. Dam., possibly damaging; Prob. Dam., probably damaging; Toler., tolerated.
*Larger GERP scores denote variants more likely to be deleterious.
†Smaller subPSEC scores denote increasingly deleterious variants.
‡Phred-like scores calculated using coordinates of mouse mutation lifted over to the orthologous human protein.
§Missing values were not contained in the alignment created by the HMM.
¶Mouse and human orthologs have a different amino acid at the variant site.
jjAbsent in GRCh37.
Miosge et al. PNAS | Published online August 12, 2015 | E5191
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
SE
E
CO
M
M
EN
TA
RY
known to cause a mouse phenotype, where it was estimated that
only 21% of missense mutations cause a measurable individual
phenotype (26). Of the four missense mutations here that pro-
duced a phenotype, three (Btk, Ets1, and Il7r) were inferred by
PolyPhen2 to be probably damaging and one (Rag1) as possibly
damaging. One missense variant (Il7r), which produced the
expected mutant phenotype in mice, was predicted to be a benign
change with human-specific PolyPhen2, whereas it was predicted
probably damaging by the mouse-specific calculation (Table S2).
Conversely, none of the 12 missense mutations predicted to be
benign had a measurable blood cell immune phenotype by flow
cytometry. Hence, from this set of tested mutations in essential
immune genes, none of the inference tools appear to generate a
high rate of false-negative calls. In contrast, 10 of the 30 de novo
missense mutations were called as probably damaging by Poly-
phen2, yet only 3 of these (30%) resulted in the expected pheno-
type. A further nine missense mutations were inferred as possibly
damaging, yet only one of these (11%) produced the expected
mutant phenotype. Fifteen mutations received a Polyphen2 score
of 0.85 or greater, yet only 4 of these (27%) were sufficient to
cause a discernable immune cell abnormality in individual ho-
mozygous mice. PolyPhen2 probably damaging predictions ap-
peared the most reliable indicator of a mutant phenotype, although
SIFT predictions (20%) and Condel aggregated predictions (23%)
were of similar utility. Table 1 and Table S2 include Phred-like
scores calculated with the CADD method (13) for each ortholo-
gous human mutation corresponding to each mouse mutation. The
CADD scores correctly prioritized only two of the four mutations
with a measurable in vivo phenotype (Btk and Rag1), assigning
these the highest two scores, whereas the other two received rel-
atively low scores. By contrast, Polyphen2 correctly predicted all
four as probably damaging. CADD assigned a score of greater than
20 to 13 missense mutations, yet only 2 of these (15%) had a
measurable phenotype. Thus, use of CADD did not improve the
prediction of in vivo immune cell phenotypes.
Functional Inferences for All Potential Mutations in 23 Immune Genes.
The disparity between the predicted and observed effects of the
missense mutations above led us to ask what the range of func-
tional inferences was like for all possible missense mutations in
the same set of essential immune genes. We determined the
exhaustive set of all 89,887 possible single missense mutations in
the 23 essential immune system genes studied above and calcu-
lated their PolyPhen2 scores (labeled All possible in Fig. 1).
These potential mutations produce a characteristic “hourglass”
shape previously observed (23) where the range of Polyphen2
scores is concentrated toward being either deleterious or benign
and less likely to be of intermediate effect. Half of all potential
missense variants in these genes receive a PolyPhen2 score
greater than 0.85.
As opposed to all possible mutations, we also analyzed all
missense mutations generated by ENU in the same set of 23 es-
sential immune genes but independent of any phenotypic testing.
These ENU-induced mutations were identified by exome se-
quence analysis of 2,081 G1 offspring of ENU-treated C57BL/6
mice and this allowed us to consider the impact of the charac-
teristic T/A → A/T and A/T → C/G substitutions produced by
ENU. Of a total of 136,970 ENU-induced coding variants across
the mouse genome, 388 nonsynonymous variants were identified
in the 23 essential immune genes (ENU observed in Fig. 1). Only
33 of these were bred to homozygosity and tested for in vivo im-
mune phenotypes as described above, and the remaining 355
represent de novo mutations of unknown phenotype. Comparison
of kernel density plots in Fig. 1 between these variant sets in-
dicates that the ENU Observed set tended toward higher Poly-
Phen2 scores than the All Possible set. Restricting the All Possible
set to just T/A → A/T and A/T → C/G substitutions did not
replicate this effect; hence, this appears not to be due to the
characteristic pattern of ENU-induced mutations. The disparity
in sample sizes between these variant sets is large (89,887 All
Possible vs. 246 ENU Observed). Iterative random sampling
(with replacement) of the All Possible variant set to produce a
subset of the same size as the ENU Observed set indicated that
the median PolyPhen2 value of the ENU Observed set is not
significantly higher than the All Possible set at P = 0.02.
For comparison, we also computed Polyphen2 scores for an
independent set of ENU-induced mutations in the same 23 genes,
but representing alleles discovered by phenotype-driven blood cell
screening followed by meiotic mapping and DNA sequencing
(ENU phenotype selected in Fig. 1 and Table S4). These al-
leles were identified using the same flow cytometric panel by
screening peripheral blood samples from thousands of G3 progeny
from hundreds of G1 mice, where the G1 parents had not been
exome sequenced to detect their ENU-induced mutations. When
G3 animals were identified with discernible abnormalities in their
lymphocyte subsets, and these were proven heritable by identifying
the same immune defect in first- or second-degree relatives
from later generations of the same pedigree, exon and exome
sequencing followed by allele-specific genotyping was used to
identify the causative mutation (23, 26). The phenotypically selected
set comprised 19 mutations in 12 of the 23 genes studied here:
Bcl2, Btk, Cd22, Il7r, Jak3, Lig4, Prkdc, Ptpn6, Ptprc, Rasgrp1, Satb1,
and Tnfaip3 (Table S4). Eleven (58%) were missense mutations,
Fig. 1. Spectrum of functional consequences predicted by PolyPhen2 for
different sources of missense variants in 23 essential immune system genes.
PolyPhen2 scores were calculated for the following sets of missense variants:
All possible, the complete set of 89,887 possible amino acid substitutions
caused by single missense changes in the 23 mouse immune system genes
listed in Table 1; ENU observed, 388 mostly unphenotyped, de novo muta-
tions found in the 23 genes by exome sequencing of 2,081 G1 mice; ENU
phenotype selected, mutations in the 23 genes discovered by flow cyto-
metric screening of thousands of G3 offspring of ENU-exposed mice; Mouse-
rat, missense variants between the C57BL/6J mouse and Brown Norway rat
genome sequences; Mouse taxa, missense variants between the four wild-
derived, inbred strains representing Mus spretus, Mus musculus musculus,
Mus musculus domesticus, and Mus musculus castaneus; Mouse Lab strains,
missense variants between the genomes of 14 inbred laboratory mouse
strains; B6 mouse substrains, missense variants between the genomes of
inbred strains C57BL/6J and C57BL/6N; Human-Chimp, missense variants in
the orthologous 23 immune genes between the reference human and
chimpanzee genome; Human variation, missense variants in the same immune
genes detected by population-scale human exome sequencing (36). The bar-
plots in gray indicate the number of variants present in each set. Purple violin
plots are kernel density plots representing the distribution of PolyPhen2 scores
for each variant set. The white dot indicates the median PolyPhen2 value for
each set. The black bars are box-and-whisker plots: thick black bar extends
from the first to the third quartile; thin black lines extend to the lowest and
highest data points within 1.5 times the interquartile range.
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4 (21%) were stop-gain or nonsense mutations (compared with 9%
of unphenotyped mutations in the same genes), and 3 (16%) were
mutations that disrupted exon splice sites. Compared with the dis-
tribution of all possible missense mutations, the PolyPhen2 scores
for phenotypically selected missense mutations were strongly biased
toward higher values: 82% received scores greater than 0.85.
Functional Inference of Rodent Interspecies and Interstrain Variants.
Given the distribution of scores for all possible missense muta-
tions, we next asked what range of PolyPhen2 scores would be
calculated for inherited nonsynonymous variants between mouse
and rat in the same 23 essential immune genes. Alignments of
these mouse genes with orthologous rat genes (27) were obtained
from Ensembl Compara (28), and PolyPhen2 scores were calcu-
lated for all missense variants between the two rodent species,
which have been separate for 12–24 My (29, 30). Individual neu-
trally evolving nucleotide positions within the mouse and rat ge-
nomes have been mutated on average between 0.15 and 0.2 times
since species divergence (27), so it would be expected that be-
tween 9,427 and 12,569 missense variants are likely to have arisen
in the 62.8 Kb of coding sequence within the 23 essential immune
genes during this time. Because the rat sequence comes from
highly inbred individuals of the Brown Norway strain (27), the set
of mouse-rat missense immune gene variants is expected to have
been subject to many intensified generations of purifying selection
to remove deleterious variants. Fig. 1 shows that functional in-
ference scores calculated with PolyPhen2 for mouse-rat variants
were almost exclusively benign. In the small number of cases
where a deleterious prediction was made, investigation of the
orthologous mouse and rat sequences demonstrated that the del-
eterious variants originated from areas of low homology in the
pairwise protein sequence alignment. In the investigated subset
of these low-homology protein regions, it was apparent that the
UniProt reference sequences chosen for the Compara mouse/rat
alignment were not the identical splice form, and the deleterious
substitutions lay within short regions due to alignment of non-
orthologous exons. Even without excluding these seemingly non-
homologous nucleotides and assuming that all variants are
nonrecent and have been subject to extensive purifying selection,
the deleterious overcall rate of PolyPhen2 is still just 4.68%
(deleterious variants/total variants = 40/854 = 0.0468). Similarly,
among other functional inference tools, the rates of deleterious
overcalling were determined: MutationAssessor, 3.30% (25/758 =
0.0330); SIFT, 2.05% (13/634 = 0.0205; excluding low confidence
predictions); PANTHER, 4.44% (15/338 = 0.0444; Pdel > 0.5).
Overall, these tools appear remarkably accurate by this measure,
and these values are likely an overestimate as some of the variants
will be of recent origin or spurious due to local misalignment.
As the likely evolutionary age of a mutation decreases, the
time for purifying selection to occur on deleterious variants is di-
minished and the number of deleterious variants as a proportion of
the total variants is expected to be greater. Much genomic data
exist for mouse strains, especially the recently diverged laboratory
strains ofMus musculus (31, 32). Missense variants between mouse
strains in the 23 immune genes above were collected from the
Sanger Institute mouse genomes resource (31). The divergences
between the four sequenced wild-derived mouse strains, repre-
senting four divergent mouse taxa (Mus spretus, Mus musculus
musculus, Mus musculus domesticus, andMus musculus castaneus),
are much less than the mouse-rat divergence and are estimated to
be not greater than 1.6 My (for musculus/spretus) (33). Each of the
four sequenced, wild-derived mouse strains has nevertheless un-
dergone many generations of laboratory-based inbreeding before
genome sequencing, potentially exerting strong purifying selection
against deleterious missense mutations that might have arisen since
strain/subspecies divergence. Fig. 1 shows the range of PolyPhen2
scores for 52 missense variants in the 23 essential immune genes
between the mouse subspecies (Mouse Taxa): only 5.7% (3/52) of
those observed between mouse taxa received a PolyPhen2 score
greater than 0.85 compared with 50% of all possible missense
variants in the same immune genes. This result implies that most
amino acid substitutions in the 23 immune genes that receive a
PolyPhen2 score of greater than 0.85 are indeed sufficiently dele-
terious to be removed over many generations by purifying selec-
tion, either during the divergence of wild-mouse strains or during
fixation to homozygosity by laboratory inbreeding.
We extended this analysis to missense variations of very recent
origin that exist between inbred strains of laboratory mice. Be-
tween the 14 Mus musculus laboratory strains for which a full
genome sequence has been obtained (31) 116 missense variants
were identified within the set of 23 essential immune genes. The
divergences between laboratory Mus strains are complicated, but
a large number of the variants identified between strains will be
of much more recent origin than those that exist between Mus
taxa—of the order of a hundred years. The range of PolyPhen2
scores for these variants (Fig. 1, Mouse Lab Strains) includes
12.9% (15/116) with a PolyPhen2 score of 0.85 or greater, rep-
resenting an apparently increased fraction of possibly damaging
or probably damaging variants than the interspecies Mus vari-
ants, but still much lower than the random set of all possible
variants. The range also includes a great many benign variants
that may predate the strain divergences or are evidence for the
effect of purifying selection even over a few hundred genera-
tions, especially during the inbreeding conducted over the last
century to produce these strains. The inbred C57BL/6J and
C57BL/6N substrains have only been genetically separate for
∼220 generations, since 1951 (32), and their genomes have only
32 missense variants in the 23 essential immune genes studied.
Although the number of variants is small and the median score is
benign, these variants will be mostly of very recent origin, and a
higher proportion is computationally inferred to be deleterious
(Fig. 1, B6 Mouse Substrains).
Functional Inference of Human Missense Variants in 23 Immune Genes.
Because missense mutations in many of the immune genes studied
above are already known to cause devastating human immune
deficiency or autoimmune disorders, we performed a parallel set
of analyses of human missense variants in the same genes. Within
these 23 genes, PolyPhen2 scores were calculated for the 84 mis-
sense variants identified between the human reference genome
and the chimpanzee genome sequence (34) [Pan troglodytes; hu-
man-chimp divergence 5–7 Mya (35)]. The range of scores was
similar to those for missense variants between mouse taxa: the
median score being benign (0.001), and only 5.6% (5/84) receiving
a score greater than 0.85 (Fig. 1, Human-Chimp). However, a very
different distribution was observed when we calculated PolyPhen2
scores for the set of all missense variants within these same genes
detected in 6,503 human genomes by exome sequencing (36) (data
release ESP6500SI-V2). The distribution of scores for all observed
human variants was similar to the distribution observed for all
potential missense variants in these immune genes, with approxi-
mately half (987/2,061 = 47.9%) receiving a score of 0.85 or
greater (Fig. 1, Human Variation). Most of these human pop-
ulation variants are likely to be of relatively recent origin, because
those with a minor allele frequency of 5% or greater account for
1.7% (35/2,026) of the total variants. Of these more prevalent and
presumably older missense mutations, only 20% (7/35) have a
PolyPhen2 score >0.85.
Systematic Comparison of Prediction and in Vitro Phenotype for
Mutations in TP53. As noted above, a limitation of the in vivo im-
mune cell phenotyping tests is the potential for clinically signifi-
cant partial loss-of-function mutations to be masked by compen-
sating processes, such as lymphocyte homeostatic expansion to
counter diminished lymphocyte differentiation, and by shielding of
the mice in the laboratory from normal exposure to a wide range of
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pathogens and dietary fluctuations. We therefore sought an in-
dependent approach to compare computational inferences with ex-
perimentally measured effect in a random set of unselected missense
mutations, using experimental testing in vitro by quantitative assays
with the least possibility for compensation or environmental mask-
ing. A comprehensive mutation dataset meeting these criteria exists
for the human tumor suppressor gene and protein, TP53 (also called
p53) (37). Loss-of-function mutations in TP53 are the most frequent
somatic mutation in human cancer and cause highly penetrant im-
mune system cancers when experimentally bred to homozygosity in
the germ line of mice. WT TP53 suppresses tumor development by
blocking cell division and inducing apoptosis, primarily by binding to
defined DNA sequence motifs in numerous target genes and en-
hancing their transcription into mRNA (38). The transcription-
enhancing activity of WT TP53, and each possible single amino
acid substitution arising from single nucleotide mutations, has been
systematically quantified by expressing each mutant in yeast in vitro
and measuring transcription-enhancing activity against different
TP53-binding enhancer sequences from the human TP53 target
genes p21WAF1,MDM2, BAX, 14–3-3σ, p53AIP1, GADD45,NOXA,
and p53R2. Each TP53 target sequence has been inserted into an
enhancerless reporter gene encoding a fluorescent protein (37).
When WT or mutant TP53 was expressed, transcription and mean
accumulation of the fluorescent protein in a population of yeast
cells was measured with a spectrophotometer (37).
We calculated the PolyPhen2 score for all 2,314 potential TP53
missense mutations arising from single nucleotide substitutions
and plotted the score for each mutation against its measured
p21WAF1 transcriptional enhancer activity, the latter normalized to
the activity of WT TP53 (Fig. 2A). The transactivation (TA) assay
results are similar among the differing TP53 target binding se-
quences (Table S5), as are the plots of PolyPhen2 score against TA
activity (Fig. S1). Fig. 2A shows that the set of all possible muta-
tions in the resulting plots cluster into three clear density regions.
In a first cluster, 640 TP53 mutations (31.6%) had TA activity
diminished to less than 50% of WT and received PolyPhen2 scores
of 0.8 or greater. The mutations in this first cluster appear to
represent true-positive (TP) predictions. A second cluster in-
cludes 831 mutations (41.0%) and had good transcriptional ac-
tivity, greater than 50% of WT, and received a PolyPhen2 score
of 0.2 or less. This cluster appears to represent true-negative (TN)
predictions. However, the third clear cluster of 462 mutations
(22.8%) also had WT or near WT TA activity yet received a
PolyPhen2 score of 0.8 or higher. This cluster represents apparent
false-positive (FP) predictions of the effect of missense muta-
tions, and its range of PolyPhen2 scores was comparable to the
TP predictions (Fig. 2A). Of the 1,102 mutations predicted to be
deleterious with score of 0.8 or greater, 42% had good TA ac-
tivity measured in yeast with a reporter carrying the TP53-binding
sequence from p21WAF1. When these 1,102 predicted delete-
rious mutations were tested for activity against TP53-binding se-
quences from other target genes, the fraction that were FP pre-
dictions ranged from 34% for MDM2 sequences to 61% for
P53R2 sequences (Table S5 and Fig. S1). By contrast, false-
negative (FN) predictions, where mutants have less than 50% of
WT TA activity yet are predicted not to be damaging (PolyPhen2 ≤
0.2), accounted for only 93 of the 2,026 mutations (4.6%).
We performed parallel analyses of all possible 2,314 TP53
missense mutations using MutationAssessor and CADD (Fig. 2 B
and C and Tables S6 and S7), yielding a similar clustering of all
possible mutations into three main groups of TN, FP, and TN
predictions. However, unlike PolyPhen2 that produces a simple
bimodal distribution of scores, CADD and MutationAssessor gave
a broader spread of scores, and a trimodal distribution in the case
of CADD. Both of these measures appeared to spread out scores
at the upper end of the deleterious range so that the distribution
of scores for FPs tended to be lower than the range of scores for
TPs. This was especially pronounced for CADD scores: 45% of
mutations with a score of 20 or greater were FP predictions
A B C
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Fig. 2. Comparison of computationally predicted
damage with experimentally measured activity of
TP53. (A–C) Analysis of all 2,314 amino acid sub-
stitutions in human TP53 that can arise from a single
nucleotide substitution. The transcription-enhancing
activity of each mutant, acting on the p21WAF1 target
sequence in yeast (37), is shown on the y axis nor-
malized to the activity of WT TP53 and multiplied by
100. Predicted damage for each possible mutation is
plotted on the x axis, calculated by (A) PolyPhen2;
(B) MutationAssessor; and (C) CADD. Regions marked
with dashed lines denote true positives (TP), true
negatives (TN), false positives (FP), and false nega-
tives (FN). (D–F) The same analyses performed on
1,191 somatically acquired TP53 missense mutations
from human cancers in the TP53 database. (G–I) The
same analyses of 172 germ-line TP53 missense mu-
tations found by clinical sequencing, primarily per-
formed when the clinical phenotype was consistent
with a germ-line TP53 mutation.
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(retaining at least 50% of WT activity), but only 19.5% of muta-
tions with a score of 30 or greater were FP by the same measure.
Evidence for Nearly Neutral TP53 Mutations. As there are a large
number of unique TP53 mutations in both the FP (CADD
score > 20; TA activity > 50%) and the group of TN mutations
with CADD score < 5 but TA activity > 50%, it was possible to
compare the distribution of transcriptional activity values be-
tween these groups in aggregate (Fig. 3). This comparison showed
that the mean activity of the FP set of mutations was 86% of the
mean activity in the TN set, with the difference being statistically
significant. A smaller difference, although still statistically signifi-
cant, was observed in the groups of TN and FP mutants resolved
by Polyphen2 and MutationAssessor scores (Fig. S2). Hence a
large fraction of mutations predicted to be deleterious by the
various algorithms may not be FP functional inferences with no
actual effect, but instead appear to be nearly neutral mutations of
small effect (39). Fig. 2C also shows that many intermediate points
lie between the CADD TN and FP categories (Phred-like score > 5
and < 20). When these intermediate values are included in the
TN category, this category remains significantly distinct from
the FP category (Fig. S2).
Some apparent FP mutations might have lost some other
function critical for TP53 in human cells not measured in the
yeast assay. To explore this possibility, we prepared comparable
plots for a set of 1,191 distinct amino acid substitutions identified
in human cancers and obtained from the curated TP53 mutation
database (IARC TP53 Database, R17) (40). Compared with the
42% FP rate found for all mutations with PolyPhen2 score > 0.8,
in the cancer-selected somatic mutation set, this was reduced to
25% (Fig. 2C and Table S5). The decrease in FP predictions is
likely to be due to the cancer mutation set being enriched for
mutations that diminish TP53 transcriptional activity to less than
50% of WT (667/1,192, 53%) compared with the full set of
mutations (733/2,026, 36%), consistent with previous analysis
using a cutoff of 20% of WT activity (40); 82.8% of the TP subset
of TP53 mutations was found in two or more independent cases
of cancer (reported in the TP53 mutation database), whereas
only 27.7% of the FP nearly neutral subset was found recurrently
(Fig. S3A). The small FN subset also had a higher fraction found
recurrently in cancer (60.0%), emphasizing the importance of
experimental testing to identify this small but important subset of
mutations. TN mutations (26.1%) were no more likely to be
found recurrently in cancer than FP mutations, suggesting that
these subsets represent passenger mutations that confer no neo-
plastic advantage.
The same analysis was performed on a phenotypically selected
set of 172 TP53 missense mutations found by sequencing germ-
line DNA in patients with types of tumors and age of onset
suggesting a loss-of-function TP53 germ-line mutation (IARC
TP53 Database, R17) (40). Only 8% of those that were predicted
to be deleterious by PolyPhen2 retained >50% activity in the
yeast assay, representing a 5.25-fold lower fraction of FP pre-
dictions than for all possible mutations. The particularly low rate
of FP predictions in the germ-line set is likely to reflect the high
proportion of these mutations that lack transcriptional activity,
especially in families with highly penetrant cancer meeting the
criteria of familial Li-Fraumeni syndrome, where 92% of muta-
tions have less than 20% of WT transcriptional activity (40). In
other words, when the clinical phenotype is sufficiently clear and
specific for profound loss-of-function mutations in a particular
gene, simply finding a rare missense mutation in that gene is
already highly predictive, so that computational predictions pose
a lower risk of FPs.
The higher concordance between prediction and actual effect
among cancer-selected somatic mutations and in phenotypically
selected germ-line mutations in TP53 implies that the yeast tran-
scriptional assay measures the relevant TP53 function for tumor
suppression. However, it does not rule out the possibility that
some FP predictions might disrupt other evolutionarily conserved
TP53 functions. Interestingly, FP mutations were concentrated
outside the core DNA-binding domain residues 102–292 (41) (Fig.
S3B), in contrast to the 95% of oncogenic mutations recorded in
TP53 that lie within the DNA-binding domain (42). An example
of a functionally important mutation that lies outside the DNA-
binding domain and does not have a direct effect on transactivation
is the E388A substitution that disrupts conjugation of SUMO1 to
K396 in TP53 (43). SUMO1 conjugation at this site has a regula-
tory effect on TP53 activity (44), but the transactivation assays in
yeast (37) indicate this has little effect on the core transactivation
mechanism. The PolyPhen2 score for this change (0.893) predicts it
is probably damaging, but as the change has little effect of trans-
activation (p21WAF1 assay value = 105.5), this data point is classified
as a FP inference in Fig. 2A.
Discussion
The discordance between the predicted and actual effect of
missense mutations revealed here creates the potential for many
FP conclusions in clinical whole genome sequencing. Due to the
large number of candidate missense variants revealed by whole
exome or genome sequencing of any individual, computational
prediction of the functional importance of each mutation is widely
used to prioritize candidates for further analysis. However, current
functional inference tools rely heavily on sequence conservation
information. As we have found, these functional predictions do
not effectively differentiate between mutations that are immedi-
ately clinically relevant, because they ablate or markedly reduce
function of an essential protein, and those that are nearly neutral
because they only decrease the function of the corresponding
protein by 10% (39). FN predictions were also a small but sig-
nificant subset of mutations in the systematic analysis of TP53.
Hence, for interpretation of a clinical genome sequence at pre-
sent, it is essential to measure experimentally the consequence of
any missense mutation thought to be causal.
Fig. 3. Distribution of measured TP53 transactivation activity from true-
negative and false-positive TP53 mutations. From all possible TP53 missense
mutations, the distribution of measured transcriptional activity values is
shown for those inferred as true negative (TN, CADD score < 5 and trans-
activation activity >50; blue, n = 322) or as false positive (FP, CADD score >
20 and transactivation activity >50; red, n = 573). The mean normalized
activity was 108.8 for the TN set and 93.4 for the FP set. The distribution of
values for each set is unlikely to be the same (Kolmogorov–Smirnov D =
0.3427 P < 2.2e−16; Wilcox W = 57,261.5, P < 2.2e−16).
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Two lines of experimental evidence from our work indicate that
this lack of differentiation has the potential for overcalling caus-
ative mutations. First, 73% of predicted deleterious missense
mutations arising from de novo single nucleotide substitutions in
23 essential immune system genes did not sufficiently disrupt
protein function to produce an observable defect in the expec-
ted subset of blood lymphocytes in individual homozygous mice.
Absence of a phenotype in vivo may occur by compensation: for
example, a lymphocyte production defect can be compensated by
lymphocyte homeostatic expansion. A discernable in vivo pheno-
type may also require an environmental cofactor such as malnu-
trition or exposure to a particular infectious agent. For that
reason, we turned to the TP53 gene for a complementary analysis
of predicted versus actual effects of all possible single nucleotide,
missense mutations, taking advantage of a dataset where the ex-
perimentally determined phenotype of each mutation has been
measured in a simple in vitro assay. Even under these simplified
conditions, 42% of the missense TP53 mutations that were pre-
dicted to be deleterious caused little or no measurable decrease in
the protein’s transcription-enhancing activity.
The plots in Fig. 2, especially those of CADD Phred-like scores,
show that mutations that are computationally predicted to be
deleterious have a bimodal distribution. Half drastically decreases
protein activity to a mean of 17% ofWT, and it is this group that is
of interest in clinical cases with onset in childhood or adolescence
as suspected monogenic or oligogenic disease. The other half,
despite most being scored just as likely to be deleterious, actually
only slightly decrease protein activity, to a mean of 86% of WT.
Discerning the subtle shift in activity caused by these nearly neu-
tral mutations required us to consider the FP mutants as a group,
comprising hundreds of independent measurements. Because they
have effects on protein activity that are barely measurable in the
laboratory, these nearly neutral mutations are unlikely to cause
monogenic diseases but may be relevant to diseases that have a
more complex basis involving interaction of many weakly damaged
genes and environmental factors.
Presumed nearly neutral FP mutations were frequent among
unselected sets of missense mutations (de novo ENU mutations,
all possible TP53 mutations) but were rare in sets of mutations
that had been subject to phenotypic selection. When applied to
missense variants in the 23 essential immune system genes be-
tween inbred mouse and rat species, or between inbred mouse
taxa, Polyphen2 only predicted 4.7% and 5.7%, respectively, to
be deleterious. Because 50% of random mutations in the same
23 genes are predicted to be deleterious, the much lower fre-
quencies among mutations that have become fixed in these
species/strains implies that most of the FP predictions in the
random mutation sets are indeed deleterious over evolutionary
scales. This feature was not restricted to mouse mutations, be-
cause a similarly low rate of 5.6% was predicted to be deleterious
in the set of variants in the 23 essential immune genes between
the consensus human and chimpanzee genome sequences com-
pared with 48% of the predominantly rare variants in the same
23 genes present in a population of 6,503 people for whom
exome sequences had been obtained.
At first sight, it appears paradoxical that nearly neutral mu-
tations in essential immune genes will be efficiently removed
from the species’ gene pool despite having no easily discernible
impact on the immune system of individual homozygotes. One
possible explanation is that these subtle variants are individually
sufficient to cause a serious problem in conjunction with par-
ticular environmental stressors such as malnutrition and patho-
genic microbes. Another explanation comes from decades of
research into the evolution of protein molecules and the nearly
neutral theory of molecular evolution (39, 45). Mathematical
models predict that slightly disadvantageous nearly neutral al-
leles will be lost over many generations through random drift in
large populations, even when these alleles reduce fecundity by as
little as 1% (39). For essential immune genes, that small dif-
ference in fecundity could result from one extra bout of influenza
per lifetime, which would not be perceived as clinically significant.
In addition to genetic drift in large populations, truncating selec-
tion has the potential to remove nearly neutral mutations from the
gene pool more rapidly (46). This model considers that, as the
number of slightly damaging alleles increases in the population, by
Poisson distribution a subset of individuals will inherit a larger
burden of nearly neutral alleles affecting a critical function (46),
for example, in RAG1, RAG2, LIG4, DCLRE1C, and PRKDC and
other genes required for VDJ recombination. Although none of
these mutations would be of clinical consequence individually, the
chance inheritance of three or more subtle defects in the same
pathway may be sufficient to cause recurrent infections or Omenn’s
syndrome-like autoimmune manifestations. Previously, we demon-
strated experimentally how three heterozygous loss-of-function mu-
tations in sequential steps in a biochemical pathway—affecting Lyn
kinase, its substrate CD22, and the CD22-binding tyrosine phos-
phatase SHP1—only precipitate B-cell deficiency in individuals that
inherit all three but not any pair or single mutation (47). Some of
the 23 immune genes studied here have essential roles outside the
immune system, and those other functions may be more sensitive
to disruption by apparently FP mutations. For example LIG4,
DCLRE1C, and PRKDC are critical for DNA damage repair in all
cells, and it is conceivable that small decreases in their activity could
subject these variants to purifying selection over evolutionary
timescales because of more rapid aging of stem cells (48).
The same question about subtle loss-of-function arises for the
apparent FP predictions among TP53 mutations. These apparent
FP predictions were frequent in the set of random TP53 muta-
tions (42%) but much lower in sets of TP53 mutations that had
been positively selected for TP53 loss-of-function either as a
result of being found by selective resequencing in cancer cells
(25%) or in the germ line of young cancer patients with sus-
pected Li-Fraumeni syndrome (8%). Most of the TP somatic
mutations were found recurrently in different cancers, consistent
with these being driver mutations that confer a growth advantage
for neoplastic cells. By contrast, most of the apparent FP somatic
mutations that retained greater than 50% of transactivation ac-
tivity were singleton observations, as would be expected if these
were random passenger mutations. These singleton FPs might
nevertheless represent driver mutations that provide a more
subtle growth advantage. A 10% decrease in TP53 transcrip-
tional activity is difficult to distinguish from WT in individual
laboratory tests but may nevertheless confer a selective advan-
tage when this effect is compounded over hundreds of cell di-
visions or when combined with other partial loss-of-function
mutations in the TP53 tumor suppression pathway that may have
arisen earlier in the evolution of the neoplastic cell clone.
A similar explanation may apply to the 10% of apparent FP
predictions for germ-line TP53 mutations. Indeed one of this set
came from a clinical case that did not display the age of onset and
pattern of sarcomas typical of Li-Fraumeni syndrome. Instead this
individual displayed a syndrome of familial adenomatous poly-
posis (FAP) that was at the severe end of the spectrum and carried
an additional germ-line mutation in the APC tumor suppressor
gene that is typically inactivated in FAP (40).
In clinical genome sequencing, the risk of FP calling of missense
mutations is likely to be highest when the clinical phenotype does
not match a distinct Mendelian syndrome but could be explained
by defects in hundreds of genes, for example, in sporadic cases of
autoimmune disease or in common variable immune deficiency.
Here it will be particularly critical to validate computational pre-
dictions experimentally by biochemical tests and recreating the
mutations in animals (49). By contrast, the FP problem demon-
strated here is minimized when the clinical phenotype can be re-
fined sufficiently that only one or two genes could explain it—for
example, when a person develops multiple cancers at an early age
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including uncommon sarcomas typical of Li-Fraumeni syndrome.
Our findings underscore the importance of acquiring two additional
types of information to interpret missense variation identified by
clinical genome sequencing: (i) direct experimental measurement
of the consequences of a candidate mutation, using as specific and
sensitive an assay as possible; and (ii) much more specific human
phenotyping, capable of narrowing the set of candidate genes to a
handful related to a particular biochemical pathway or syndrome.
Experimental analysis of the connection between nearly neutral
mutations and in vivo immune or cancer phenotypes poses a major
challenge and will likely require very large numbers of replicate or
iterative measurements.
Materials and Methods
Generation of Random Mouse Mutants, Sequencing of Mouse Exomes, and
Variant Calling. Generation of pedigrees from mice treated with ENU, se-
quencing of exomes of these mice, and computational identification of ENU-
induced point mutants were performed as previously described (23). This
research was approved by the animal experimentation and ethics committee
of the Australian National University (protocol number A2014/61).
Detailed Description of Mouse-Specific PolyPhen2 Changes. PolyPhen2 (12) scores
were calculated from a local mouse-specific installation of PolyPhen version
2.1.0. Local installation required using the mouse specific UniProt (50) and
Pfam (51) databases during setup followed by the subsequent mapping of all
mouse UniProt protein sequences to mouse assembly (mm9) coordinates. This
mapping allows mouse variant genomic coordinates to be converted directly
to UniProt amino acid locations giving PolyPhen2 access to mouse-specific
protein annotations (often different from the human homolog annotations),
thus often resulting in more accurate PolyPhen2 scores. The mapping was
accomplished by searching the CCDS (consensus coding sequence; ref. 52) gene
sets for exact UniProt protein sequence matches and was successful for 93% of
all mouse UniProt entries. The remaining 7% of nonmapping UniProt entries
were provided as input to PolyPhen2 as a UniProt protein FASTA-formatted
file and relative protein coordinates (which is a less specific input option
available with PolyPhen2). To calculate many thousands of PolyPhen2 scores in
a timely manner, UniProt-specific PolyPhen2 calculations were cached, hence
avoiding duplicate calculations for variants occurring in UniProt entries pre-
viously encountered in other samples.
Calculation of Functional Inferences. Mouse PolyPhen2 scores were calculated
as described above. SIFT (6) scores were obtained from the Variant Effect
Predictor (53) and from the SIFTWeb server (www.siftdna.org). MutationAssessor
(mutationassessor.org) (7) and PANTHER (www.pantherdb.org) (10) scores were
calculated for mouse-specific UniProt entries using public webservers provided
by the method authors. CADD scores (13), which are presently only calculated
from human data, were determined by mapping the coordinate of each mouse
mutant to the orthologous base in the human genome with liftOver [via the
University of California, Santa Cruz (UCSC) genome browser] (54), providing
that the orthologous amino acid in the human reference was identical to that
in the mouse reference . Scores for these humanized mutations were obtained
from the CADD Web server (cadd.gs.washington.edu). GERP (11) scores were
derived from the UCSC Genome Browser (54). Condel weighted average scores
were calculated using PolyPhen2, SIFT, and MutationAssessor scores using the
Perl code provided by the Condel authors (15).
Allele-Specific Genotyping. Competitive allele-specific genotyping was per-
formed using the KASP system (Kbioscience). A pair of WT and mutant allele-
specific oligonucleotide primers were designed to anneal to sequence flanking
the variant site. These primers were conjugated with a tail sequence that
contained a FRET cassette labeled with allele-specific dyes. With these pri-
mers, sample DNA was amplified with a thermal cycler and dye values read
with a FluoStar Optima fluorescent microplate reader (BMG Labtechnolo-
gies). Homozygous and heterozygous genotypes were distinguished by
whether one or two fluorescent signals, respectively, were detected.
Mouse Phenotyping.Mouse phenotypes were appraised for most mutations by
eight-color flow cytometry on peripheral blood. Two hundred microliters of
blood was collected by retro-orbital bleeding into tubes containing 20 μL
heparin (Sigma: 1,000 U/mL in PBS). Red blood cells were lysed, and samples
were stained in 96-well plates alongside WT C57BL/6 mouse controls as pre-
viously described (55). Granulocytes were enumerated by forward and side
scatter of laser light. The antibodies used to detect B, T, and NK populations
were as follows: anti-B220 (RA3-6B2; BD Pharmingen), anti-IgM (R6-60.2; BD
Pharmingen), anti-IgD (11-26c.2a; BioLegend), anti-CD3 (17A2; eBioscience),
anti-CD4 (RM4-5; BioLegend), anti-CD44 (IM7; BioLegend), anti-KLRG1 (2F1;
eBioscience), and anti-NK1.1 (PK136; BD Pharmingen). To detect splenic
marginal zone B (MZB) cells in Dock8 mutant mice, spleens were harvested,
and single cell suspensions were stained with the following antibodies to
distinguish MZB cells (B220+, IgM high, CD21 high, CD23 negative) from
follicular B cells (B220+, IgM intermediate, CD21 intermediate, CD23 posi-
tive): anti-B220 (RA3-6B2; BD Pharmingen), anti-IgM (II/41; eBioscience), anti-
CD21 (7E9; BioLegend), and anti-CD23 (B3B4; Biolegend). Samples were ac-
quired using a LSR II flow cytometer (BD Bioscience) and analyzed using
FlowJo software (FlowJo LLC).
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Fig. S1. Analysis of PolyPhen2 predicted damage scores compared with the measured transactivation activity of all possible TP53 missense mutations using
binding sequences from eight different TP53 target genes. The target binding sequences used in each transactivation assay are (A) p21WAF1, (B) MDM2,
(C) BAX, (D) 14–3-3σ, (E) p53AIP1, (F) GADD45, (G) Noxa, and (H) p53R2.
Miosge et al. www.pnas.org/cgi/content/short/1511585112 1 of 9
Fig. S2. Distributions of residual TP53 transactivation activities of PolyPhen2-, MutationAssessor-, and CADD-assigned true-negative and false-positive mu-
tations. Measured TP53 transactivation activity for true-negative (TN; blue) and false-positive (FP; red) categories of TP53missense mutations identified in Fig. 2
A–C using inference scores calculated with (A) PolyPhen2, (B) MutationAssessor, and (C) CADD. For PolyPhen2, the mean normalized activity was 106.1 for the
TN set and 94.6 for the FP set (Kolmogorov–Smirnov D = 0.2385, P = 2.454e−14; Wilcox W = 210,343.5, P = 3.541e−16). For MutationAssessor, the mean nor-
malized activity was 104.1 for the TN set and 95.4 for the FP set (Kolmogorov–Smirnov D = 0.1792, P = 2.204e−10; Wilcox W = 327,022.5, P = 3.364e−12). For
CADD, when intermediate values (score >5 and <20) are included with the TN category, the mean normalized activity was 105.3 for the TN set and 93.4 for the
FP set (Kolmogorov–Smirnov D = 0.2401, P < 2.2e−16; Wilcox W = 190,543.5, P < 2.2e−16).
Miosge et al. www.pnas.org/cgi/content/short/1511585112 2 of 9
Fig. S3. Incidence and location of apparent false-positive TP53 somatic mutations. (A) Unique TP53 somatic mutations found in human cancers, separated into
categories as shown in Fig. 2D and ranked by the number of independent occurrences in separate cancer cases. Red, true positive; green, true negative; blue,
false positive; purple, false negative. (B) The ideogram shows the major functional domains of the TP53 protein. Plotted against this are the number of false-
positive mutations in 20 amino acid bins: from the set of all possible TP53 mutations, those that were predicted to be deleterious with Polyphen2 score >0.8 yet
actually retained >40% of WT transactivation activity. Unlike most oncogenic TP53 mutations that occur in the DNA-binding domain (red), false-positive
mutations appear concentrated in the extremities of the transactivation and tetramerization domains.
Miosge et al. www.pnas.org/cgi/content/short/1511585112 3 of 9
Table S1. Expected cellular phenotypes of null mutants
Gene symbol Expected phenotype Gene name
Bcl2 Low B and T cells (56, 57) B cell leukemia/lymphoma 2
Btk Reduced mature B cells (58–60) Bruton agammaglobulinemia tyrosine kinase
Cd22 Low IgM expression on mature B cells (61–63) CD22 antigen
Cd74 Low CD4 T cells (64, 65) CD74 antigen
Dclre1c Absence of B and T cells (66) DNA cross-link repair 1C
Dock8 Absence of MZB cells in spleen in
ENU mutant mice (67)
dedicator of cytokinesis 8
Ets1 Reduced T cells (68, 69) E26 avian leukemia oncogene 1
Hnrnpl Reduced T cells in conditional knockout (70) heterogeneous nuclear ribonucleoprotein L
Il2ra Activated (increased CD44hi) T cells and
enlargement of spleen and LN (71)
interleukin 2 receptor, alpha chain
Il7r Low lymphocytes (72) interleukin 7 receptor
Itch Activated (increased CD44hi) T cells (73) itchy, E3 ubiquitin protein ligase
Itpkb Absence of T cells (74) inositol 1,4,5-trisphosphate 3-kinase B
Jak3 Low lymphocytes (75, 76) Janus kinase 3
Lig4 Low B and T cells in ENU mutant (48) ligase IV, DNA, ATP-dependent
Prkdc Absence of B and T cells (77–79) protein kinase, DNA activated, catalytic polypeptide
Ptpn6 Early death, immunodeficiency, autoimmunity
in spontaneous mutants (80, 81); reduced B cells,
down-regulation of IgM and IgD on mature
B cells in ENU mutants
protein tyrosine phosphatase, nonreceptor type 6
Ptprc Low B and T cells (82) protein tyrosine phosphatase, receptor type, C
Rag1 Absence of B and T cells (83) recombination activating gene 1
Rag2 Absence of B and T cells (84) recombination activating gene 2
Rasgrp1 Low mature T cells (85) RAS guanyl releasing protein 1
Satb1 Small mice, early death, low and abnormal T cells (86) special AT-rich sequence binding protein 1
Tbx21 Low NK and NK T cells (87) and Th1 response (88) T-box 21
Tnfaip3 Increased granulocytes and activated (CD44hi)
T cells in ENU mutant
tumor necrosis factor, alpha-induced protein 3
Miosge et al. www.pnas.org/cgi/content/short/1511585112 4 of 9
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Table S5. Apparent accuracy of PolyPhen2 predictions for different sets of TP53 mutations
Variant set
True positive
(pph2 ≥ 0.8
and TA ≤ 50)
True negative
(pph2 ≤ 0.2
and TA > 50)
False Positive
(pph2 ≥ 0.8
and TA > 50)
False negative
(pph2 ≤ 0.2
and TA ≤ 50)
% false-positive
predictions among
mutations with
pph2 ≥ 0.8
All possible variants,
target gene TP53
binding sequence
WAF1 640 (31.6%) 831 (41.0%) 462 (22.8%) 93 (4.6%) 42%
MDM2 728 (35.9%) 709 (35.0%) 373 (18.4%) 217 (10.7%) 34%
BAX 660 (32.6%) 778 (38.4%) 441 (21.8%) 147 (7.3%) 40%
14–3-3σ 619 (30.6%) 817 (40.3%) 482 (23.8%) 107 (5.3%) 44%
p53AIP1 621 (30.6%) 753 (37.1%) 482 (23.8%) 173 (8.5%) 44%
GADD45 566 (27.9%) 809 (39.9%) 536 (26.5%) 115 (5.7%) 49%
NOXA 470 (23.2%) 869 (42.9%) 631 (31.2%) 55 (2.7%) 57%
p53R2 433 (21.4%) 864 (42.7%) 668 (33.0%) 60 (3.0%) 61%
Clinically observed variants,
WAF1 binding sequence
Somatic 560 (47%) 377 (31.6%) 188 (15.8%) 67 (5.6%) 25%
Germ line 132 (76.7%) 22 (12.8%) 12 (7.0%) 6 (3.5%) 8%
Table S6. Apparent accuracy of MutationAssessor predictions for different sets of TP53 mutations
Variant set
True positive
(MA ≥ 2
and TA ≤ 50)
True negative
(MA < 2
and TA ≥ 50)
False positive
(MA ≥ 2
and TA ≥ 50)
False negative
(MA < 2
and TA ≤ 50)
% false-positive
predictions among
mutations with
MA ≥ 2
All possible variants,
target gene TP53
binding sequence
WAF1 651 (28.2%) 935 (40.5%) 581 (25.2%) 142 (6.1%) 20%
MDM2 765 (33.1%) 796 (34.5%) 466 (20.2%) 283 (12.3%) 38%
BAX 678 (29.4%) 877 (38.0%) 554 (24.0%) 200 (8.7%) 27%
14-3-3σ 632 (27.4%) 929 (40.3%) 599 (26.0%) 148 (6.4%) 20%
p53AIP1 626 (27.1%) 848 (36.7%) 605 (26.2%) 233 (10.1%) 28%
GADD45 579 (25.1%) 923 (40.0%) 653 (28.3%) 155 (6.7%) 19%
NOXA 484 (21.0%) 999 (43.3%) 747 (32.4%) 78 (3.4%) 9%
p53R2 449 (19.4%) 998 (43.2%) 783 (33.9%) 79 (3.4%) 9%
Clinically observed variants,
WAF1 binding sequence
Somatic 93 (57.1%) 35 (21.5%) 17 (10.4%) 18 (11%) 51%
Germ line 138 (75.4%) 20 (10.9%) 18 (9.8%) 7 (3.8%) 28%
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Table S7. Apparent accuracy of CADD predictions for different sets of TP53 mutations
Variant set
True positive
(Phred ≥ 20
and TA ≤ 50)
True negative
(Phred < 20
and TA ≥ 50)
False positive
(Phred ≥ 20
and TA ≥ 50)
False negative
(Phred < 20
and TA ≤ 50)
% false-positive
predictions among
mutations with
Phred ≥ 20
All possible variants,
target gene TP53
binding sequence
WAF1 708 (30.7%) 941 (40.8%) 573 (24.8%) 85 (3.7%) 45%
MDM2 832 (36.0%) 812 (35.2%) 449 (19.5%) 215 (9.3%) 35%
BAX 731 (31.7%) 879 (38.1%) 550 (23.8%) 147 (6.4%) 43%
14-3-3σ 671 (29.1%) 916 (39.7%) 610 (26.5%) 109 (4.7%) 48%
p53AIP1 702 (30.4%) 870 (37.7%) 582 (25.2%) 156 (6.8%) 45%
GADD45 617 (26.7%) 909 (39.4%) 666 (28.9%) 116 (5.0%) 52%
NOXA 508 (22.0%) 971 (42.1%) 773 (33.5%) 54 (2.3%) 60%
p53R2 470 (20.4%) 968 (42.0%) 812 (35.2%) 57 (2.5%) 63%
Clinically observed variants,
WAF1 binding sequence
Somatic 102 (62.6%) 34 (20.9%) 18 (11.0%) 9 (5.5%) 15%
Germ line 140 (76.5%) 19 (10.4%) 19 (10.4%) 5 (2.7%) 12%
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5.2 Further discussion 
In this two-part study we aimed to answer the following questions. 
1) How effective are the tools designed to predict the functional significance 
of missense mutations? 
2) Do the tools work as effectively on non-human samples as human 
samples? 
3) Why do most tools seem to call certain mutations damaging despite there 
being no discernable phenotype?  
4) Can we offer an explanation of this “overcalling” phenomenon using real 
data sets? 
To attempt to answer these questions two separate data sets measuring real 
protein function were utilized and compared to the predictions from a variety of 
functional inference computational tools such as Polyphen2 (56) and CADD 
(58). The first data set was generated in-house as part of the larger ENU mouse 
project (69), consisting of 33 mice breed to homozygosity, each containing a 
unique missense mutation spread across 23 essential immune system genes. 
Mutations were selected that produced a missense mutation in genes that, when 
rendered null, caused a fully penetrant and well-characterized phenotype in the 
mouse immune system easily detectable by flow cytometry of peripheral blood 
lymphocytes. The second data set consisted of a comprehensive mutation data set 
for the tumour suppressor gene TP53. This data set was generated by 
systematically quantifying the transcription enhancing activity of WT TP53 by 
expressing each mutant in yeast in vitro and measuring transcription-enhancing 
activity against different TP53-binding enhancer sequences for all possible 
missense mutations (63).  
 With the mouse data we were able to directly compare the prediction of 
the functional inference tools with real functional data and importantly, by 
focusing on genes that when rendered null caused a fully penetrant and well-
characterized detectable phenotype, determine whether variable penetrance is 
responsible for the often poor performance of these tools as has been suggested 
(85). While an extremely valuable data set for ruling out variable penetrance as 
the cause of overcalling, several other possible explanations remain: i) With 
known redundancy in the immune system (86), uncharacterized compensatory 
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processes may be masking the mutation effects ii) Sterile laboratory conditions 
were preventing the mice from exposure to pathogens required for the immune 
response iii) The ‘human-centric’ focus of the computational tools means subtle 
differences either in mouse/human homologs or the transcripts selected for each 
organism may affect the scoring. To address the human-centric nature of the 
tools we installed the complex polyphen analysis pipeline locally, replacing all 
human protein data with the appropriate mouse protein data. We applied both the 
default human and the mouse specific versions of polyphen to 30 of the 33 
mouse mutations, with the other 3 mutations creating stop codons that produced 
a phenotype as expected.  For the 30 mutations tested, 20 were predicted to be 
damaging by the default human polyphen yet only 4 produced a phenotype (20% 
success) with the remaining 10 correctly predicted to be not damaging, 
confirming that false positives are a bigger problem than false negatives. The 
mouse specific version of polyphen made some small improvements (e.g. Rag1 
mutant which produced a phenotype changed from ‘possibly damaging’ to 
‘probably damaging’ using mouse polyphen) but overall the scores were well 
correlated between versions of polyphen meaning this difference is unlikely 
responsible for the overcalling we observe. 
 Lastly, to investigate whether environmental masking or compensation 
were responsible for overcalling, an exhaustive TP53 functional data set was 
analysed, a valuable data set as loss of function TP53 mutations are the most 
common somatic mutation in human cancer and known to cause highly penetrant 
immune system cancers when bred to homozygosity in the germ line of mice. In 
this analysis the entire set of all missense mutations was compared to functional 
assay scores for all possible 2314 missense mutations. The results showed that 
while the overcalling problem is less pronounced than in the mouse data set, 
there are still ~25% of all mutations predicted to be damaging that have no 
impact on transactivation function compared to the relatively small ~5% of non-
damaging predictions that did impact transactivation function. After discounting 
the last remaining commonly held explanation for the observed overcalling we 
considered why this issue persisted regardless of the tool selected and the 
functional data set utilized for comparison.  In the end, we proposed that the 
persistent overcalls result from the reliance of the tools on conservation across 
species, and that the overcalls corresponds to nearly neutral mutations of small 
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effect (62); mutations that are subject to purifying selection yet do not 
necessarily produce a phenotype in a single individual.  To test this hypothesis, 
additional data sets were analysed for the 23 genes studied in the mouse data set, 
focusing on data sets subject to differing degrees of purifying selection. At one 
extreme we considered all possible missense mutations across the 23 genes while 
at the other extreme we considered all missense variants between the mouse and 
rat, species which have been separate for 12–24 million years (87). These results 
appear to support this hypothesis with ~50% of all possible mutations in the 23 
genes predicted to be damaging contrasting with the mouse-rat mutations being 
classified as almost exclusively benign.  A similar comparison for humans 
generated similar results with ~50% of all possible missense variants in the 23 
genes had damaging predictions while almost all human-chimp missense variants 
had benign predictions. Both these results support the hypothesis that the 
overcalls correspond to nearly neutral mutations as data subject to long periods 
of purifying selection (e.g. mouse-rat and human-chimp missense mutations) are 
largely predicted to be benign while data sets subject to shorter periods of 
purifying selection (e.g. all possible mutations) are often predicted to be 
damaging.  
  These results highlight a critical gap in our ability to relate genotype to 
phenotype in a clinical setting and make clear that current functional inference 
tools are unable to differentiate immediately actionable relevant mutations from 
nearly neutral mutations.  The results further highlight the problem with 
overreliance on such tools in any variant prioritization strategy, particularly when 
being used in the clinical setting. By proposing a novel explanation for the 
observed overcalling, we are hopeful this will lead to an understanding that using 
such tools in isolation may not be appropriate for use in the clinical. Instead these 
tools need to be part of a broader overall strategy. Finally, using this analysis and 
others, it may be possible to implement a next generation of functional inference 
software able to differentiate between truly damaging and nearly neutral 
mutations based on currently unknown differences in the signature of their 
mutations.   
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ABSTRACT
Background.Massively parallel sequencing technology is being used to sequence highly
diverse populations of DNA such as that derived from heterogeneous cell mixtures
containing both wild-type and disease-related states. At the core of such molecule
tagging techniques is the tagging and identification of sequence reads derived from
individual inputDNAmolecules, whichmust be first computationally disambiguated to
generate read groups sharing common sequence tags, with each read group representing
a single input DNA molecule. This disambiguation typically generates huge numbers
of reads groups, each of which requires additional variant detection analysis steps to be
run specific to each read group, thus representing a significant computational challenge.
While sequencing technologies for producing these data are approaching maturity, the
lack of available computational tools for analysing such heterogeneous sequence data
represents an obstacle to the widespread adoption of this technology.
Results.Using synthetic data we successfully detect unique variants at dilution levels of
1 in a 1,000,000 molecules, and find DeeepSNVMiner obtains significantly lower false
positive and false negative rates compared to popular variant callers GATK, SAMTools,
FreeBayes and LoFreq, particularly as the variant concentration levels decrease. In
a dilution series with genomic DNA from two cells lines, we find DeepSNVMiner
identifies a known somatic variant when present at concentrations of only 1 in 1,000
molecules in the input material, the lowest concentration amongst all variant callers
tested.
Conclusions. Here we present DeepSNVMiner; a tool to disambiguate tagged se-
quence groups and robustly identify sequence variants specific to subsets of starting
DNA molecules that may indicate the presence of a disease. DeepSNVMiner is an
automated workflow of custom sequence analysis utilities and open source tools
able to differentiate somatic DNA variants from artefactual sequence variants that
likely arose during DNA amplification. The workflow remains flexible such that it
may be customised to variants of the data production protocol used, and supports
reproducible analysis through detailed logging and reporting of results. DeepSNVMiner
How to cite this article Andrews et al. (2016), DeepSNVMiner: a sequence analysis tool to detect emergent, rare mutations in subsets of
cell populations. PeerJ 4:e2074; DOI 10.7717/peerj.2074
is available for academic non-commercial research purposes at https://github.com/
mattmattmattmatt/DeepSNVMiner.
Subjects Bioinformatics, Computational Biology, Genomics
Keywords NGS, Deep sequencing, Rare mutations, Variant detection
INTRODUCTION
Deep sequencing of a restricted set of gene targets in a large population of cells has
rapidly become a key application of second-generation sequencing, allowing a census of
variation to be conducted on an in vivo biological system (Fu et al., 2011; Hiatt et al., 2013;
Jabara et al., 2011; Kinde et al., 2011; Kivioja et al., 2012; Schmitt et al., 2012). Applications
of this technology allow polling of sequence variation in cancer subtypes (Forshew et al.,
2012), ascertainment of minimal residual disease (Bidard, Weigelt & Reis-Filho, 2013),
ascertainment of malignancies or antibody specificity in the immune system (Georgiou
et al., 2014) and observation of the emergence of drug resistant virus point-mutants
(Al-Mawsawi et al., 2014).
The central technique in molecule tagging that allows disambiguation of these deep
sequence datasets is the attachment of a random unique sequence identifier (UID) to
the end(s) of input DNA, either prior to or simultaneously with amplification of target
sequences (Fig. 1). Hence, even though subsequent polymerase amplification of target
sequences may introduce errors, mapping these sequences to their UID sequence allows
easy differentiation of sequence variation that was originally present in the input DNA
from variation that has been introduced during subsequent amplification steps. Recently
developed methods for molecule tagging rely on digital PCR, a process where individual
DNA molecules are assessed individually (Vogelstein & Kinzler, 1999). Several variants of
this technique have now been described (Dressman et al., 2003; Ottesen et al., 2006) with
the common thread being the binding of oligonucleotide to each individual input DNA
molecule prior to or during amplification. This technique is not to be confused with
sample barcoding or multiplexing, a process where individual samples are tagged with
small oligonucleotides and pooled in a single lane for sequencing.
In comparison to traditional massively parallel sequencing, molecule tagging has an
additional step where a small unique oligonucleotide is attached to each DNA molecule
prior to polymerase chain reaction (PCR) amplification. While both techniques generate
huge numbers of sequenced DNA molecules in parallel a potential issue with traditional
sequencing is that the introduction of erroneous base calls into a single DNA molecule
can result in inaccurate sequence information being amplified in subsequent PCR steps.
Such issues are not necessary prohibitive for reliable variant detection when samples are
relatively homogeneous however, mainly due to the relatively low base error and PCR
bias rates (Ross et al., 2013; Schirmer et al., 2015), and the ability to remove candidate PCR
duplicates reads using tools such as SAMTools (Li et al., 2009 ) or SAMBLASTER (Faust
& Hall, 2014). When the samples being sequenced are heterogeneous however, traditional
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Figure 1 DeepSNVMiner barcode and adaptor processing. A sample sequence read which has
undergone molecule tagging with a ten base pair UID consisting of five bases each attached to the
5′ and 3′ end. DeepSNVMiner first removes any adapters followed by the removal of the unique sequence
identifier (UID) from the raw sequence data. The UID sequence information is preserved in the FASTQ
header allowing for variant detection on read groups sharing a common UID.
variant detection methods often fail to reliably detect rare variants due to the small fraction
of the original material containing the variant of interest and differences in the variant
detection algorithms (Field et al., 2015). With molecule tagging techniques, we are able to
overcome PCR issues and detect rare variants within heterogeneous samples due to the
attachment of UIDs, effectively allowing the differentiation of amplification error from
variation present in the original DNA molecules (Kinde et al., 2011).
While the utility of sequencing tagged samples is clear, the analysis of sequence data
generated with UID tags is non-trivial and, as yet, software or a computational workflow
does not exist in the public domain to allow easy calling and tallying of this mutation
information. The fundamental technical challenge of working with such data is largely due
to the wide variety of methods for attaching UIDs, methods that generate vastly different
UIDs with regard to total sequence length and their position on themolecules relative to the
sequence of interest and/or adaptors. The ability to work with such data requires software
where users can first define the nature of the specific UID in their experiment, followed by
an analysis workflow where UIDs are temporarily removed from raw sequence data for the
alignment step and later restored as a means of grouping the individual reads by common
UID. Finally, variants must be called within each group of input molecules sharing a
common UID, a computationally intensive task given the huge numbers of groups often
generated in a single experiment. To address this need we present DeepSNVMiner, a tool
able to detect rare single nucleotide variants and small indels specific to a single amplified
DNA molecule identified by a unique tagged sequence identifier. The DeepSNVMiner
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workflow consists of grouping reads by UID tag sequences and calling variant bases in
UID groups, thus identifying mutations that existed in single molecules from the original
heterogeneous input DNA. DeepSNVMiner is a standalone-automated workflow that runs
in a Linux or Macintosh environment and has been successfully used even on modest
desktop hardware.
MATERIALS & METHODS
Cell lines used
Two cell lines were utilised in the dilution series experiment, HEK293 and OCI-LY10.
HEK293 is available from ATCC (accession CRL-1573; http://www.atcc.org/products/all/
CRL-1573.aspx) and OCI-LY10 from Ontario Cancer Institute (accession CVCL_8795;
https://www.abmgood.com/OCI-Ly10-Cell-Lysate-Data-Sheet-L134.html).
Software input
Running DeepSNVMiner requires three input files; paired-end FASTQ read files and
a BED file containing the specific locations of targeted genomic region(s). An initial
configuration step is also required to determine the location of three required external
resources; Burrows-Wheeler Aligner (BWA) (Li & Durbin, 2009), SAMtools (Li et al.,
2009), and a reference genome FASTA file with BWA index files.
Workflow design
The workflow to disambiguate sequence variants from their unique sequence ID tags
groups involves multiple steps involving both purpose built tools and calls to external
binaries (Fig. 2).
First, the sequence read dataset is subjected to preliminary quality control, to remove
low quality reads or those containing predominantly N calls (and hence avoid assigning
UID groups of consecutive N’s). The data is next interrogated for the presence of obvious
adaptor sequence, which may contaminate UID tags if left untrimmed. Each UID tag is
then identified based on the user defined input and removed from the FASTQ sequence
line and appended to the existing FASTQ read header. These filtered reads and headers are
written to new FASTQ files with the UID header information later used to detect variants
specific to common UID groups. DeepSNVMiner is flexible with regard to the structure
of the UID tag as both the expected UID length and strand location of the UID typically
vary depending on the tagging protocol and/or sequencing technology used. For example,
frequently the UID is appended solely at the 5′ end of the amplified region, but in other
protocols the sequence from both the 5′ and the 3′ ends needs to be concatenated to derive
theUID.Next, themodified reads are aligned to a reference genome sequence with BWA (Li
& Durbin, 2009) using a set of alignment parameters that are permissive of mismatches but
which penalise opening a gap within the alignment, especially at the ends of sequence reads.
Variant bases are then identified base-by-base using the SAMTools calmd command (Li
et al., 2009) within a predefined set of user-specified target genomic locations input from a
BED-format file. SAMtools calmd is used instead of the more standard SAMtools/BCFtools
workflow, as running themillions of commonUID groups we typically observe through the
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Figure 2 DeepSNVMiner workflow.DeepSNVMiner Workflow consists of seven major steps: UID
definition, sequence data QC, UID processing and grouping, alignment, variant detection, report
generation, and optionally graphing.
entire SAMtools/BCFtools workflow is computationally prohibitive. Output from calmd is
next parsed and variant positions and the reads in which they occur are tallied and grouped
according to read UIDs. By default, common UID groups of 5 or more reads of which at
least 40% detect the same variant are classified as a variant ‘super mutant’ and variants
reported in two or more super mutants further classified as a ‘super group.’ This default
value of 40% was chosen to allow successful super mutant detection even in the rare cases
where a super mutant was missed due to an identical UID tag being added to two distinct
DNAmolecules. Examination of pilot data determined lowering this threshold did not add
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any false positive super mutants and further, users of the software are able to override the
defaults and determine the appropriate value for each cut-off based on the nature of their
dataset and the method by which it was generated. Finally, optional summary graphics of
the variants in the context of sequence read depth and chromosomal position are created
using R.
Workflow implementation
The overall workflow is comprised of discrete command-line interface calls to both
custom- and open source-tools as well as UNIX utilities. All commands are stored within
a configuration module and executed by a Perl wrapper script to allow chaining together
of each command and automation of the multifaceted workflow. This also allows for easy,
frequent customisation of workflow commands (should this be desired) and the capturing
of specific commands and run-level information into a log file that contributes to analysis
reproducibility. The workflow has the facility to allow it to be resumed or re-run from any
point midway through the analysis.
The workflow commands, specifically, are various calls to several purpose-built tools
(implemented in Perl), external open-source bioinformatics software tools and UNIX
utilities. Custom Perl scripts are used to perform workflow steps to identify, remove and
store UID tags from each read, to aggregate and summarise variant calls within UID groups
and to generate final reports and graphs. Alignment of sequence reads is accomplished
using BWA, variant calling is done with SAMtools calmd, and graphing performed with R.
Identification and cleaning of reads containing runs of Ns is performed using sed and awk
commands piped to other UNIX utilities such as cut, sort, uniq, and cat which are required
to manipulate the output of these tools.
Output
The final report contains a listing of all variants detected, based on either the user-configured
expected variant frequency or default parameters (e.g., a commonUID groupmust contain
at least five reads with at least 40% sharing the same variant). For each called variant, the
output super mutant summary reports the chromosome and genomic coordinate(s), the
variant base, the UID, the number of total variant reads in the groups, the number of reads
in the group and the fraction of variant reads. The super group report contains information
on recurrent super mutants (grouped by common genomic coordination and variant base)
and additionally reports their frequency.
RESULTS AND DISCUSSION
We developed DeepSNVMiner to disambiguate tagged sequence groups within mixed cell
populations and detect sequence variants specific to individual amplified DNA molecules.
To assess the performance of DeepSNVMiner we first compare it to the well known variant
callers FreeBayes, (http://arxiv.org/abs/1207.3907), Genome analysis toolkit (GATK)
(McKenna et al., 2010), SAMTools/BCFtools (Li, 2011), and LoFreq (Wilm et al., 2012)
using simulated tagged sequence data at increasing variant dilution levels. Next, we test
DeepSNVMiner by running a dilution series with genomic DNA from two cells lines: one
of which is known to contain a known heterozygous somatic variant.
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Figure 3 Variant caller false positive rate at increased dilution levels. False positive rates for Deep-
SNVMiner compared to FreeBayes, GATK, LoFreq, and SAMTools at increasing variant dilution levels us-
ing synthetic data.
Comparison with existing software
To test the effectiveness of DeepSNVMiner at increasing dilution levels two datasets
containing 100-bp paired-end reads from chromosome 22 of the human reference genome
(GRCh37) were created, with each read-pair having a randomly generated 10 bp barcodes
attached at the 5′ end to simulate the attachment of a UID sequence tag to the original
DNAmolecule. The first input data set contained nomutations while the second input data
set contained randomly generated single nucleotide variants (SNVs) with each mutated
read duplicated randomly between 1 to 50 times within the FASTQ files to simulate the
polymerase chain reaction (PCR) replication process of initial DNA fragments. Mixing the
two data sets in appropriate concentrations simulated dilution levels of 0%, 50%, 90%,
99%, 99.9%, 99.99%, 99.999%, and 99.9999%with 4,000,000 million total paired end reads
ultimately added to each FASTQ file. For each dilution level the FASTQ files were first
aligned to chromosome 22 and variants called using DeepSNVMiner, FreeBayes, GATK,
SAMTools, and LoFreq run with default parameters or as suggested in documentation
(Table S1). False positive (Fig. 3) and false negative rates (Fig. 4) were then calculated
(Table S2).
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Figure 4 Variant caller false negative rate at increased dilution levels. False negative rates for
DeepSNVMiner compared to FreeBayes, GATK, LoFreq, and SAMTools at increasing variant dilution
levels using synthetic data.
Table 1 Variant caller ability to detect known heterozygous mutation at different dilution levels. A
dilution series was performed with genomic DNA from two cells lines: HEK293 containing wild-type
MYD88 and OCI-LY10 containing known heterozygous L265P MYD88 mutation. The ability to detect
the known heterozygous mutation was determined for DeepSNVMiner, FreeBayes, GATK, LoFreq, and
SAMTools at increasing dilution levels.
Dilution Percent Deep- SNVMiner FreeBayes GATK LoFreq SAMTools
0 Detected Detected Detected Detected Detected
90 Detected Not detected Detected Detected Not detected
99 Detected Not detected Not detected Detected Not detected
99.9 Detected Not detected Not detected Not detected Not detected
99.99 Not detected Not detected Not detected Not detected Not detected
99.999 Not detected Not detected Not detected Not detected Not detected
99.9999 Not detected Not detected Not detected Not detected Not detected
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Figure 5 DeepSNVMiner dilution series results. To measure the sensitivity of DeepSNVMiner a
dilution series containing known heterozygous L265P MYD88 mutation was performed. DeepSNVMiner
was able to detect the mutation in a sample where only 1 in 1,000 samples contained the mutation.
Real data evaluation
To evaluate the performance of DeepSNVMiner on real data versus other variant callers, we
performed a dilution series using a mixture of genomic DNA from two cell lines HEK293
andOCI-LY10 (Table S3). Cell line OCI-LY10 carries a heterozygous pointmutation within
the MYD88 gene at L265P or chr3:38172641 (GRCh37), a somatic mutation occurring
frequently in non-Hodgkin lymphoma (Ngo et al., 2011). It would be clinically useful to
have a method to detect and enumerate rare cells carrying this mutation in samples of
blood or bone marrow. For each cell mixture in the dilution series, a 116 bp genomic
region surrounding chr3:38172641 was amplified using primers with UID tags and sample
ID tags and a per-sample average of 183 thousand paired-end reads were sequenced on
an Illumina MiSeq. The resulting sequence reads were analysed with DeepSNVMiner,
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FreeBayes, GATK, LoFreq, and SAMTools and the ability to detect the heterozygous
mutation was measured.
DeepSNVMiner was successfully able to detect the mutation in dilution levels down to
1/1000 compared to 1/100 for LoFreq, 1/10 for GATK, and only in the non-diluted sample
for FreeBayes and SAMTools (Table 1). In the non-diluted sample, DeepSNVMiner was
able to detect the mutation in 4,055 separate super mutants consisting of 59,038 total
DNA sequences and at the lower range of detection (1/1000), DeepSNVMiner detected the
variant in 6 separate super mutants consisting of 120 total DNA sequences (Fig. 5)
The mutation was reliably detected at concentrations of 1/1000 by DeepSNVMiner
but not in concentrations of 1/10000 indicating the lower detection limit lies somewhere
in this range. However, it should be noted this limit is imposed by current laboratory
methodology however, as DeepSNVMiner remains capable of achieving the theoretical
limits of the technology imposed by the chosen length of UID sequences.
CONCLUSIONS
Wepresent DeepSNVMiner; an integrated tool set and automated workflow to allow robust
and reliable identification of sequence variants present in a subset of sequences within a
tagged input DNA sample. This tool makes available the analysis procedure required to
support SafeSeqs and similar UID tagged sequence datasets. DeepSNVMiner has been built
to allow easy automation and reproducibility and makes this technique available to a wide
range of applications.
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Table S1: Variant caller commands 
 
Variant caller Version Command 
DeepSNVMiner 1.0 run_deepsnv.pl -read1_fastq R1.fq -read2_fastq 
R2.fq -coord_bed chr22.bed -filename_stub test 
           
FreeBayes 1.0.2-6 freebayes -f chr22.fa bam_file > freebayes.vcf  
 
GATK 3.2.2 1) java -jar GenomeAnalysisTK.jar -T 
HaplotypeCaller -R chr22.fa -L chr22.intervals -
I bam_file -o gatk.gvcf -variant_index_type 
LINEAR -variant_index_parameter 128000 --
minPruning 3 -ERC GVCF -contamination 0.0   
--maxNumHaplotypesInPopulation 200              
--max_alternate_alleles 3  
 
2) java -jar -T GenotypeGVCFs -R chr22.fa -L 
chr.intervals -V gatk.gvcf-o gatk.vcf 
 
LoFreq 2.1.2 lofreq call -f chr22.fa -o lofreq.vcf bam_file 
 
SAMTools 0.1.19 samtools mpileup -C50 -uDEf chr22.fa bam_file 
| bcftools view -vcg - > sam.vcf 
 
 
Variant caller commands utilized in our example.  The commands listed match the 
exact commands run with the exception of the shortening of file names. The 
commands were chosen by either following documentation suggestions, or else by 
using default options.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2: False positive rates for variant callers at increasing dilution levels 
 
Dilution 
Percent 
Total 
Variants 
Deep- 
SNVMiner  
FreeBayes GATK  LoFreq  SAMTools 
0 799962 0.014 0.16 34.05 0.18 31.94 
50 408518 0.012 0.15 29.43 0.18 30.11 
90 81708 0.012 0.17 28.22 0.21 26.09 
99 8211 0.043 0.21 15.78 0.17 46.15 
99.9 811 0.149 0.18 16.33 3.45 0 
99.99 74 0 1.72 30.14 21.43 N/A 
99.999 8 0 0 50.00 50.00 N/A 
99.9999 2 0 N/A 0 N/A N/A 
 
False positive rates for DeepSNVMiner compared to FreeBayes, GATK, LoFreq, and 
SAMTools at increasing variant dilutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3: False negative rates for variant callers at increasing dilution levels 
 
Dilution 
Percent 
Total 
Variants 
Deep- 
SNVMiner  
FreeBayes GATK LoFreq  SAMTools 
0 799962 41.74 31.35 71.35 66.52 99.85 
50 408518 29.76 31.79 63.48 68.40 99.89 
90 81708 17.83 31.45 33.86 77.41 99.90 
99 8211 15.59 32.03 18.32 78.32 99.91 
99.9 811 17.39 31.94 17.26 79.28 99.88 
99.99 74 9.46 22.97 31.08 70.27 100 
99.999 8 0 25.00 25.00 50.00 100 
99.9999 2 0 100 0 0.00 100 
 
False negative rates for DeepSNVMiner compared to FreeBayes, GATK, LoFreq, and 
SAMTools at increasing variant dilutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4: Dilution series for cell lines HEK293 and OCI-LY10 
 
Sample HEK293 wt MYD88 OCI-LY10 L265P MYD88 
Sample1 0% 100% 
Sample2 90% 10% 
Sample3 99% 1% 
Sample4 99.9% 0.1% 
Sample5 99.99% 0.01% 
Sample6 99.999% 0.001% 
Sample7 99.9999% 0.0001% 
Sample8 99.99999% 0.00001% 
Sample9 99.999999% 0.000001% 
Sample10 100% 0% 
 
To measure the sensitivity of DeepSNVMiner a dilution series was performed with 
genomic DNA from two cells lines: (i) HEK293 (Human Embryonic Kidney): wild-
type MYD88 (ii) OCI-LY10 (Ontario Cancer Institute, lymphoma cell line 10): 
heterozygous L265P MYD88 mutation.  
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6.2 Further discussion 
This publication describes DeepSNVMiner, software to detect rare 
variants contained in sequence data from a heterogeneous population of cells. 
While the laboratory techniques for attaching unique identifiers to each DNA 
molecule prior to the amplification step have reached maturity, there is currently 
no available software to reliably detect rare variants that are present in sub-
populations of cells.  Existing standard variant detection tools are unable to work 
with mixed sequence data as the underlying statistical models typically expect 
homogeneous sequence data from a single population, an assumption that fails 
with a mixed population of cells.  With most sequencing platforms yielding error 
rates in the order of ~1% (88), such tools are incapable of differentiating the real 
signal from the rare variants from the general background noise inherent in the 
data. Cancer variant detection software is more suitable for the task (given that 
its model expects sequence data from both tumour and normal cells) yet is still 
unable to detect variants in very highly heterogeneous sequence data due to the 
thousands of cells contained in the mixed sequence data. Given the lack of 
readily available software solutions for this increasingly important sequencing 
application, DeepSNVMiner was initially written to support an internal project 
trying to detect rare variants within mixed cell populations of Sjogren syndrome 
patients, with the software later generalised and released as an open-source tool. 
 Internally, DeepSNVMiner is a complete analysis pipeline for detecting 
variants in mixed sequence data sets and implemented to output completely 
reproducible bioinformatic workflows with detailed logging occurring from the 
onset. The workflow consists of five major components; FASTQ checking, 
barcode grouping, alignment to the reference genome, variant detection, and 
reporting. DeepSNVMiner works by accepting raw FASTQ sequence files with 
UIDs, extracting the unique identifier from the sequence column, and generating 
a new filtered FASTQ file with the identifier removed from the sequence row 
and added to the header row. The filtered FASTQ files are next aligned to the 
reference genome using BWA (76), reads are grouped by common UID, and 
variants called using SAMtools (89) fillmd on each group of reads in user 
specified genomic regions only. Variant detection output is next parsed, variants 
in read groups are identified, summary reports are generated, and plots generated 
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using the software package R (90). 
The software is designed to be extremely flexible with regard to the 
nature of the input sequence data, an important feature given the increasing 
diversity of laboratory techniques available for generating data sets of this 
nature.  Users are able to precisely define the unique identifying barcode (UID), 
whether this barcode consists of sequence from the 5′ end, the 3′ end, or some 
combination of sequence from both ends. The software is also flexible with 
regard to defining exactly what a variant looks like within each group of reads 
sharing a UID. Users are able to define the minimum number of reads required to 
constitute a read group and further define what fraction of reads must contain the 
same variant base to be considered a true rare variant. The flexibility in defining 
both what a UID looks like and what constitutes a variant in each UID group 
allows users to customise input parameters in such a way that the software is able 
to effectively detect rare variants in their unique data sets.  
 While grouping reads by common UID and searching for variants within 
each read group ultimately allow the detection of rare variants, the data sets 
presented several technical challenges needing custom solutions.  First, given the 
huge number of common UID groups within each data set (typically 10000s of 
unique read groups), traditional variant detection for each group became 
computationally prohibitive and was not feasible without the use of significant 
HPC resources.  To remedy this, DeepSNVMiner incorporated the very fast 
SAMtools view/fillmd command, a command capable of identifying bases not 
matching the reference genome from a single read.  While not designed to detect 
variants per se, by parsing the command’s output, grouping reads by common 
UID, and searching for variants within each group, I was able to reduce the run 
time by three orders of magnitude, essentially making the software able to run in 
a standard desktop environment. The other major technical challenge to solve 
was how to effectively search only the genomic regions of interest; as such data 
sets target a restricted set of gene targets.  For this, users are able to pass in a bed 
file containing the genomic regions of interest meaning the run time scales 
linearly with the size of the genomic regions to search.  By limiting the search 
space to the regions of interest, run time is further minimized compared to 
exhaustively searching the entire genome.  
 In real control cell line data sets, DeepSNVMiner is able to detect 
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variants as scarce as 1 in 1000 molecules present in input material, something no 
existing publicly available software is able to do. Using simulated data sets, 
DeepSNVMiner does even better and detects variants present in 1 in 1000000 
molecules, a feat other standard variant callers are unable to do. The lack of 
available computational tools for analysing such heterogeneous sequence data 
has represented an obstacle to the widespread adoption of this technology, an 
obstacle which DeepSNVMiner aims to remove.  With the widespread adoption 
of this tool, researchers will hopefully be able to utilise this technology to gain a 
greater understanding of disease progression within mixed populations of cells. 
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Chapter 7: Massively parallel sequencing of the 
mouse exome to accurately identify rare, induced 
mutations: an immediate source for thousands of new 
mouse models 
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Accurate identification of sparse heterozygous single-nucleotide variants (SNVs)
is a critical challenge for identifying the causative mutations in mouse genetic
screens, human genetic diseases and cancer. When seeking to identify causal
DNA variants that occur at such low rates, they are overwhelmed by false-
positive calls that arise from a range of technical and biological sources. We
describe a strategy using whole-exome capture, massively parallel DNA sequen-
cing and computational analysis, which identifies with a low false-positive rate
the majority of heterozygous and homozygous SNVs arising de novo with a
frequency of one nucleotide substitution per megabase in progeny of N-ethyl-
N-nitrosourea (ENU)-mutated C57BL/6j mice. We found that by applying a
strategy of filtering raw SNV calls against known and platform-specific variants
we could call true SNVs with a false-positive rate of 19.4 per cent and an esti-
mated false-negative rate of 21.3 per cent. These error rates are small enough
to enable calling a causative mutation from both homozygous and heterozygous
candidate mutation lists with little or no further experimental validation. The effi-
cacy of this approach is demonstrated by identifying the causative mutation in
the Ptprc gene in a lymphocyte-deficient strain and in 11 other strains with
immune disorders or obesity, without the need for meiotic mapping. Exome
sequencing of first-generation mutant mice revealed hundreds of unphenotyped
rsob.royalsocietypu
2
 on April 23, 2015http://rsob.royalsocietypublishing.org/Downloaded from protein-changing mutations, 52 per cent of which are predicted
to be deleterious, which now become available for breeding
and experimental analysis. We show that exome sequencing
data alone are sufficient to identify induced mutations. This
approach transforms genetic screens in mice, establishes a gen-
eral strategy for analysing rare DNA variants and opens up a
large new source for experimental models of human disease.blishing.org
Open
Biol2:1200612. Introduction
Genetic traits in mammals have long posed a great challenge
in connecting them to their causal DNA variant. This is
especially true when that variant is a single-nucleotide substi-
tution and is present on only one of the two copies of a
chromosome. Finding such a single-nucleotide substitution
in a genome as large as humans or mice without huge num-
bers of false positives and without reducing the search to a
sub-chromosomal region by meiotic mapping has been an
unattainable goal. Single-nucleotide variants (SNVs) rep-
resent a major source of de novo and inherited genomic
variation in humans, mice and other mammals, and, as
such, new strategies are needed to identify and analyse
these variants accurately on a genome-wide scale.
Genetic analyses of mammalian traits are often performed
in inbred C57BL/6 laboratory mice. These mice have a
known homogeneous reference genome sequence and have
a uniform genetic background that allows experimental
reproducibility and transplantation experiments. In these
mice, treatment with the chemical mutagen N-ethyl-N-
nitrosourea (ENU) efficiently generates random single-base
mutations in the germline DNA (reviewed in [1]). Diseases
and traits resulting from these ENU-induced mutations can
be detected by phenotypic screening procedures relevant to
an area of biological investigation.
The bottleneck of the ENU mutagenesis approach has long
been in identifying a single disease-causing mutation in an
entire genome of possibilities. Until recently, the approach
employed has been arduous: to out-cross affected mice to
another inbred strain and then use a panel of common
strain-specific variants to meiotically map the causal mutation
to a sub-region of an individual chromosome of less than 20
megabases (Mb). Once limited to a relatively short list of pos-
itional candidate genes, PCR amplification of all exons in the
mapped interval followed by Sanger sequencing could then
be performed and variants identified by a combination of
automated and manual review of the sequence traces. This
has proven to be an effective strategy, although it can take
several years and is labour-intensive, expensive and often
confounded by modifier genes introduced during the cross
to another inbred strain.
To date, all but the smallest minority of causative ENU-
induced mutations have been shown to reside in the exonic por-
tion of the genome. Approximately 75 per cent are caused by
SNVs in protein-coding exons that result in missense or non-
sense mutations and the remaining approximately 25 per cent
are SNVs in splice donor–acceptor sites that disrupt correct
mRNA splicing to cause protein truncations, deletions or non-
sense-mediated decay [2]. Hence, sequencing of the exome
rather than the whole genome should identify almost all inter-
esting ENU-induced variants. Array- and solution-based DNA
capture technologies [3,4] can now reliably enrich a DNA
sample for coding regions, enabling massively parallelsequencing to be undertaken on a greatly reduced proportion
of the genome. Exome capture followed by sequencing has
already become an established technique in human genetics
and an early vanguard of reports has identified the genetic
cause of a number of monogenic diseases (reviewed in [5]). In
most of these studies, prior information regarding a general
chromosomal location of the genetic lesion was known,
heritability information was available or a candidate gene
approach was used. One feature of all of these studies was
the difficulty in discerning causative, deleterious mutations
from normal genetic variation and sequencing errors.
In the mouse, early studies [6–8] using slightly different
approaches have identified ENU-induced mutations using
massively parallel sequencing information. Zhang et al. [8]
identified a previously known ENU-induced mutant by
sequencing cloned bacterial artificial chromosomes from a
2.2 Mb genomic region that had first been defined by meiotic
mapping. Arnold et al. [6] applied shallow sequencing of the
entire mouse genome to detect putative mutations and, fol-
lowing this, they performed extensive validation by Sanger
sequencing and meiotic mapping. Yabas et al. [7] mapped a
novel ENU mutation to a region of the X-chromosome, and
identified the mutation by oligonucleotide bait-mediated cap-
ture and deep sequencing of exonic DNA fragments within
this region. Fairfield et al. [9] provided an extensive demon-
stration of the utility of exome capture technology for
identifying both homozygous and heterozygous ENU-
induced and spontaneous mutations in nine mouse strains.
However, in all cases these studies relied on at least coarse
meiotic mapping information or considerable validation of
SNV calls to identify the causative mutation. Fairfield et al.
[9] suggest that an exome sequence as a sole source of infor-
mation may not be enough to identify disease-causing
induced mutations without extensive SNV validation.
In this study, we have investigated whether exome capture
followed by sequencing provides sufficient information alone
to reliably identify the rare, ENU-induced, de novo mutations
in C57BL/6j mice. We generated exome datasets for 12 mutant
mouse strains, including a matched technical and biological
replicate dataset for one strain. We present methodology
developed to identify both homozygous and heterozygous
ENU-induced mutations and use this to identify 12 primary
causative mutations and two disease-causing incidental
mutations. We also reveal hundreds of potentially deleterious
ENU mutations in first-generation (G1) mice that are immedi-
ately available for phenotypic and experimental analysis in
their progeny. Our results demonstrate that exome sequencing
provides highly reliable information which by itself is suffi-
cient to identify ENU-induced mutations selected either by
phenotype or by the nature of the gene that is mutated.
These results provide an immediate source for thousands of
new experimental models for understanding human diseases
and establish a strategy that can be extended for identifying
rare SNVs in outbred mice, humans and other species.3. Results
3.1. Generation and detection of induced, de novo
single-nucleotide variants
Many parallel mouse pedigrees, each segregating a different
set of random, de novo mutations induced in the C57BL/6j
ENU-treated
C57BL/6j male 
ENU-treated
C57BL/6j male 
C57BL/6j
female 
C57BL/6j
female 
G1 progeny
G2 progeny
G3 progeny
Figure 1. Summary of the structure of ENU-mutated mouse pedigrees. Each pedigree is initiated by two unrelated G1 founders. Each of these founders inherits a
random set of de novo point mutations (coloured circles) on the paternal chromosomes, induced by ENU treatment of their male parent. These G1 founders will carry
on average one to two DNA variants per Mb and 90 exonic ENU-induced mutations. Second-generation (G2) progeny of these mice inherit a theoretical 45 ENU-
induced exonic mutations, all of which are carried in the heterozygous state. Two productive sibling–sibling matings of the G2 mice result in third-generation (G3)
progeny that carry approximately 94% of the founding ENU-induced, protein-coding mutations, of which on average five are homozygous in any given mouse.
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shown in figure 1. Each pedigree was founded by two unre-
lated G1 mice conceived from male C57BL/6j mice that had
been treated with three doses of ENU administered at
90 mg kg21 to induce random point mutations in spermato-
gonial stem cells [2,10,11]. Based on published mutation
rates [12–14], we estimated that each of these G1 animals
would carry approximately one de novo SNV per Mb of
the paternal genome, of which around 45 would result in a
non-synonymous exonic mutation. Intercrossing of the G1
animals transmitted half of these mutations in heterozygous
state to each of their second-generation (G2) offspring.
Intercrossing the G2 animals subsequently transmitted
approximately 94 per cent of the mutations to offspring, a
subset of which was inherited in homozygous state in
third-generation (G3) animals (figure 1).
We developed a workflow (figure 2a) to use massively
parallel sequencing reads as a sole data source to identify
exonic ENU-induced mutations in 15 DNA samples taken
from mutated mice (see electronic supplementary material,
table S1). These samples were prepared and enriched for
exonic sequences using either Agilent or Nimblegen sol-
ution-based capture technologies. Each exome sample was
then sequenced as paired-end reads in a full lane of an
Illumina GAIIx sequencer or as a multiplexed, bar-coded
sample in an Illumina HiSeq sequencer, and the resultantreads aligned to the C57BL/6 mouse reference genome
using the BWA aligner [16]. Table S1 in the electronic sup-
plementary material shows the numbers of reads sequenced
and the number of reads aligned to exonic target regions
per sample. The exome capture efficiency was uniformly
high with approximately 40 to 55 per cent of all DNA
sequenced being exonic. Based on a mouse genome size of
2493 Mb [15] and 37 Mb of exonic sequence, using consensus
coding sequence (CCDS) exons [18], this represents on aver-
age a 30.6-fold (s ¼ 3.3) sequence enrichment. Across the
coding portion of the genome sequence, coverage was gener-
ally better than 85 per cent at 5 times depth and better than 70
per cent at 20 times depth, although coverage was distinctly
less for the sex chromosomes (see electronic supplementary
material, figure S1).
Raw SNVs relative to the C57BL/6 reference sequence
were called using SAMTOOLS [17]. In the inbred C57BL/6j
mice we analysed, we would expect the number of true var-
iant calls to be low (approx. 50 exonic SNVs) and almost
entirely due to ENU treatment of the G0 male mouse that
founded their line. However, in each animal, of the order of
10 000 raw SNVs were called across the entire genome, of
which 500–750 SNV calls were located in exons and/or
near exon splice sites (see electronic supplementary material,
table S2). Multiple sources can be attributed to these variant
calls, potentially being due to genetic drift of the C57BL/6j
(a)
exome enrichment
sequencing
align reads to reference
genome (with BWA) 
call raw SNVs versus
reference genome (with
SAMTOOLS)
 
filter for coding or
splicing variants 
filter for non-synonymous
variants 
remove multi-SNV genes
ENU-induced mutations
DNA extraction
raw SNV 
calls 5011
overlap 
exons
overlap 
splice 
sites
574
non-synonymous
387
not in dbSNP
not a common SNV
39
3
3712
87
54
12
360
78
not in a multi-SNV 
gene
3 39
42
homozygous heterozygous
(b)
filter known variation
(dbSNP, common exome
variants)
Figure 2. Workflow and filtering strategy used to identify de novo protein-changing mutations. (a) Following DNA extraction, exome enrichment and sequencing,
reads were aligned to the mouse reference genome [15] using BWA [16] and variation between the two genomes identified using SAMTOOLS [17]. The set of raw
SNVs was subsequently filtered to annotate known variation and other apparent SNVs known not to be ENU-induced. SNVs were further filtered to annotate those
that fell within coding regions (or adjacent splice donor/acceptor sites) and were non-synonymous changes. Finally, as ENU treatment is known to introduce a
uniform genomic distribution of mutations, genes that contained multiple SNVs were filtered from the final set of variants. (b) Using this cumulative filtering
strategy against a single replicate exome sequence of the nimbus mouse, the initial 8723 variant calls reduced to a final set of three homozygous and 39
heterozygous putative mutations. Circles representing homozygous and heterozygous SNV numbers are coloured orange and blue, respectively.
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of sequencing errors in massively parallel sequencing. How-
ever, many of the variants appear to be called because of
technical issues associated with aligning large numbers of
short reads to a large genome containing repeated or highly
similar sequence regions. To reduce these raw variant calls
to a smaller number highly enriched for ENU-induced
mutations, we applied a series of filters to remove known
variants (present in dbSNP) and/or recurrent false-positive
variants (figure 2a). We assert that between multiple, unre-
lated mouse exome sequences, de novo ENU-induced
nucleotide changes should be unique to individual pedigrees,whereas other sources of variants should recur. Based on this
reasoning, we collated a list of SNVs that recurred in more
than one unrelated mouse and found this list to be a very
effective filter for false-positive and potentially sequencer-
and enrichment-specific variants. A further filter was applied
to remove variants where they originate from a gene with
multiple SNV calls, assuming that in any single ENU-
mutated mouse it is highly unlikely that the same gene will
have multiple mutations and that the calls are due to incor-
rect alignment of sequence reads between members of gene
families. Figure 2b shows the efficacy of each individual filter-
ing step applied and the outcome of the filters applied in a
G2 parent
(female)
25
2/19
24,2,1
6
4/4
0,0,3
1
1/1
0,0,1
9
8/9
1,1,7
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12/12
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2
2/2
0,0,2
3
2/2
0,0,3 1
1/1
0,0,1
10
4
12
9
8
0
G3 sibling G3 proband(exome in triplicate)
0
11
1/8
31
25/25
1
1/1
7
0/5
7
0/6
0
0
1
1/1
3
3/3
0
0
1
0/1
0 0
tech. rep.
3
(4) 
tech. rep.
2
(4) 
(a)
(c)
tech. rep.
1
(39)
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3
(38)
tech. rep. 
2
(43)tech. rep.
1
(3)
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Figure 3. Sensitivity and specificity of mutation detection in the nimbus mutant mouse pedigree assessed through technical and biological replicate datasets. Venn
diagrams of overlap of filtered variant calls between three technical replicate exome sequence datasets, showing putative (a) homozygous and (b) heterozygous
ENU-induced mutations. The red, green and blue circles each indicate separate technical replicates, and the coloured numbers associated with each denote the total
number of variants called in each dataset. Upper numbers within each sector show the number of filter-passing SNVs called in one, two or all three technical
replicates. The numbers below show the fraction of these SNVs that were validated as true mutations by independent, custom, SNV-specific PCR assays. The
denominator in each case is the number of SNVs where an SNV-specific PCR assay was established successfully. (c) Overlap of filtered variant calls from a set of four
biological replicates, representing two parental G2 nimbus mice and two of their G3 offspring. One of the G3 offspring (labelled G3 proband) is the same mouse as
that sequenced in the technical replicates shown in (a) and (b). The variant numbers shown for this mouse are pooled values from the three technical replicates.
Both G2 nimbus mice and the sibling of the G3 proband (labelled G3 sibling) are unaffected by the lymphopaenia phenotype. Upper numbers within each sector of
the four-way Venn diagram show the total number of filter-passing heterozygous and homozygous SNVs called in one or more of the replicates from this pedigree.
The numbers immediately below show the fractions of biologically replicated SNVs that were validated as true mutations by independent, custom, SNV-specific PCR
assays. In the case of technically replicated data from the proband (the red circle), the third line of data in each region of overlap shows the number of times a
variant was seen in one, two or three replicates (formatted as: single count, double count and triple count).
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 on April 23, 2015http://rsob.royalsocietypublishing.org/Downloaded from cumulative manner. Overall, from a set of several thousands
of raw variant calls, the cumulative filtering reduced this
number mostly to less than 10 homozygous and 50 heterozy-
gous exonic variants per mouse (see electronic supplementary
material, table S2), closely approximating the expected rate
(figure 1).3.2. Sensitivity and specificity of single-nucleotide
variant detection
To assess the reliability of SNV calls made from a single
exome dataset, we performed a technical and biological repli-
cation experiment on G2 and G3 animals from a pedigree
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some G3 offspring. These nimbus mutant animals displayed a
fourfold reduction in the percentage of CD3þ T cells and
represented 8 of a total of 30 phenotyped individuals,
suggesting that nimbus was a recessive trait. We sequenced
the exome of one proband G3 affected nimbusmouse in tripli-
cate (technical replicates) and also sequenced the exome of
both G2 parents and an unaffected G3 sibling (loosely
termed biological replicates). Figure 3a,b shows that the
SNVs called in each of the technical replicates of the pro-
band’s exome were highly replicable. The total number of
coding changes called in each replicate was 47, 42 and 42,
of which 34 were called in all three replicates, representing
72, 81 and 81 per cent of the SNVs called in each individual
exome analysis. The triplicated SNV calls comprised three
homozygous and 31 heterozygous mutations. We successfully
established custom, SNV-specific PCR assays (Amplifluor
assays; see §5.4) for 50 of the SNVs called in one or more of
these replicates. From 50 successful assays, 100 per cent (28
of 28) of the triplicated SNV calls were validated as true
mutations in this pedigree, whereas of the SNV calls that
were present in only one or two of the replicate analyses
only 14 per cent (3 of 22) were validated and the remainder
were established to be false positives (figure 3a,b and
table 1). From these technical replicate data the false-positive
call rate among our filtered variants can be estimated as
19.4 per cent, calculated from an average of six false-positive
calls per replicate exome as a proportion of the 31
true-positive SNVs.
In mouse spermatogonial stem cells and the mice con-
ceived from the resulting sperm, ENU has been found to
induce a biased set of nucleotide substitutions. Several pre-
vious studies have shown an abundance of TA–CG
transitions and TA–AT transversions (ranging between
36–43% and 22–44% of changes, respectively [2,12,14,19])
and GC–CG transversions very rarely or never occur
[14]. Of the validated 31 true-positive SNVs shown in
table 1, 35.5, 38.7 and 0 per cent were TA–CG, TA–AT
and GC–CG changes, respectively. Of the remaining 19
non-replicated, false-positive SNV calls, 26.3, 0 and 15.8
per cent were TA–CG, TA–AT and GC–CG changes,
respectively.
Exome analysis of the G2 parents of our G3 nimbus pro-
band mouse would be expected to reveal all the true ENU
variants present in the proband mouse. Likewise, approxi-
mately half of the true variants should have also been
inherited by the G3 sibling of the proband. Figure 3c shows
a Venn diagram detailing the overlap between the SNVs
called in the exome sequence of the two parents and sibling
compared with those in the pooled technical replicate
exome sequence of the proband. As expected, all of the
seven homozygous mutations called in the proband or its sib-
ling (three in proband þ four in G3 sibling) were also called
in heterozygous state in both parents. Of the total of 31 vali-
dated mutations present in the G3 proband, 28 were called in
one or both parents (table 1). Inspection of the sequence data
for the two parent G2 exomes revealed that the false-negative
mutations were present, but the number of variant reads fell
below the required coverage and/or read ratio thresholds
used for SNV calling. That three of the 31 true mutations
were not identified in one or more of the replicate analyses
indicates a technical false-negative rate of 9.7 per cent per
exome analysis. However, this estimate does not accommodate
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Figure 4. The influence of sequence quality scores and read depth on the identification of true-positive and false-positive SNVs. (a) False-positive calls with respect to read
depth and quality score, shown for a single exome dataset generated from the G3 nimbus mouse (technical replicate 1 from figure 3). Variant calls on this dataset were
compared with the PCR-validated true-positive and false-positive SNVs called in the technical replicate exome datasets of the G3 nimbus proband. Green and red points are
true- and false-positive SNV calls, respectively. The distribution of read depth frequencies over all exonic bases is indicated by the red line in the top graph. The red bars in the
right-hand graph indicate the distribution of quality scores also ascertained for all exonic bases. (b) Results of simulation experiment performed to generate random subsets of a
single exome dataset, being one of the triplicate exome runs for the nimbus proband (technical replicate 1). The panel shows tallies of true-positive heterozygous (green), false-
positive heterozygous (red), true-positive homozygous (blue) and false-positive homozygous (grey) SNV calls plotted against the number of input reads, which are incremental
proportions of an Illumina GAIIx lane. Numbers alongside the green dots indicate the median read depth determined for each true-positive data point. Plotted above are the
proportions of the exome covered at 20 depth or better for each proportion of the input read set.
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ently because they lie in exons that are inefficiently captured
and exhibit low sequence coverage.
The false-negative rate of SNV detection can also be esti-
mated from the distribution of sequence read depths
generated at random across a whole genome. The depth of
reads obtained from random short-read sequencing approxi-
mates a Poisson distribution and the probability of observing
both alleles at a single site in a diploid genome is a binomial
function of read depth [20,21]. A combination of these two
distributions can be used to estimate the false-negative SNV
call rate based simply on the mean read depth [20–22].
While the distribution of read depths obtained from exome
capture appears to be mostly Poisson distributed, this
approximation does not hold for sites that are poorly
enriched by hybridization to exomic baits (see electronic sup-
plementary material, figure S2), which are also the sites
where low coverage is likely to result in the greatest incidence
of false-negative calls. In order to estimate an accurate false-
negative SNV call rate we used the observed distribution of
sequence read depths rather than that derived from a Poisson
function. In this manner, we calculated the false-negative
SNV call rate in the nimbus G3 proband mouse as 21.3 percent. The average read depth from this dataset was 39.5,
but 14.6 per cent of CCDS exomic bases were not covered
at all, this being the major source of missing SNV calls.
Increasing the amount of sequence data does reduce the
false-negative rate slightly, but still a large number of geno-
mic sites will remain poorly covered, either owing to it
being difficult to design capture baits to these regions or
owing to extreme GC content reducing the efficiency of
hybridization of some areas of the genome (data not shown).
Taking the SNV calls from a single replicate exome from
the nimbus proband G3 mouse, we investigated whether or
not validated true- and false-positive SNVs differed in
sequence coverage or quality. Figure 4a shows that false-posi-
tive SNVs had unusually high or low read depth, or had
lower quality scores, relative to the depth and quality of
reads across all exonic nucleotides. However, in these data
the read depths and quality scores of false-positive variants
overlap with those of true-positive calls. While we have
chosen to minimize the false-negative rate as much as
possible, if it were desirable to reduce the false-positive call
rate at the expense of the false-negative rate, this could
potentially be achieved with more stringent filtering against
read depth and quality score.
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we simulated an exome sequencing experiment where incre-
mental proportions of one lane of exome sequence reads were
randomly sampled from a full lane of G3 nimbus exome data
(figure 4b). While reliable homozygous variant calls (blue
dots in figure 4b) were made at even shallow read depths, a
substantially greater depth was required for reliable hetero-
zygous variant calls. True-positive heterozygous variant
calls (green dots in figure 4b) increased significantly with
increasing depth up to a total of 30 million reads. Ninety-
three per cent of true-positive mutations were detected with
35–40 million reads (22–26 times median depth). With
increasing the read depth beyond this value, relatively few
additional true positives were called but the number of
false-positive heterozygous SNV calls doubled.
3.3. Functional validation of causative mutation in
nimbus strain
To identify the mutation causing the recessive lymphopaenia
phenotype in the nimbus strain, we performed Amplifluor
assays on each of the three homozygous mutations identified
in the proband exome sequence to trace their inheritance in
the pedigree. Homozygosity for a C-to-T mutation identified
at Chr1 : 139 986 182 bp was found to co-segregate with the
lymphopaenia phenotype (table 2). This change lies 1 bp
upstream of exon 18 of the Ptprc gene and disrupts the intro-
nic-1 G nucleotide of the consensus splice acceptor sequence
[34], which is otherwise absolutely conserved across ver-
tebrates. PCR amplification of the mutant Ptprcnim mRNA
showed the first 14 bp of exon 18 were deleted compared
with the spliced wild-type mRNA and putatively the AG
nucleotides at þ13 to 14 of exon 18 from an alternative splice
acceptor site. This altered splicing leads to a frameshift in the
mutant transcript from the truncated start of exon 18 onwards.
Ptprc encodes the CD45 protein, which is a tyrosine phospha-
tase receptor type C. CD45 is an abundant protein in the
plasma membrane of leukocytes and plays critical roles in lym-
phocyte development in mice and humans (reviewed in [35]).
Mice homozygous for the Ptprcnim mutation indeed had almost
no CD45 protein on the surface of their B-lymphocytes (2% of
wild-type controls) as measured by flow cytometric staining
with antibodies to CD45 (figure 5b), while heterozygous
mice showed an approximately 50 per cent reduction in the
expression of CD45. The lymphopaenia in nimbus homozy-
gotes matches that in mice and humans with other null or
severe loss-of-function mutations in Ptprc [29,36,37].
3.4. Identification of causal mutations in
11 additional strains
The successful use of exome analysis to identify causative
mutations without meiotic mapping was repeated for 11
other ENU pedigrees with immune disorders or obesity, apply-
ing the same analysis to individual exome sequences from
proband G3, G4 or G5 mice (table 2). In each of these pedigrees,
the causative mutation was revealed solely using exome
sequence data followed by SNV-specific Amplifluor PCR
typing to correlate the SNV genotypes with the phenotype in
the pedigree, without the need for meiotic mapping. The
mutations found in each of these strains variously included pre-
mature stop codons, disrupted splice donor or acceptor sitesand missense changes. The correlation between genotype and
phenotype, together with the similar phenotype of independent
mutant alleles of the same genes, provided strong corroboration
that the mutations identified by exome sequencing were indeed
responsible for the phenotypes observed in these mice.
A mean of 6 homozygous and 36 heterozygous mutations
were called in the exome sequence of each of the proband
individuals from the strains analysed in table 2. These num-
bers are small enough to contemplate exhaustive validation
of each SNV and typing of siblings by Amplifluor PCR
assays to test phenotype–genotype concordance, although
in many cases a knowledge of the function of the mutant
genes allowed candidate mutations to be prioritized. Of the
nine strains for which a recessive mutant was sought, the cau-
sative variant needed to be selected from on average only 6.4
(s ¼ 3.8) candidate mutations. Two of the strains required the
causative variant to be identified in a heterozygous form. In
these two strains the heterozygous candidate mutation lists
were tractably just 40 and 13 variants long.
The incidental mutations revealed by exome sequencing
of proband mice in each pedigree represent a remarkable
resource for gene-driven testing for other phenotypes.
On average, 35.5 (s ¼ 13.7) heterozygous exonic mutations
were identified in the G3, G4 and G5 mice presented in
table 2. Applying the false-positive rate of 19.4 per cent
deduced above, on average each G3, G4 or G5 mutant
mouse will carry around 29 incidental heterozygous
mutations. This gene-driven strategy was successfully
reduced to practice in the strain ENU16NI3b, where the orig-
inal phenotype of low KLRG1 protein on the surface of NK
cells occasionally co-occurred with ashen coat colour or
stunted growth, neither of which could be explained by a
mutation in the KLRG1 gene. With reference to the mutation
list obtained from exome sequencing of the G3 proband
mouse in this strain, two additional incidental mutations
were found by Amplifluor PCR to segregate with each inci-
dental phenotype. A homozygous missense mutation in
Rab27a co-segregated with ashen coat colour in this pedigree,
and an independent Rab27a mutation has previously been
shown to cause the same trait through a defect in melano-
some transport [31]. A homozygous nonsense mutation in
the thyroglobulin gene, TgR1471X, was found to co-segregate
in the same pedigree with stunted growth, and this comp-
lements an independent study that showed that a
spontaneous missense mutation in the Tg gene caused
stunted growth, hypothyroidism and goiter in an AKR
mouse substrain [32]. The new TgR1471X strain provides a
C57BL/6j mouse model for human thyroid dyshormono-
genesis 3 syndrome (OMIM: 274700), which was first
shown to result from a similar R1510X nonsense mutation
in thyroglobulin [38].
3.5. Mutant first-generation mouse resource
The sensitivity and specificity of detecting heterozygous
de novo mutations established above opened up a broader
strategy to develop mouse experimental models based on
tracking specific mutations in gene-driven phenotypic
screens, as had been done for the Tg and Rab27a mutations.
To make it possible to do this in a systematic way, we
extended the exome sequencing approach to identify novel
protein-changing mutations arising in the G1 founders of
ENU mutagenized pedigrees, prior to any phenotypic
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all the mutations are heterozygous (figure 1). We sequenced
the enriched exomes of eight different G1 mice as a bar-
coded, pooled sample on an Illumina HiSeq sequencing
run. This provided a greater number of reads per exome
than the datasets generated on the GAIIx sequencers, and
yielded better than 20 times sequence depth over 80.7 per
cent (s ¼ 1.8%) CCDS exons. As expected, very few homozy-
gous variants were identified in the filtered variant lists,
presumably being rare variants previously unobserved in
the parental C57BL/6j stock. The numbers of heterozygous
variants in the G1 mice (m ¼ 59.6, s ¼ 13.1) were higher
than those found in G3, G4 or G5 mice (m ¼ 36.5, s ¼ 13.7;
table 2), which was as expected since a fraction of ENU-
induced alleles will be lost in each subsequent generation
owing to random drift and purifying selection. Hence,
given the information presented in figure 4b, we would
expect that the majority of true ENU-induced mutations
have been detected from these datasets.
Of the 454 unique mutations detected across these eight
G1 mice, 18 (4%) created a premature stop codon, 65 (14%)
putatively disrupted an mRNA splice donor/acceptor site
and 370 (81%) caused an amino acid substitution (see elec-
tronic supplementary material, table S4). We altered
PolyPhen2 [39] to use mouse sequence databases (rather
than the default human inputs) and calculated scores for mis-
sense G1 mutations. Figure 6 shows a comparison of these
scores with those calculated for a set of previously character-
ized ENU-induced mutations known to cause immunological
traits. For the causal missense mutations, PolyPhen2 correctly
assigned a very high score (greater than 0.95) of ‘probably
damaging’ to 75 per cent and an intermediate to high score
(0.44–0.95) of ‘possibly damaging’ to a further 15 per cent.
This result validates the predictive accuracy of PolyPhen2
when applied to novel mouse mutations. Of the 370 de
novo missense mutations identified in G1 mice, 134 (36%)
were assigned a ‘probably damaging’ score of greater than
0.95 and 59 (16%) were classified as ‘possibly damaging’
with a score of 0.505–0.897. The genes affected by these
272 potentially damaging mutations include those known
to cause human disease through to entirely unexplored
genes with intriguing expression patterns and protein
domains (see electronic supplementary material, table S3).
By identifying de novo ENU mutations in G1 founders in
this way and then breeding, genotyping and phenotyping
their G2 and G3 offspring, this approach provides an
immediate source for new experimental models for
understanding human diseases and traits.4. Discussion
The pursuit of gene function that starts with the identification
of medically important phenotypes displayed by individual
mammals (the so-called forward-genetics) has until now
been constrained by the time-consuming and expensive bot-
tleneck of mapping these traits to their underlying genetic
cause. Conversely, reverse genetics approaches based on
knocking out individual genes in embryonic stem cells
remain constrained by a comparably time-consuming and
expensive bottleneck of converting the embryonic stem cells
into a pedigree of mice that can be phenotypically evaluated.
Here we have shown that exome capture followed by
CD45R
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Figure 5. Nimbus results from a loss of function mutation in the Ptprc gene. (a) Schematic diagram showing the location of single nucleotide mutation at
Chr1:139986183 at the þ1 intronic position of the exon 17 splice donor sequence and the location of the corresponding region in the encoded CD45 protein (TM,
transmembrane domain; FNIII, fibronectin III-like domain; PTP, protein tyrosine phosphatase). (b) Loss of CD45 protein expression. Bold black lines show flow
cytometric staining with antibody to the B-cell-specific CD45R isoform on IgMþ, IgDþ B lymphocytes in blood from (i) Ptprcþ/þ wild-type (wt), (ii) Ptprcnimbus/þ
heterozygous or (iii) Ptprcnimbus/nimbus homozygous mouse, compared with negative control staining on CD3þ T cells in the same mouse (thin black line) and
compared with positive control staining with the same antibody on B cells in a wt mouse (grey shaded area).
rsob.royalsocietypublishing.org
Open
Biol2:120061
13
 on April 23, 2015http://rsob.royalsocietypublishing.org/Downloaded from massively parallel DNA sequence analysis reliably identifies
the majority of homozygous and heterozygous ENU-induced
mutations. Not only does this eliminate the bottleneck to for-
ward genetics by identifying causal mutations without the
need for meiotic mapping, but also it bypasses a key restric-
tion for reverse genetics by revealing thousands of possibly
damaging mutations in live-breeding C57BL/6j mouse pedi-
grees that are immediately available for experimental analysis
of gene function.
By technical and biological replication of exome analyses
and confirmation of individual SNV calls by PCR, we have
shown that both homozygous and heterozygous protein-
changing mutations induced by ENU de novo in live-breed-
ing pedigrees of C57BL/6j mice can be called reliably with
an estimated sensitivity of 78.7 per cent and a specificity of
80.6 per cent. In 11 separate C57BL/6j mutant strains from
forward genetics screens for immune system disorders or
obesity, we were able to bypass the need for meiotic mapping
and identify short lists of protein-changing ENU-induced
mutations that were heterozygous or homozygous inproband individuals from these pedigrees, among which
we were able to identify a causative mutation that explained
the immunological or obesity phenotype. In identifying
ENU-induced mutations, we found massively parallel
sequencing data to be highly reliable and sources of error
were predictable, such that by filtering commonly called var-
iants (along with previously observed genetic variation) we
were able to restrict the false-positive call rate to less than
20 per cent while not incurring a disproportionate false-nega-
tive call rate. In terms of the read depth required to reliably
identify heterozygous mutations, we found that around 35
million paired-end sequence reads are sufficient to identify
more than 90 per cent of these changes.
Fairfield et al. [9] have also produced an extensive demon-
stration of exome capture and sequencing in mice to identify
causative mutations. In their study, exome sequence data
were used in combination with meiotic mapping information
to identify causal mutations without a large validation
burden. Our results both confirm and extend this study.
Laudably, the Fairfield et al. [9] study describes three
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Figure 6. Violin plot comparing PolyPhen2 scores for incidental and causative
mutations. The black bars represent a boxplot where 50% of values lie within the
main bar. Thewhite dot indicates the median polyphen value for each set of scores.
The blue region is a kernel density plot representing the distribution of PolyPhen2
scores. The numbers of mutations included in the plot were: incidental mutations,
n ¼ 325 and causative mutations, n ¼ 40. A Mann–Whitney test for the
equality of the mean PolyPhen2 score of the incidental and causative mutations
indicated a significant difference in score (W ¼ 4168, p¼ 0.0000862).
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even with the aid of meiotic mapping information. They
speculated that, in those strains where the causal mutation
could not be identified, it probably lay outside the chromo-
somal regions enriched by exome capture. Our analysis
provides further insight into this problem and shows that,
in approximately one of five mouse strains, we can expect a
causal mutation to remain undetected owing to it not being
efficiently captured prior to sequencing and/or subsequently
detected. We found that solution capture methods commer-
cialized by Agilent and Nimblegen are both effective at
specifically concentrating the coding part of the mouse
genome, but that a consistent approximately 15 per cent por-
tion of exonic regions is absent from subsequently sequenced
reads, regardless of how deeply the captured DNA is
sequenced. This may be a fundamental limitation of exome
enrichment technologies, perhaps indicating that some geno-
mic regions may be resistant to efficient hybridization with
capture baits and/or the PCR amplification steps in the cap-
ture and library preparation protocols. From analysis of
exome datasets from related mice, in a small number of
cases known heterozygous variants were only poorly
detected owing to a very few reads supporting the mutant
genotype. This effect may indicate that in some local
sequence contexts the mutant genotype is out-competed by
the reference genotype during sequence capture.
Mutated C57BL/6j inbred mice provide an ideal system
for tackling the challenges of identifying rare, de novo
mutations from a background of normal genetic variation.
While the laboratory mouse is an inbred organism with very
little genetic variation, we found that it was necessary to con-
trol for even this small amount of variation through a series of
data filtering strategies employing catalogues of known strain
variants and other sources or recurring false positives in order
to identify true mutations with high specificity. Givensufficient data for a specific mouse strain (10–20 individual
exome sequences), this strategy of cataloguing recurrent var-
iants has also proven effective in identifying ENU-induced
mutations in mice out-crossed to strains other than C57BL/6j
(data not shown). We found that detection of ENU-induced
mutations can be further enhanced by technical replication of
exome analysis and by biological replication taking advantage
of heritability information in closely related individuals. Taken
together, this information makes pathogenic mutation detec-
tion in outbreeding mammals (such as humans) a more
tractable possibility.
We have shown that it is feasible to also perform these
exome analyses in multiplexed, bar-coded samples from
many separate G1 founder mice. This makes it straightfor-
ward to analyse the exomes of hundreds of G1 founder
mice per year and propagate the mutations they carry in
live-breeding pedigree structures such as the ones employed
here (figure 1). Given the number of protein-changing
mutations we identified in each G1 mouse (table 3), a live-
breeding resource of 350 pedigrees bred for two generations
from 700 G1 mice each year would reveal 42 000 new
protein-changing mutations per year, of which around half
are expected to be deleterious. Hence, reliable identification
of induced mutations has the potential to transform genetic
screens of genes of unknown function and produce mouse
models of hundreds of human diseases.5. Material and methods
5.1. Mutant mouse generation
The nimbus mouse strain was generated by treating pure
C57BL/6j male mice with the mutagen ENU at the Australian
Phenomics Facility of the Australian National University as pre-
viously described [10]. Briefly, adult male animals received
90 mg of ENU per kilogram of body weight by three weekly
intraperitoneal injections. Once fertility was regained after a
further eight weeks, the animals were mated with C57BL/6j
females to generate G1 offspring carrying a unique cohort
of heterozygous SNVs. A subset of SNVs was brought to
homozygosity through unrelated G1 crosses followed by inter-
crossing to G3 (as shown in figure 1). A peripheral blood screen
for lymphocyte subsets identified the nimbus strain at G3 as dis-
playing a mild lymphopaenia. All other mutated mouse strains
sequenced were generated via this protocol.
5.2. Exome enrichment and sequencing
DNAwas extracted from ear tissue of affected mice and 3.5 mg
prepared as paired-end genomic libraries (PE-102-1001: Illu-
mina, San Diego, CA). Technical replicates were produced
from the same DNA sample. Exome enrichment was per-
formed using either the SureSelect Mouse Exome kit
(G7550A-001: Agilent, CA) or the SeqCap Mouse Exome kit
(early access: Nimblegen, Madison, WI) following the
manufacturer protocols. Four amplification cycles were used
in the library pre-capture PCR using Herculase II fusion
polymerase (600677, Stratagene) and eight cycles in the post-
enrichment amplification for both capture technologies.
Enriched libraries were diluted to 10 nM concentrations
before further dilution to 7–8 pM for cluster generation and
sequencing-by-synthesis on either the Illumina Genome
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reads. Each library sequenced on an Illumina GAIIx was
sequenced on a single lane of an eight-lane flow-cell, whereas
libraries sequenced on the Illumina HiSeq were multiplexed
in a pool of 10 samples and sequenced together, and disambig-
uated using sample bar-coding.ypublishing.org
Open
Biol2:1200615.3. Single-nucleotide variant detection workflow
A custom workflow was developed to process sequence
reads to detect ENU-induced mutations. This workflow
holds together a number of open-source analysis tools and
employs a Perl code-base to perform custom filtering, report-
ing and job process control (figure 2a). BWA (v. 0.5.9-rc16;
[16]) with default settings was chosen to align paired-end
reads to the reference mouse genome (mm9/NCBIM37).
Reads aligning to multiple genomic locations were removed
and raw SNV calls were made using SAMTOOLS (v. 0.1.15;
[17]) with parameters set to allow a less conservative calling
rate than the default settings, which significantly involved
disabling the base alignment quality filtering function. Raw
SNV calls were classified as homozygous or heterozygous on
the basis of the ratio of alleles (hom. 0.8 variant allele; het
two alleles. 0.3) and then annotated as to whether they
were also present in dbSNP (v. 128; http://www.ncbi.nlm.
nih.gov/snp/), whether they commonly occurred in our
exome data and, where appropriate, whether they were
strain-specific variants identified from the Sanger Institute
mouse genomes sequencing project (http://www.sanger.ac.
uk/resources/mouse/genomes/). Commonly occurring var-
iants were collated from all exome data collected by our
laboratory. Further annotation of variants was performed to
determine overlap with CCDS exons [18] and denote non-
synonymous changes (using ANNOVAR [40]). Changes that
lay in potential splice donor–acceptor sites immediately adja-
cent to exon boundaries (out to 10 intronic bases) were also
annotated. Using these annotations, we filtered the variant
list to only include non-synonymous or splice donor–accep-
tor site changes that were novel to a particular sample.
From this filtered list of variants, for each exome a list of
genes containing more than one variant was compiled for
each sample and then used to further filter variants across
all samples that were found in these multi-SNV genes.5.4. Variant validation
SNVs were validated using Amplifluor assays (Chemicon,
Temecula, CA). Primers were designed using the Assay
architect online tool (http://apps.serologicals.com/AAA/
mainmenu.aspx). Fluorescent intensities were detected
using a Fluostar optima (BMG). The individual affected
mice used in the study and a C57BL/6j control were analysed
for each SNV assay.6. Acknowledgements
The authors acknowledge funding from the National Health
and Medical Research Council (Australia), the Wellcome
Trust, the National Institutes of Health (USA) and the
Australian Government.
rsob.
16
 on April 23, 2015http://rsob.royalsocietypublishing.org/Downloaded from Referencesroyalsocietypublishing.org
Open
Biol2:1200611. Acevedo-Arozena A, Wells S, Potter P, Kelly M, Cox
RD, Brown SDM. 2008 ENU mutagenesis, a way
forward to understand gene function. Annu. Rev.
Genomics Hum. Genet. 9, 49–69. (doi:10.1146/
annurev.genom.9.081307.164224)
2. Justice MJ, Noveroske JK, Weber JS, Zheng B, Bradley A.
1999 Mouse ENU mutagenesis. Hum. Mol. Genet. 8,
1955–1963. (doi:10.1093/hmg/8.10.1955)
3. Albert TJ et al. 2007 Direct selection of human
genomic loci by microarray hybridization. Nat.
Methods 4, 903–905. (doi:10.1038/nmeth1111)
4. Gnirke A et al. 2009 Solution hybrid selection with
ultra-long oligonucleotides for massively parallel
targeted sequencing. Nat. Biotechnol. 27,
182–189. (doi:10.1038/nbt.1523)
5. Ng SB, Nickerson DA, Bamshad MJ, Shendure J.
2010 Massively parallel sequencing and rare
disease. Hum. Mol. Genet. 19, R119–R124.
(doi:10.1093/hmg/ddq390)
6. Arnold CN, Xia Y, Lin P, Ross C, Schwander M, Smart
NG, Mu¨ller U, Beutler B. 2011 Rapid identification of
a disease allele in mouse through whole genome
sequencing and bulk segregation analysis. Genetics
187, 633–641. (doi:10.1534/genetics.110.124586)
7. Yabas M et al. 2011 ATP11C is critical for the
internalization of phosphatidylserine and differentiation
of B lymphocytes. Nat. Immunol. 12, 441–449. (doi:10.
1038/ni.2011)
8. Zhang Z et al. 2009 Massively parallel sequencing
identifies the gene Megf8 with ENU-induced mutation
causing heterotaxy. Proc. Natl Acad. Sci. USA 106,
3219–3224. (doi:10.1073/pnas.0813400106)
9. Fairfield H et al. 2011 Mutation discovery in mice by
whole exome sequencing. Genome Biol. 12, R86.
(doi:10.1186/gb-2011-12-9-r86)
10. Nelms KA, Goodnow CC. 2001 Genome-wide
ENU mutagenesis to reveal immune regulators.
Immunity 15, 409–418. (doi:10.1016/S1074-
7613(01)00199-6)
11. Probst FJ, Justice MJ. 2010 Mouse mutagenesis with
the chemical supermutagen ENU. Methods Enzymol.
477, 297–312. (doi:10.1016/S0076-6879(10)77015-4)
12. Boles MK et al. 2009 Discovery of candidate disease
genes in ENU-induced mouse mutants by large-
scale sequencing, including a splice-site mutation
in nucleoredoxin. PLoS Genet. 5, e1000759.
(doi:10.1371/journal.pgen.1000759)
13. Quwailid MM et al. 2004 A gene-driven ENU-based
approach to generating an allelic series in any gene.
Mamm. Genome 15, 585–591. (doi:10.1007/
s00335-004-2379-z)
14. Takahasi KR, Sakuraba Y, Gondo Y. 2007 Mutational
pattern and frequency of induced nucleotide
changes in mouse ENU mutagenesis. BMC Mol.
Biol. 8, 52. (doi:10.1186/1471-2199-8-52)
15. Waterston RH et al. 2002 Initial sequencing and
comparative analysis of the mouse genome. Nature
420, 520–562. (doi:10.1038/nature01262)16. Li H, Durbin R. 2009 Fast and accurate short read
alignment with Burrows–Wheeler transform.
Bioinformatics 25, 1754–1760. (doi:10.1093/
bioinformatics/btp324)
17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J,
Homer N, Marth G, Abecasis G, Durbin R, Subgroup
GPDP. 2009 The sequence alignment/map format
and SAMtools. Bioinformatics 25, 2078–2079.
(doi:10.1093/bioinformatics/btp352)
18. Pruitt KD et al. 2009 The consensus coding sequence
(CCDS) project: identifying a common protein-coding
gene set for the human and mouse genomes. Genome
Res. 19, 1316–1323. (doi:10.1101/gr.080531.108)
19. Gue´net J-L. 2004 Chemical mutagenesis of the
mouse genome: an overview. Genetica 122, 9–24.
(doi:10.1007/s10709-004-1442-8)
20. Levy S et al. 2007 The diploid genome sequence of
an individual human. PLoS Biol. 5, e254. (doi:10.
1371/journal.pbio.0050254)
21. Wheeler DA et al. 2008 The complete genome of an
individual by massively parallel DNA sequencing.
Nature 452, 872–876. (doi:10.1038/nature06884)
22. Wendl MC, Wilson RK. 2008 Aspects of coverage in
medical DNA sequencing. BMC Bioinform. 9, 239.
(doi:10.1186/1471-2105-9-239)
23. Otipoby KL, Draves KE, Clark EA. 2001 CD22
regulates B cell receptor-mediated signals via two
domains that independently recruit Grb2 and
SHP-1. J. Biol. Chem. 276, 44 315–44 322.
24. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe
M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T.
2001 Haematopoietic cell-specific CDM family protein
DOCK2 is essential for lymphocyte migration. Nature
412, 826–831. (doi:10.1038/35090591)
25. D’Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI,
Curran T. 1995 A protein related to extracellular matrix
proteins deleted in the mouse mutant reeler. Nature
374, 719–723. (doi:10.1038/374719a0)
26. Verhagen AM et al. 2009 A kinase-dead allele of
Lyn attenuates autoimmune disease normally
associated with Lyn deficiency. J. Immunol. 182,
2020–2029. (doi:10.4049/jimmunol.0803127)
27. Bosma GC, Custer RP, Bosma MJ. 1983 A severe
combined immunodeficiency mutation in the mouse.
Nature 301, 527–530. (doi:10.1038/301527a0)
28. Chen H et al. 1996 Evidence that the diabetes gene
encodes the leptin receptor: identification of a mutation
in the leptin receptor gene in db/db mice. Cell 84,
491–495. (doi:10.1016/S0092-8674(00)81294-5)
29. McNeill L, Salmond RJ, Cooper JC, Carret CK,
Cassady-Cain RL, Roche-Molina M, Tandon P,
Holmes N, Alexander DR. 2007 The differential
regulation of Lck kinase phosphorylation sites by
CD45 is critical for T cell receptor signaling
responses. Immunity 27, 425–437. (doi:10.1016/j.
immuni.2007.07.015)
30. Urba´nek P, Wang ZQ, Fetka I, Wagner EF, Busslinger
M. 1994 Complete block of early B celldifferentiation and altered patterning of the
posterior midbrain in mice lacking Pax5/BSAP.
Cell 79, 901–912. (doi:10.1016/0092-8674(94)
90079-5)
31. Wilson SM et al. 2000 A mutation in Rab27a causes
the vesicle transport defects observed in ashen
mice. Proc. Natl Acad. Sci. USA 97, 7933–7938.
(doi:10.1073/pnas.140212797)
32. Kim PS, Hossain SA, Park YN, Lee I, Yoo SE, Arvan P. 1998
A single amino acid change in the acetylcholinesterase-
like domain of thyroglobulin causes congenital goiter
with hypothyroidism in the cog/cog mouse: a model
of human endoplasmic reticulum storage diseases.
Proc. Natl Acad. Sci. USA 95, 9909–9913. (doi:10.
1073/pnas.95.17.9909)
33. Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby
KL, Clark EA, Goodnow CC. 1998 Polygenic
autoimmune traits: Lyn, CD22, and SHP-1 are
limiting elements of a biochemical pathway
regulating BCR signaling and selection.
Immunity 8, 497–508. (doi:10.1016/S1074-
7613(00)80554-3)
34. Roca X, Olson AJ, Rao AR, Enerly E, Kristensen VN,
Børresen-Dale A-L, Andresen BS, Krainer AR,
Sachidanandam R. 2008 Features of 50-splice-site
efficiency derived from disease-causing mutations
and comparative genomics. Genome Res. 18,
77–87. (doi:10.1101/gr.6859308)
35. Hermiston ML, Xu Z, Weiss A. 2003 CD45: a critical
regulator of signaling thresholds in immune cells.
Annu. Rev. Immunol. 21, 107–137. (doi:10.1146/
annurev.immunol.21.120601.140946)
36. Kung C et al. 2000 Mutations in the tyrosine
phosphatase CD45 gene in a child with severe
combined immunodeficiency disease. Nat. Med. 6,
343–345. (doi:10.1038/73208)
37. Zikherman J, Jenne C, Watson S, Doan K, Raschke
W, Goodnow CC, Weiss A. 2010 CD45-Csk
phosphatase-kinase titration uncouples basal and
inducible T cell receptor signaling during thymic
development. Immunity 32, 342–354. (doi:10.
1016/j.immuni.2010.03.006)
38. Targovnik HM, Medeiros-Neto G, Varela V, Cochaux
P, Wajchenberg BL, Vassart G. 1993 A nonsense
mutation causes human hereditary congenital
goiter with preferential production of a 171-
nucleotide-deleted thyroglobulin ribonucleic acid
messenger. J. Clin. Endocrinol. Metab. 77,
210–215. (doi:10.1210/jc.77.1.210)
39. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE,
Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR.
2010 A method and server for predicting damaging
missense mutations. Nat. Methods 7, 248–249.
(doi:10.1038/nmeth0410-248)
40. Wang K, Li M, Hakonarson H. 2010 ANNOVAR:
functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 38,
e164. (doi:10.1093/nar/gkq603)
 131 
7.2 Further discussion 
In this publication we describe our production pipeline to detect rare, 
ENU induced mutations in mice using targeted exome sequencing. While 
historically forward genetic approaches have required huge amounts of time and 
expense to map the traits of interest to their underlying genetic cause, here we 
demonstrate how we are able to detect most homozygous and heterozygous 
ENU-induced mutations using targeted exome capture and sequencing without 
any pre-existing meiotic mapping information. Further, we are able to perform 
this task in a highly automated, high-throughput manner with low estimated false 
positive and false negative rates (~20%), all run in a completely reproducible in-
house framework. 
 To determine whether detecting ENU variants solely from exome 
sequence data in mice was feasible, a bespoke prototype pipeline was 
constructed in early 2010 to demonstrate proof of concept. This pipeline 
consisted of a MySQL tracking database and detailed configuration files 
containing sample metadata as well as the exact commands to run for the 
alignment, variant detection, annotation, and summary steps. The first iteration 
of the pipeline detected a huge numbers of variants; yielding variant lists too 
large for manual interrogation essentially making causal variant identification 
impossible without additional mapping information. We expected to observe 
only ~35 true ENU mutations per exome given the homogeneous genetic 
background of C57BL/6 mice and the ENU mutation rate of 1 mutation per mega 
base. Yet many more mutations were being detected per exome indicating the 
likely presence of both technical and biological replicate variants.  To identify 
and remove variants resulting from technical replicates a strategy was devised 
where mutations common to unrelated mice would be catalogued and de-
prioritised from subsequent variant lists.  While this strategy effectively removed 
most technical replicates, special care had to be taken to correctly track mouse 
relationships in order to prevent the erroneous removal of important ENU 
mutations common to related mice. To identify and remove variants arising from 
biological replicates, a similar strategy was devised where each new group of 
mice from a previously un-encountered strain was used to generate a list of 
common strain specific variants that could be used to filter out such variants for 
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all mice of this strain encountered in the future.  Collectively these custom 
strategies reduce the number of candidate causal mutations to less than 50 
variants per exome, which, when combined with extensive annotation allow 
researchers to routinely identify the important causal variant. 
Next, a production pipeline based on the prototype was required, with the 
new version able to process huge number of samples in a highly automated and 
reproducible manner. The implementation of the production system proved a 
significant undertaking requiring reengineering and redesign of the prototype, a 
task that ultimately took one year to complete. The first major challenge was 
making the pipeline highly automated and capable of processing large number of 
samples simultaneously, a task we accomplished by deeply integrating the 
system with high-performance computing resources (HPC) and minimising the 
requirements for manual intervention. The production system was designed to 
run primarily on HPC clusters at the National Computational Infrastructure, and 
to run on their large raijin system (http://nci.org.au/nci-systems/national-
facility/peak-system/raijin/), the 38th largest supercomputer in the world 
(http://www.top500.org/). In order to cope with the wide variety of analysis steps 
required a generic wrapper for running a single step was implemented to reflect 
the fact that any large workflows can be broken down into smaller analysis 
components and ultimately individual system commands.  The process for 
running a step consists of reading the pre-generated sample-specific 
configuration file; a file that contains all information required to run each step 
such as job pre-requisites, command arguments, external modules to load, and 
compute requirements. After ensuring prerequisite conditions have been met, 
job(s) are submitted and monitored until completion when step-specific quality 
control is performed with the exact command run recorded in both the tracking 
database and log file. The final task performed by the wrapper is the submission 
of the next analysis job, a process that continues until the final analysis step is 
complete. Total workflow automation is crucial not only during routine sample 
analysis but also in both detecting and recovering from errors that inevitably 
occur. Our system works to detect and recover from both catastrophic errors 
(errors that cause the entire analysis to halt) as well as non-fatal errors that 
generate incorrect output with non-fatal errors being particularly problematic 
both in wasting ensuing CPU cycles and in making it difficult to identify the 
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exact point of failure. Overall, the focus on automation makes possible both the 
seamless addition of new analysis steps as well as the ability to resume analysis 
from any failed step facilitating easy recovery from unforeseen events such as 
hardware failure. 
 The ability to unequivocally reproduce past analysis results is of the 
utmost importance in informatics pipelines particularly in light of the fast 
moving nature of both sequencing technologies and bioinformatics software 
development. Unfortunately reproducibility is far from the norm in biological 
sciences with a study discovering less than half of the microarray studies 
published in Nature Genetics were reproducible (91).  To ensure complete 
reproducibility our system employs multiple tracking methods using an 
underlying MySQL database and a detailed log file, with each method capable of 
reproducing any previous workflow independently. While this design decision 
was initially implemented to ensure output consistency, it has proven useful in 
diagnosing pipeline crashes by offering two distinct reference points for 
identifying the exact point of failure.  In addition to recording the system 
commands run during analysis steps, full reproducibly requires all files and 
external binaries utilised to be versioned with this information recorded in both 
log files and the database.  This includes the version of external software used, 
the version of the in-house code base, and external annotation data set versions.  
External annotation data in particular represents a challenge for truly 
reproducible results with both rapid updates and changes in format common the 
norm for annotation data sets.  In our system, to manage external annotations 
effectively and consistently, annotations are parsed from the original data source 
and converted into a standard file format utilising a standardised naming scheme.  
Groups of common annotation files are stored in time-stamped directories thus 
allowing the most up to date annotation information to be automatically detected 
and incorporated into each new analysis. This consistent handling of annotations 
allows for seamless updates when new annotation versions become available and 
also simplifies the reanalysis of large numbers of samples when important 
annotation sets like dbSNP (2) are updated. Collectively, these features allow the 
system to reproduce any previous result and thus meet this important system 
requirement. 
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The production version of the pipeline has been extremely successful 
since its inception, being run in high-production mode for four years while 
undergoing very little change. To date it has analysed 666 ENU mice and 2075 
G1 mice and detected causal variants in over three quarters of all ENU mice 
sequenced with numerous resultant publications, some of which are detailed in 
Chapter 8. The overall flexibility of the design of this pipeline allowed it to serve 
as the template for the creation of a human exome analysis pipeline, a pipeline 
that has analysed 525 human exomes to date and generated four additional 
publications detailed in Chapter 8. Overall the implementation of this approach 
has transformed genetic screens in mice, and establishes a general strategy for 
analysing rare DNA variants while opening up a large new source for 
experimental models of human disease. This success of this system and the 
resultant discoveries will potentially lead to a much greater understanding of the 
underlying mechanism of human disease. 
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Chapter 8: Other publications 
 
I am included as an author on the additional eight publications summarized 
below. These publications detail discoveries made by the software developed 
during my PhD candidature. 
 
1) Taupin, D, W. Lam, D. Rangiah, L. McCallum, B. Whittle, Y. Zhang, D. 
Andrews, M. Field, C. C. Goodnow and M. C. Cook (2015). "A deleterious 
RNF43 germ line mutation in a severely affected serrated polyposis kindred." 
Human Genome Variation 2. 2015; 16;2:15013 
 
Summary: “We report a germ line nonsense mutation within the extracellular 
domain of the RING finger ubiquitin ligase RNF43, segregating with a severe 
form of serrated polyposis within a kindred. The finding provides evidence that 
inherited RNF43 mutations define a familial cancer syndrome.” 
Contribution: This work made extensive use of our variant identification system 
and the causal variant was identified using a prototype of the VASP tool. 
 
2) Johar, A. S, C. Mastronardi, A. Rojas-Villarraga, H. R. Patel, A. Chuah, K. 
Peng, A. Higgins, P. Milburn, S. Palmer, M. F. Silva-Lara, J. I. Velez, D. 
Andrews, M. Field, G. Huttley, C. Goodnow, J. M. Anaya and M. Arcos-Burgos. 
(2015). "Novel and rare functional genomic variants in multiple autoimmune 
syndrome and Sjogren's syndrome." Journal of Translational Medicine 2015; 13: 
173. 
 
Summary: “Novel and rare exonic mutations that may account for 
autoimmunity were identified. Among those, the LRP1/STAT6 novel mutation 
has the strongest case for being categorised as potentially causative of MAS 
given the presence of intriguing patterns of functional interaction with other 
major genes shaping autoimmunity.” 
Contribution: This work used our variant detection system to identify the 
variants deemed likely causative. 
 
3) Dunkerton, S., M. Field, V. Cho, E. Bertram, B. Whittle, A. Groves and H. 
Goel  (2015). "A de novo mutation in KMT2A (MLL) in monozygotic twins 
with Wiedemann-Steiner syndrome." American Journal of Medical Genetics Part 
A. 2015; 167A(9):2182-7. 
 
Summary: “In this study, we have identified a de novo mutation in KMT2A 
associated with psychomotor developmental delay, facial dysmorphism, short 
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stature, hypertrichosis cubiti, and small kidneys. This finding in monozygotic 
twins gives specificity to the WSS. The description of more cases of WSS is 
needed for further delineation of this condition. Small kidneys with normal 
function have not been described in this condition in the medical literature 
before.” 
Contribution: This work made extensive use of our variant identification system 
and the causal variant was identified using a prototype of the VASP tool. 
 
4) Lee, C. E, D. A. Fulcher, B. Whittle, R. Chand, N. Fewings, M. Field, D. 
Andrews, C. C. Goodnow and M. C. Cook (2014). "Autosomal dominant B cell 
deficiency with alopecia due to a mutation in NFKB2 that results in non-
processible p100." Blood. 2014; 124(19):2964-72. 
 
Summary: “A novel NFKB2 mutation confers a severe B cell deficiency but 
antibody production is partially preserved. Unprocessed p100 results in an IκB-
like action on the canonical NF-κB pathway.” 
Contribution: This work used our variant detection system to identify the 
causative variant. 
 
5) Enders, A, A. Short, L. A. Miosge, H. Bergmann, Y. Sontani, E. M. Bertram, 
B. Whittle, B. Balakishnan, K. Yoshida, G. Sjollema, M. A. Field, T. D. 
Andrews, H. Hagiwara and C. C. Goodnow. (2014). "Zinc-finger protein ZFP318 
is essential for expression of IgD, the alternatively spliced Igh product made by 
mature B lymphocytes." Proceedings of the National Academy of Science of the 
United States of America. 2014; 111(12): 4513-4518. 
 
Summary: “Mammalian B lymphocytes make antibodies of five different heavy 
chain isotypes, IgM, IgD, IgG, IgE, and IgA. The different isotypes are produced 
at discrete stages in B-cell development from a single immunoglobulin heavy 
chain (Igh) gene, either by irreversible rearrangement of the gene to make IgG, 
IgE, or IgA or by alternative splicing of the RNA transcribed from the Igh gene 
to coexpress IgM and IgD. Developmentally regulated trans-acting factors have 
been hypothesized to control IgM and IgD expression from large Igh RNAs, but 
these factors have remained elusive for several decades. Here, using a genome 
wide mutation screen in mice, we identify an obscure gene, Zfp318, as encoding 
a specific and essential factor promoting IgD expression in mature B cells.” 
Contribution: The mouse exome pipeline was utilised to discover the candidate 
variant and due the unknown nature of the gene prior to publication, extensive 
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custom work was performed in order to confirm no other candidate variants 
existed in the mapped region. 
 
6) Ellyard, J. I., R. Jerjen, J. L. Martin, A. Lee, M. A. Field, S. H. Jiang, J. 
Cappello, S. K. Naumann, T. D. Andrews, H. S. Scott, M. G. Casarotto, C. C. 
Goodnow, J. Chaitow, V. Pascual, P. Hertzog, S. I. Alexander, M. C. Cook and 
C. G. Vinuesa (2014). "Whole exome sequencing in early-onset cerebral SLE 
identifies a pathogenic variant in TREX1." Arthritis & Rheumatology. 2014; 
66(12):3382-6 
 
Summary: “Our study is the first to demonstrate that whole exome sequencing 
can be used to identify rare or novel deleterious variants as genetic causes of 
SLE and, through a personalized approach, improve therapeutic options.” 
Contribution: This work used our variant detection system to identify the causal 
variant.  Custom work to identify rare variants (<0.02 MAF) was required as the 
causal variant was reported in dbSNP at low frequencies in the general 
population. 
 
7) Daley, S. R., K. M. Coakley, D. Y. Hu, K. L. Randall, C. N. Jenne, A. 
Limnander, D. R. Myers, N. K. Polakos, A. Enders, C. Roots, B. Balakishnan, L. 
A. Miosge, G. Sjollema, E. M. Bertram, M. A. Field, Y. Shao, T. D. Andrews, 
B. Whittle, S. W. Barnes, J. R. Walker, J. G. Cyster, C. C. Goodnow and J. P. 
Roose. (2013). "Rasgrp1 mutation increases naive T-cell CD44 expression and 
drives mTOR-dependent accumulation of Helios+ T cells and autoantibodies." 
Elife 2013; 2: e01020. 
 
Summary:  “Here we analyze a new mouse missense variant, Rasgrp1 with an 
ENU-mutated EF hand in the Rasgrp1 Ras guanine nucleotide exchange factor. 
Rasgrp1  mice exhibit anti-nuclear autoantibodies and gradually accumulate a 
CD4 Helios+ PD-1+ CD4+ T cell population that is dependent on B cells. Despite 
reduced Rasgrp1-Ras-ERK activation in vitro, thymocyte selection in Rasgrp1  is 
mostly normal in vivo, although CD44 is overexpressed on naïve thymocytes and 
T cells in a T-cell-autonomous manner.” 
Contribution: The mouse exome pipeline was utilised to discover the causal 
variant 
 
8)  Bergmann, H., M. Yabas, A. Short, L. Miosge, N. Barthel, C. E. Teh, C. M. 
Roots, Bertram, F. Mackay, A. J. Rimmer, R. J. Cornall, M. A. Field, T. D. 
Andrews, C. C. Goodnow and A. Enders (2013). "B cell survival, surface BCR 
and BAFFR expression, CD74 metabolism, and CD8- dendritic cells require the 
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intramembrane endopeptidase SPPL2A." Journal of Experimental Medicine 
2013; 210(1): 31-40. 
 
Summary: “In this study, we show that mice with an inactivating mutation in 
the intramembrane protease signal peptide peptidase–like 2A (SPPL2A) 
unexpectedly exhibit profound humoral immunodeficiency and lack mature B 
cell subsets, mirroring deficiency of the cytokine B cell–activating factor 
(BAFF). The findings illuminate an important role for the final step in the 
CD74–MHC II pathway and a new target for protease inhibitor treatment of B 
cell diseases.” 
Contribution: The mouse exome pipeline was utilised to discover the causal 
variant 
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